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The envelope glycoproteins of Maedi-Visna virus consist of a surface glycoprotein (gpl35)
which is responsible for the characteristic spikes on the surface of the virion, and a
transmembrane protein (gp41) whose function includes linkage to the surface glycoprotein,
anchoring it to the virion envelope. The external glycoprotein is required for attachment to the
host cell via a receptor molecule present on the surface of the cell. Cells of the macrophage
lineage are the main target cells in MVV infection in vivo. The host humoral response is
targeted to the surface glycoprotein resulting in neutralizing antibody production. The
relevance of these antibodies is not understood as virus infection persists despite this active
immune response. The external glycoprotein has also been shown to be susceptible to
antigenic variation.
Expression of gpl35 as three overlapping fragments in the bacterial pGEX system was
undertaken with a view of using the recombinant protein as a source of immunogen to raise
monoclonal antibodies. These and the three recombinant fragments could be used for epitope
mapping. However, these fragments proved to be toxic to bacterial cells resulting in low yields
and high levels of contamination. In depth studies were carried out to improve the yield and
attempts were made to raise immune polyclonal sera. Characterization of these sera is
described.
Recombinant protein studies were extended to express gpl35 in the baculovirus expression
system. This resulted in a reliable source of recombinant protein that was devoid of
contamination and was easily purified. This protein was glycosylated and was recognised by
MW-infected sheep sera. Preliminary studies were carried out to determine its interaction
with sheep fibroblasts and hence its use to isolate the host cell receptor.
Attempts were made to raise monoclonal antibodies against gpl35 purified from virions by
lectin affinity chromatography. The development of a screening assay is described. This
approach did not result in the generation of any anti-gpl35 monoclonals. The preparation of
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1.1 Introduction to maedi-visna virus; an ovine lentivirus: isolation,
transmission and pathology
The retrovirus family are characterized as RNA viruses that use a viral-encoded reverse
transcriptase to replicate via a DNA template. Members of the family include the oncovirinae,
the spumavirinae and the lentivirinae. Lentivirus infections are characterized by a period of
'latency' followed by the development of clinical disease which follows a slow, progressive
course. Lentiviruses fall into two classes; the immunodeficiency viruses which predominantly
infect T-lymphocytes resulting in their depletion, and include the human immunodeficiency
viruses; HIV-1 and HIV-2 (Barre-Sinoussi, 1983, Gallo et al„ 1984, Levy et al., 1984),
simian immunodeficiency virus; SIV (Letvin et al., 1985), and feline immunodeficiency vims;
FIV (Pedersen et al., 1987). The second class of lentiviruses infect ungulate animals and are
characterized by infection of cells of the monocyte/macrophage lineage resulting in immune-
mediated organ specific diseases. These include maedi-visna virus of sheep; MVV
(Sigurdsson, 1954), caprine arthritis encephalitis vims; CAEV (Crawford et al., 1980) and
equine infectious anaemia vims; EIAV (Valle and Carre, 1904, Cheevers et al., 1985) which
has an acute disease progression unique to this lentivirus.
Maedi-visna vims was first isolated from Icelandic sheep in the 1940's (Sigurdsson,
1954, Sigurdsson et al., 1957). The disease was described as an emaciating, respiratory
disease and it is from this that the vims derives its name; maedi (dysponea) and visna
(wasting) (Gudnadottir and Palsson, 1967). The introduction of this vims to Iceland originated
from the importation of a flock of sheep from Gennany in 1933, and resulted in a full scale
epidemic by 1940 with a subsequent slaughter and devastating depletion of the sheep
population. Maedi-visna is now a worldwide problem and is of great economic and veterinary
importance. Isolates have been described in the U.S.A., known as ovine progressive
pneumonia vims (Marsh, 1923, Kennedy et al., 1968, Cutlip and Laird, 1976), South Africa
(Querat et al., 1990), France, the Netherlands where it is known as zwoegerzietkte (Ressang et
al., 1968, De Boer, 1970) and the U.K. (Dawson et al., 1979, Watt et al., 1990). However,
MVV is not found in Australia and New Zealand. More recently, the importance of studying
MVV has been linked to its use as a model for HIV-1 infection without the complication of
lymphocyte infection, since it shares pathological, virological and epidemiological features.
The major mode of transmission of MVV is horizontal via the respiratory tract. This is
probably exacerbated by close housing conditions (Houwers and van der Molen, 1987). A
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study by de Boer et al. (1979) indicated that the incidence of transmission is proportional to
the length of exposure where 81% of uninfected lambs became infected when housed with a
flock of infected ewes for 1 year. The incidence of infection has also been shown to be
elevated amongst sheep suffering from sheep pulmonary adenomatosis (SPA) (Dawson et al.,
1990), probably as a consequence of increased respiratory fluid caused by SPA (DeMartini et
al., 1987). There is no evidence of vertical transmission (de Boer et al., 1979, Sihvonen,
1980), although 2 out of 11 lambs derived by hysterectomy from infected ewes showed
progressive pneumonia even though they had been kept in isolation immediately after birth
(Cross et al., 1985). This suggested that the lambs had been infected prior to or at birth (Cross
et al., 1985). There is no evidence of transmission through the mother's colostrum to the lamb
as is seen in CAEV transmission (Ellis et al., 1983). However, the presence of MVV infected
cells within colostrum has been reported (Sihvonen, 1980). Minor transmission through
faecally contaminated drinking water has been described (Sigurdsson, 1954). MVV is not
transmitted sexually as is HIV and other immunodeficiency viruses.
The incubation period of MVV varies from 1 to 4 years. It is thought to be prevalent in 80-
85% of the sheep population in Western Europe and U.S.A. (Cutlip et al., 1977), with only
25% developing clinical disease (Crawford et al., 1981). MVV infection is diagnosed by the
presence of serum antibodies to the major core antigen (Petursson et al., 1976, Griffin et al.,
1978, Oliver et al., 1981) and the envelope glycoprotein (Adams et al., 1985, Adams and
Gorham, 1986). Clinical disease is characterized as progressive lesions in one or more organs,
including lungs, CNS and joints, leading to severe illness and usually death. Respiratory
disease becomes apparent by slight dysponea, loss of condition and listlessness. Dysponea will
progress leading to respiratory difficulties, and at post mortem lungs can weigh 2-4 times the
normal weight (Marsh, 1923, Sigurdsson, 1954, Cutlip and Laird, 1976, Oliver et al., 1981).
Histologically, the alveolar septa are thickened due to the accumulation of plasma cells,
mononuclear phagocytes and lymphocytes, which leads to total obliteration of alveoli
(Georgsson and Palsson, 1971). There is a presence of lymphoid follicles consisting of
lymphocyte aggregates with germinal centres of large lymphoblasts (Lairmore et al., 1986),
and smooth muscle hyperplasia (Watt et al., 1992). The histopathology seen in maedi bears
some resemblance to lymphoid hyperplasia in children with AIDS, and thus is a useful model
for studying HIV infection.
The neurodegenerative aspect of the disease becomes apparent by aberrations in gait,
weakness in hind legs and eventually this leads to paralysis. The cause of encephalitis is
thought to be due to inflammation within the white matter of the brain and cerebellum which
eventually leads to demyelination (Sigurdsson and Palsson, 1958). The primary lesions occur
in the glial cells (Sigurdsson and Palsson, 1958), and viral RNA and antigens have been
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located in oligodendrocytes and astrocytes (Stowing et al., 1985). The presence of viral
antigens in these cells is suggested to influence the inflammatory response which leads to
demyelination (Stowing et al., 1985).
Mastitis may be a clinical consequence caused by lymphoid hyperplasia and fibrosis
within the mammary gland, with lesions similar to those found in maedi lungs (Cross et al.,
1985, Oliver et al., 1981, van der Molen et al., 1985). Non-suppurative arthritis may develop
in tarsal and carpal joints (Oliver et al., 1981), but this is a rare event unlike in CAEV
infection. Arthritis is caused by swelling and calcification of soft tissue, fibrosis of the joint
capsule and synovium, and perivascular lymphocytic infiltration (Oliver et al., 1981).
1.2 Viral tropism
MVV predominantly infects sheep, but infection of goats has also been demonstrated (Banks
et al., 1983). There are no reports of infection of any other animal species in vivo. The major
target cells in vitro are fibroblasts cells of sheep and goats. MVV has also been shown to
recognise receptors on the surface of cells from a variety of species, including mice, rats and
human (Gilden et al., 1981). However, in vivo the cells from macrophage/monocyte lineage
are the main targets, as demonstrated by the presence of virus in macrophages taken from
infected sheep and cocultivated with fibroblasts (Narayan et al., 1982). MVV has been shown
to infect and replicate in macrophages in vitro, resulting in small quantities of virus produced
with non-cytopathic effects (Narayan et al., 1982). The extent of viral gene expression is
dependent on the activation state of the cell, such that on increased cellular differentiation
virus gene expression is increased (Gendelman et al., 1986). This may be a possible
mechanism for viral persistence in vivo such that virus may remain latent in undifferentiated
cells. In fact, clusters of infected macrophages have been found in the bone marrow of infected
sheep, which may act as a virus reservoir since the half-life of circulating monocytes and
tissue macrophages is short (Gendelman et al., 1986).
In contrast to HIV infection and other immunodeficiency lentiviruses, infection of T-
lymphocytes has not been demonstrated (Gorrell et al., 1992), although one report suggested
that cells of lymphocyte morphology in the CNS did express viral core proteins (Georgsson et
al., 1989).
Although infection of fibroblasts in vivo is not widely observed, a recent report has
suggested evidence of vims infection of fibroblasts in the CNS (Zink et al., 1994). Infection of
MVV in smooth muscle cells from the ovine aorta has been demonstrated in vitro (Leroux et
al., 1995). This may reflect of pathogenesis seen in the lungs of infected sheep. Infection of
dendritic cells in vivo has also been seen (Gorrell et al., 1992).
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1.3 Pathogenesis
The cytopathic effects characteristic of MW infection in vitro are not seen in vivo, and thus
do not explain the pathogenic mechanisms of the virus. Normal host cell defences involve
macrophages which are involved in the phagocytosis of vims-infected cells. Macrophages also
present viral antigens via MHC classll to helper T cells resulting in the proliferation of
lymphocytes whose combined effect eliminates the pathogen. The fact that the major target
cell in MW infection is the macrophage obviously complicates the usual host defence
mechanisms. The tropism for macrophages may explain the persistence of the virus in the
host, but it is thought that pathogenesis is a consequence of aberrations in the immune system.
Evidence for this will be presented below.
Early studies on MW-induced disease observed that only 1 in 100,000 cells are
infected and concluded that the severity of the lesions were not directly due to the existence of
vims-infected cells (Petursson et al., 1976). Immunosupression of infected sheep resulted in a
decrease in the extent of CNS lesions, suggesting that pathogenesis may be immune-mediated
(Nathanson et al., 1976). In contrast to the effect on lesion development, immunosupression
did not reduce the amount of recoverable virus indicating the persistence of virus despite an
effective immune response (Nathanson et al., 1976). An increase in serum immunoglobulin
levels in infected sheep compared to controls was reported (Molitor et al., 1979), although
characterization of the increased immunoglobulin was not undertaken. It could be envisaged
that elevated levels of immunoglobulin would lead to formation of immune complexes. Since
clinical disease is characterised by a local inflammatory response, the clearing of these
immune complexes could be seen to influence the pathogenesis of MW. The envelope
glycoprotein is the major target for the immune response in vivo, as is discussed in section
1.12. Transgenic sheep have been produced that express the envelope protein in vivo
(Clements et al., 1994). These sheep expressed envelope proteins in differentiated
macrophages and fibroblast cells when cutured in vitro. It was not demonstrated whether the
envelope protein was expressed in vivo, but two out of the three lambs did mount an immune
response against envelope protein. These sera were non-neutralizing. The authors comment on
the usefulness of this model in looking at the role of envelope in pathogenesis. Infection of
these sheep with MW would provide an opportunity to see if sheep would be protected.
Macrophages expressing envelope in vivo may desensitize the animal such that on infection,
inflammatory responses would be reduced (Clements et aL, 1994).
Several studies have been undertaken to characterize the cellular infiltrate in tire
lungs, which is responsible for the dysponea seen later on in infection. A 1.5-fold increase in
4
total leukocyte number and a 4-fold increase in lymphocyte numbers in infected lambs
compared to normal lambs was reported (Lairmore et al., 1988a). The predominant subset
was CD8+ cells (65%) (Lairmore et al., 1988a). This correlates with an increase in absolute
numbers of CD8+ lymphocytes found in a clinically infected sheep (Kennedy-Stoskopf et al.,
1989). Similar studies in naturally infected sheep showed an increase in cell number but no
difference in the percentage of lymphocytes (Cordier et al., 1990). However, there appeared to
be an increase in neutrophil numbers and an elevated release of neutrophil chemotactic factor
and fibronectin. This could influence the infiltration of inflammatory cells which would
correlate with lesion development (Cordier et al., 1990). There was also an increase in MHC
classll expression on the surface of macrophages (Cordier et al., 1990), which is consistent
with other workers which found that MHC classll was expressed in infected macrophages
(Kennedy et al., 1985). A lentivirus-induced interferon was described by Narayan and
colleagues who showed that the release of interferon was dependent on the interaction of
infected macrophages with T-lymphocytes (Narayan et al., 1985). This data is supported by a
similar observation that the spontaneous release of this specific interferon from lymphocytes is
increased by the presence of MW-infected macrophages (Lairmore et al., 1988b). It is
postulated that the interaction of infected macrophages with lymphocytes results in the release
of the specific interferon that increases the expression of MHC classll on infected
macrophages (Kennedy et al., 1985). Since infected cells will also be expressing viral
antigens, the increase in MHC class!! expression may result in more efficient presentation of
viral antigens to helper T cells. This may result in a distortion of the immune response leading
to a localised lymphoproliferation and a failure to clear infection (Kennedy et al., 1985).
Virus strains differ in their pathology, such that the Icelandic strains 1514 and K796 are
predominantly neurovirulent (Petursson et al., 1976), and virus isolated in the USA appears to
be mainly linked to progressive pneumonia (Cutlip and Laird, 1976). Several reports have
indicated that the characteristics of virus strains in vitro affect the extent of pathogenicity in
vivo. Several strains isolated form French MW-infected sheep differed in their replication in
vitro, that is they were either highly lytic or induced persistent infections. This indicated the
existence of genetically distinct strains ofvirus in the field which may influence the severity of
disease (Querat et al., 1984). Another study characterized virus isolates on their ability to lyse
fibroblast cells and macrophage cells in vitro (Lairmore et al., 1987). Isolates that were able
to lytically infect macrophages in vitro caused the most severe pathogenic effects (Lairmore et
al., 1987). The genetic differences for the existent of pathogenically distinct viruses is not
understood.
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The literature described so far has suggested that both the interplay of the virus with the
immune system and the replication properties in vitro may influence the severity of disease.
The role of viral antigens, other than stimulating an immune response, have been implicated in
pathogenesis. The cysteine-rich domain of MVV tat shares homology with snake venom
neurotoxins (Hayman et al., 1993). Tat-derived peptides including this motif were injected into
the brains of rats, and were shown to cause lesions (Hayman et al., 1993). It was suggested
that tat may provide a source of arginine residues for nitric oxide (NO) synthesis, and the
increased levels of NO in the brain results in cell death (Hayman et al. 1993). Transgenic mice
carrying the tat gene develop disorders of the lymphoid organs (Vellutini et al., 1994), but no
effect in the brains of mice is observed. It is suggested that tat impairs the immune response
by stimulating the proliferation of immune cells (Vellutini et al., 1994). Both these studies are
preliminary, and the mechanism for tat's role in pathogenesis is not known.
Pathogenesis appears to be mediated by a dysfunction in the regulation of the immune
response, but precisely which parts of the immune network are involved is not known.
1.4 Virus structure
MVV, in common with all. retroviruses, is characterized morphologically as a crescent shaped,
electron dense particle that buds from the plasma membrane. The virus particle comprises a
bar-shaped nucleoid, which is characteristic of lentiviruses, surrounded by a lipid coat with
protruding spikes, and is distinguishable from type-C retroviruses by the absence of an
electron-lucent region between the core and the envelope (Genderblom et al., 1987). The vims
particle varies between 80-120nm in size (Gonda et al., 1985).
Lentiviruses share a common genomic structure with other retroviruses, that is they possess
the pol, gag and env genes (Weiss et al., 1982). In addition, they have a number of additional
small open reading frames (orfs) which encode regulatory proteins. The virions contain two
copies of a positive-sense single stranded RNA genome (ssRNA) (Brahic et al., 1977), an
RNA-dependent DNA polymerase (reverse transcriptase) (Lin and Thormar, 1970), several
internal structural proteins and the whole virion is surrounded by the envelope coat containing
the major envelope glycoprotein. The vims replicates via a DNA template (Haase and
Varmus, 1973), in keeping with all retroviruses. MVV is most closely related to the non-
primate lentiviruses by phylogenetic analysis (McClure et al., 1988a, Olmsted et al., 1989),
but it is more closely related to HIV than to the onco and spumaviruses (Gonda et al., 1985).
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Up to seven different isolates of MVV have been described and sequenced; four of the isolates
are derived from the 1514 strain (Sonigo et al., 1985, Braun et al., 1987, Staskus et al., 1991,
Andresson et al., 1993), a South African strain (SA-OMVV) (Querat et al., 1990), a British
isolate (EV-1) (Sargan et al., 1991) and recently a New York isolate (Campbell et al., 1993).
These isolates only show minor differences at the molecular level, and generally share the
same genomic organisation. The organisation of the virus genome is shown in figure 1.1. The
virus genome is flanked on either side by long terminal repeats (LTRs). These are involved in
regulating viral transcription and are divided into three region; U5, R and U3. The target
sequences that influence transcription are located in 43 base pair repeats in the U3 region. A
number of potential AP-1 binding sites have been located within this region but only a TATA
box proximal sequence matches the consensus sequence for the AP-1 site (Hess et al., 1989).
The LTR shows strong promoter activity and position independent enhancer activity (Hess et
al., 1985). In addition, there is a primer binding site complementary to that for the tRNA 'Vj 2
(Sonigo et al., 1985) and a polypurine tract which acts as an initiation site for positive strand
DNA synthesis. There is also a negative response element upstream of the U3 region (Hess et
al., 1989).
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Figure 1.1: The structure of the MW genome
The map shows the position and organization of the orfs of MW. The map gives the
approximate nucleotide positions of each orf.
Key: LTR: long terminal repeates comprised of three regions; U3,R and U5.
GAG: encoding internal structural proteins: matrix, capsid and nucleoprotein.
POL: encoding reverse transcriptase, integrase and protease.
Q: vif protein ofunknown function,
tat: regulates transcription.
rev: comprised of 2 exons (closed boxes), regulates splicing of mRNA transcripts.




The life cycle of MW differs considerably in vivo and in vitro. In vitro the virus is highly
lytic leading to cytopathic effects within a 72 hour period after infection of tissue culture cells.
In contrast, in vivo MW replication is under tight control, such that recoverable virus is a
rare event. The lytic cycle in vitro leads to a massive amplification of virus genome within the
infected cell, up to 4000 copies within the cell (Brahic et al., 1977). The number of cells
infected in vivo is very low, with reports of 18% of cells recovered from the CNS containing
viral RNA (Haase et al., 1977). Subsequent studies showed that the level of infected cells in
vivo is even less, 1-3%, and contained RNA levels two orders of magnitude lower than
infected cells in vitro (Brahic et al., 1981). Contrasting results have been found when
investigating infected cells in the lung. Macrophages have been shown to contain up to 1000
copies of viral RNA, but is not known if these cells are expressing viral antigens (Gendelman
et al., 1985). Therefore there appears to be some control over viral transcription in vivo, as
will be discussed below.
The initial stages of virus replication are thought to be similar both in tissue culture
and in the host This involves the synthesis of dsDNA from the viral ssRNA genome using the
virally-encoded reverse transcriptase (Brahic et al., 1977). Several in vitro studies have been
reported looking at the kinetics of viral transcription (Sargan et al., 1994, Vigne et al., 1987,
Davis et al., 1987). These studies differed in the size of RNA transcripts and the time points
at which various RNA species were detectable also slightly differed. However, they can all be
summarised to conclude that there is a temporal regulation of RNA transcription in vitro. At
early time points (6 to 24 hours) after infection viral RNA transcripts can be detected as
multiply spliced transcripts (approximately 1.4 and 1.7 kb), containing sequences from the 3'
end, 5' end and central regions of the genome (Vigne et al., 1987, Davis et al., 1987). These
have been shown to encode the rev and tat transcripts, respectively (Sargan et al., 1994). The
functions of these two proteins is discussed in the following section 1.6.1. At later time points,
there is also a presence of singly spliced (env transcripts) and unspliced (gag and pol
transcripts) (Sargan et al., 1994).
The restriction of viral transcription in vivo is not yet understood, but it is probable
that a combination of cellular factors and parts of the viral genome, such as the LTR, are
involved.
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1.6 The proteins of MVV
1.6.1 The regulatory proteins
1.6.H Rev
Rev is a small regulatory protein of 19kDa in size, that is located predominantly in the
cytoplasm of the infected cell (Mazaiin et al., 1990), and has been shown to be essential for
productive infection (Toohey and Haase, 1994). It is thought to function in a similar manner
to that of HTV-1, in that it regulates the splicing of mRNA transcripts and that its relative
amount within the cell predicts the type of transcripts present in the infected cell. There is
evidence in MVV that early after infection only multiple spliced mRNA transcripts which
encode the regulatory proteins of tat and rev are present (as discussed in the above section).
There is a shift to incomplete splicing later in infection for the production of gag and env gene
products (Vigne et al., 1987). It is believed that as rev accumulates in the infected cell there is
a switch from multiply spliced transcripts to the singly spliced transcripts encoding the
structural proteins (Tiley et al., 1990). In contrast to HTV, the first exon of MW rev utilises
the first 37 amino acids of the env gene (Sonigo et al., 1985) and exon 2 contains the
functional domains of rev. Two functional domains within HIV-1 rev have been described: the
"RNA binding domain" is present at the N-terminus, contains a highly basic 40 amino acid
core and has a nuclear localisation signal; the "activation domain" is located at the C-terminus
and contains a leucine rich motif which interacts with cellular proteins (Hope et al., 1990).
Rev functions by binding to a rev response element (RRE) which in HIV-1 is located 3' to the
env gene. The location of the RRE binding domain has been mapped in visna (Uley et al.,
1991), as well as the leucine rich domain. The RRE of visna has been located in a similar
place to that of HTV-1 by sequence comparison, and it is predicted to form an RNA stem loop
structure, similar to HIV-1 (Tiley et al., 1991).
1.6.1ii Tat
Tat, like rev, is transcribed early in infection and is thought to play a role in the regulation of
virus replication. Tat proteins are common to all lentiviruses and all share common protein
motifs, but differ in their ability to transactivate their LTR's. HTV tat is derived from 2 exons
(Arya et al. 1985) and it strongly activates its LTR by binding to a TAR (tat activated region)
element present within the LTR. The TAR element forms an RNA stem loop structure
following its transcription to which tat and other transcription factors can bind. In contrast,
CAEV and MVV tat are derived from a single exon (Davis and dements, 1989), weakly
transactivate their LTR's and no TAR element exists since mutations within the R element of
the LTR have no effect on tat responsiveness (Hess, 1989). Tat is a 10-1 lkDa protein, sharing
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three of the conserved cysteine residues in the cysteine rich domain in HTV tat (Gourdou et al.,
1989, Davis and Clements, 1989). Visna tat has distinct domain structures to those of HIV tat
and these include an acidic activation domain at the N-terminus, hydrophobic and bulky
aromatic residues essential for tat activity and a leucine rich domain, adjacent to the N-
terminal activation domain, that acts as a negatively regulating domain (Carruth et al., 1994).
Transient expression assays have shown that tat of MW acts via AP-1 and AP-4 binding
sites located in the U3 region of the LTR to increase the rate of transcription (Gdovin and
Clements, 1992, Neuvet et al., 1993). Thus tat acts as a positive frans-activator of
transcription as well as having post transcriptional activities (Gourdou et al., 1989). Post-
transcriptional activities of tat have been suggested since deletion of the U3 region does not
affect viral transcription but a decrease in viral protein content was observed (Gdovin and
Clements, 1992). The importance of tat in the life cycle of ungulate lentivirus infection is not
known since it has been shown be is dispensable for viral replication in vitro and in vivo
(Harmache et al., 1995a).
1.6.1iii Vif (Q)
The vif gene of MW encodes at 29kDa protein that is expressed at the later stages of
infection (Audoly et al., 1992). It is located within the cytoplasm of infected cells but is not
associated with virus particles (Audoly et al., 1992). Deletion mutant studies have shown that
vif is essential for the rapid release of virus particles and for efficient virus replication, and
that it acts post translationally (Harmache et al., 1995b). These studies revealed the
importance of a domain at the C-terminus of vif, which in HIV is membrane associated. This
region in HIV-1 vif contains a hydrophobic region with the conserved SLQXL motif which is
essential for vif function (Goncalves et al., 1994). This domain is also found in non-viral
proteins associated with membranes (Oberste and Gonda, 1992). In HIV, the association of
vif with membranes has been correlated with the ability of vif to modulate the gp 120 content
of newly synthesised virions (Sakai et al., 1993).
1.6.1iv Other regulatory proteins
Sequence comparisons of the SA-OMW and other MW isolates identified an additional orf
(W) in this South African isolate (Querat et al., 1990). The function of this W gene product is
not known.
There are no reports of oris within MW related to the other auxiliary proteins of HIV,
including vpr (Ogawa et al., 1989), vpu (Strebel et al., 1987), tev (Benko et al., 1990) or nef
(Ahmad and Venkatesan, 1988).
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1.6.2 The non-structural proteins
The pol gene encodes for the non-structural proteins which are the reverse transcriptase (p66),
the protease (plO) and the integrase (p32). The pol gene products are translated directly from
the unspliced mRNA and the protease serves to cleave the gag (55kDa) and gag-pol precursor
(150kDa) polypeptides. The gag and pol genes overlap by approximately 240 nucleotides and
the pol gene is in a -1 reading frame relative to gag. Thus a ribosomal frameshift allows
expression ofpol and this strategy explains the abundance of the gag precursor polypeptide in
relation to the pol precursor (reviewed by Clements and Wong-Staal, 1992). The reverse
transcriptase encodes for RNA-dependent polymerase activity (Lin and Thormar, 1970) and
RNase H activity that degrades RNA:DNA hybrids during the reverse transcription process.
The integrase of MVV shows in vitro integrase activities including 3' processing, strand
transfer and disintegration (Katzman and Sudol, 1994). Studies with chimeras of HIV-1 and
MVV integrase have shown that the N-terminal portion does not contribute to viral DNA
specificity (Katzman and Sudol, 1995). To date, there have only been limited reports of
integration of visna DNA into the host genome (Vigne et al., 1985) and the function of
integrase in vivo is not understood.
1.6_3 The structural proteins
The gag gene, like the pol gene, is synthesized from the unspliced genomic mRNA resulting in
a large polypeptide precursor, Pr55gag (Vigne et al., 1982). This polypeptide is cleaved
intracellularly to give rise to three internal structural proteins: p30, pl6 and pl4 (Vigne et al.,
1982). Sequence analysis of the MVV genome supported the existence of these proteins
(Sonigo et al., 1985). pl6 was predicted to lie at the N-terminus of the precursor, followed by
the p24 antigen, leaving 79 residues to represent a 8.8 kDa protein. This small protein is
postulated to be the nucleocapsid by virtue that it contains a zinc-finger (Cys-X2-Cys-X9-Cys)
motif for interaction with nucleic acids. This basic motif confers the unusual mobility of these
proteins on SDS-PAGE gels, such that they migrate slowly with respect to their actual size.
This explains the difference in the predicted size of the gag precursor polypeptide (49.9kDa)
(Sonigo et al., 1985) and that observed in infected cells (55kDa) (Vigne et al., 1982). The
functions of pl6 and p24 are thought to be a membrane associated protein and the major
capsid protein, respectively, by analogy to other retroviruses.
Env is translated from a large singly spliced mRNA. The envelope glycoproteins are derived
from a 150kDa glycosylated polypeptide to give a mature 135kDa major glycoprotein (Vigne
et al., 1982). The env gene was identified by the presence of up to 28 N-glycosylation sites
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(Sonigo et al., 1985, Sargan et al., 1991). There are also three predicted major hydrophobic
regions; the first is thought to represent the signal peptide, the second contains the Arg-Lys-
Arg-Lys motif for cleavage between the transmembrane and surface glycoproteins, and the
third region probably represents the transmembrane region. No absolute size has been defined
to the surface and transmembrane proteins. Gpl35 is usually the major glycoprotein seen in
cell extracts (Vigne et al., 1982). It is noted that throughout the literature on MVV, there is
inconsistency as to the identity of gpl35 with some authors referring to it as the surface
glycoprotein. The size of the transmembrane protein has not been defined but is thought to be
between 38 and 44 kDa (Sonigo et al., 1985). The properties of both of these proteins will be
discussed in greater detail below. By analogy to other retroviruses it can be assumed that the
precursor protein, gpl35, is cleaved, and, on assembly of the virions, the surface and
transmembrane proteins become non-covalently linked.
1.7 Viral envelope protein translocation and glycosylation
1.7.1 The signal peptide and glycoprotein translocation; the role of the C-terminus of env
The envelope mRNA is translated on membrane-bound ribosomes and the signal peptide at the
N-terminus directs the protein through the secretory pathway. This pathway is common to all
cellular glycoproteins which are eventually secreted, and the signal peptide guides the
polypeptide to the endoplasmic reticulum (E.R.) via the signal recognition particle (SRP) and
the docking protein which is embedded in the membrane of the E.R.. Signal sequences are very
varied in length and amino acid composition. The signal or leader sequence is comprised of
three regions. The N-terminal region ranges in size, shows the greatest diversity and is
generally positive in charge (von Heijne, 1985). A possible role in modulating translocation in
bacteria has been proposed, but no such function has been demonstrated with eukaryotic
peptides (von Heijne, 1990). The middle hydrophobic region encompasses the signal peptide
thought to be responsible for binding to the SRP. However, due to its variation no homologous
binding region has been identified, and it may bind non-specifically to the membrane (von
Heijne, 1990). The C-tenninus can range between 5-7 amino acids and contains the signal
peptidase cleavage site. Statistical calculations have predicted that the -3 and -1 residues
determine the site of cleavage, and these amino acids are generally uncharged and small (von
Heijne, 1983, von Heijne, 1984). Membrane proteins with carboxylic tails longer than 7
amino acids are not cleaved, and will remain membrane-bound with the C-terminus inside the
cell. Although the exact mechanism by which the signal sequence translocates the polypeptide
through the E.R. is not fully understood, it is proposed that the three regions with their
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positive-hydrophobic-polar design may form a loop structure. This allows the middle
hydrophobic region to interact with the membrane, leaving the amino-temiinus on the
cytoplasmic side and the cytoplasmic tail close to the extra-cytoplasmic membrane face where
cleavage by the signal peptidase takes place (von Heijne, 1990).
Membrane proteins are classified into four categories; class I, II, III and IV,
depending on the number of times they span the membrane, the removal of the signal sequence
and the orientation in the membrane. Lentiviruses have class I type glycoproteins, that is then-
signal sequence is removed, the carboxylic terminus is retained on the cytoplasmic side of the
plasma membrane and they only span the membrane once (Hunter and Swanstrom, 1990). In
common with retroviruses, lentiviruses have an exceptionally long N-terminus sequence
preceding the signal peptide. The function of these additional amino acids is not known. This
region in FIV and ungulate lentiviruses is longer than the primate lentiviruses, 149 amino
acids in FTV (Stephens et al„ 1992) and approximately 80 amino acids for MVV (Sonigo et
al„ 1985, Sargan et al„ 1991). Deletion mutations in this region of FIV has shown that only
the initial 47 amino acids at the N-terminus is required for efficient glycoprotein processing
(Stephens et al., 1992). Also, the overall charge of this tail does not affect glycoprotein
processing, which is a feature of class I membrane proteins.
As the polypeptide is translocated across the rough E.R., the hydrophobic portion of the
transmembrane region remains anchored in the membrane and thus acts as a translocation stop
signal. The introduction of a stop codon at the N-teiminus of this region results in the
secretion of the retroviral envelope protein (Perez et al., 1987b, Hallenberger et al., 1993).
This translocation anchor confers the bitopic orientation of the retroviral envelope proteins,
such that the carboxylic end of the protein is cytoplasmic. The length of this cytoplasmic tail
varies amongst retroviruses from 50 amino acids in oncogenic retroviruses to 150 amino acids
in HIV-1. The importance of this domain is not fully understood. In the Rous sarcoma virus,
deletion of the entire region does not effect biosynthesis, transport and processing of the
envelope protein (Perez et al., 1987b). In fact the mutant virus is as infectious as the wild-
type, suggesting that the cytoplasmic domain is dispensable to the virus in vitro (Perez et al.,
1987b). Part of the cytoplasmic tail of the Mason-Pfizer monkey virus is cleaved and involves
a viral protease (Brody et al., 1992). This removal of 16-20 amino acids occurs in a late
maturation step at post-budding, since this mature form of the transmembrane protein was
seen only in infectious virions and not in infected cells. Deletions in the matrix protein affected
the cleavage of the cytoplasmic tail of the envelope protein, suggesting some form of
interaction between these two proteins (Brody et al., 1992). It is possible that binding of the
matrix protein to the cytoplasmic tail brings about a conformational change that allows
cleavage by the viral protease (Brody et al., 1992). The cleavage of the cytoplasmic domain of
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HIV-1 has not been demonstrated. No cytoplasmic cleavage was seen in the deletion studies
carried out by Yu and colleagues (1993), although the vif protein of HIV-1 has been shown to
behave as a cysteine protease and cleave envelope proteins (Guy et al., 1991).
Studies linking the cytoplasmic tail of HIV-1 with the signal sequence of the HSV-I
glycoprotein D have shown that it is associated with cellular membranes (Haffar et al., 1991).
The sequences within this region predict two amphipathic a-helixes, and it is suggested that
these two helices form a stable association that spans the lipid bilayer forming a complex
analogous to ion channels (Haffar et al., 1991). However, the role in virus assembly and
replication is not understood since truncation in this region did not affect replication (Wilk et
al., 1992, Earl et al., 1991). Vaccinia viruses were constructed that expressed progressively
larger C-teiminal deletions, and these were found to have no effect on glycoprotein transport,
cleavage or membrane anchorage (Earl et al., 1991). In fact, an enhancement in syncytia
formation was observed, suggesting that the cytoplasmic tail may play a role in the
conformational state of the extracellular and transmembrane glycoproteins (Earl et al., 1991).
More recent data has shown that deletions in the cytoplasmic tail of HIV-1 can effect the
infectivity of the virus (Yu et al., 1993). The introduction of stop codons in the cytoplasmic
tail resulted in the production of non-infectious virus, suggesting that this domain may
function in virus replication as well as virus assembly (Yu et al., 1993), contrasting earlier
reports (Wilk et al., 1992).
In summary, the cytoplasmic domain of lentiviruses may be important both in vims
assembly and in rendering the vims infectious.
1.7.2 The glycosylation state of lentiviral glycoproteins
Following transport through the E.R., the envelope proteins of lentiviruses are transported
through the glycosylation pathway of the host cell (reviewed in Fenouillet et al., 1994). The
majority of glycosylation on lentivirus envelope proteins is N-linked and glycosylation is
mediated in the lumen of the E.R.. The first step involves the transfer of a dolichol phosphate-
linked extended oligosaccharide core to an asparagine residue on the polypeptide backbone.
The asparagine is located within the motifs either Asn-X-Thr or Asn-X-Ser, where X can be
any amino acid except proline. Dolichol is a long chain of hydrophobic carbon moieties that is
able to associate with the lipid bilayer at least three times, resulting in the anchorage of the
carbohydrate core in the membrane on the lumen side. Once the oligosaccharide core is linked
to the polypeptide, it is rapidly trimmed by the loss of three glucose residues and one mannose
residue. The enzymes that catalyse this trimming are a-glucosidases I and II, and
mannosidases, receptively. They are inhibited by castanospermine and deoxymannojinimycin,
respectively and these provide useful tools when investigating the glycosylation state of viral
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proteins. Proteins are then transported to the Golgi apparatus where further trimming occurs.
In the czs-Golgi, which is the most proximal compartment to the E.R., one mannose residue is
trimmed, and a further two mannose residues are trimmed in the medial-Golgi. Varying
numbers of residues are then added, including N-acetylglucosamine, fucose and sialic acid,
and this occurs both in the medial- and /ran.?-Golgi department catalysed by glycosyl
transferases.
In summary, all N-linked glycans are composed of a N-acetylglucosamine2-mannose3
core to which a variety of other residues are added. Depending on the extent of the
modification of this core, glycans can be either characterized as the complex-type or when no
addition of residues occurs these are called high-mannose glycans.
The envelope glycoproteins of lentiviruses are heavily glycosylated and account for up to 50%
of their molecular weight MVV has up to 29 potential glycosylation sites (Sargan et al.,
1991, Sonigo et al., 1985) and HIV-1 has up to 30 sites (Fenouillet et al., 1994).
Glycosylation of envelope proteins can be demonstrated by the addition of tunicamycin to
infected cells to block glycosylation in the E.R., and this method was used to demonstrate that
the envelope protein of MVV was glycosylated (Vigne et al., 1982). The characterization of
the glycan residues on HIV-1 gpl20 has shown that 13 residues are of the complex-type and
11 are the high-mannose type (Geyer et al., 1988). The glycosylation of the transmembrane
protein is not as extensive, with the potential of five sites in HIV-1 gp41 resulting in a much
lower molecular weight than the external glycoprotein (Fenouillet et al., 1993). The identity of
glycans on MVV have not been characterized although susceptibility to neuraminidase
suggests the existence of sialic acid residues (August et al., 1977).
The functional role of glycans in lentiviruses is still not fully understood and the
majority of studies have been carried out with HIV-1. Studies on the CD4/gpl20 interaction
found that deglycosylated gpl20 was unable to bind to CD4 on the surface of cells (Matthews
et al., 1987). Mutational studies have shown that single point mutations within the
glycosylation sites do not affect the processing or function of the envelope glycoprotein, but
multiple mutations do inhibit the normal processing of gpl60 (Lee et al., 1992). The
carbohydrate moieties could be envisaged as a bulk of sugar residues, such that the loss of a
single glycosylation site will not disrupt the mass of carbohydrate, and thus its influence on
protein conformation. The results from these mutation studies are reinforced by the use of
glycosylation inhibitors. The addition of castanospermin which inhibits a-glucosidases in the
E.R. resulted in a reduction in syncytium formation (Gruters et al., 1987).
The five putative glycosylation residues of the HIV-1 transmembrane protein, gp41,
lie within the ectodomain and are flanked by the immunodominant domain, the putative
binding domain between gpl20 and gp41, and the gp41 cleavage site (Fenouillet et al., 1993).
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It is proposed that in HIV-1, the carbohydrate moieties may play a role in "hiding" the fusion
domain prior to membrane fusion. As with gpl20 studies, individual mutations within the
glycosylation sites of the transmembrane protein had no effect on envelope protein function
(Dedera et al., 1992). However, a contrasting study showed that a single mutation in the Asn-
642 residue disrupted gpl60 processing (Dash et al., 1994). The differences in the results is
thought to be a reflection on the experimental protocol used, that is the type of cells used to
infect with the mutated proviruses. When three of the five potential glycosylation sites were
mutated, Asn-621, Asn-630 and Asn-642, the cleavage of gpl60 was slower, and syncytia
formation was reduced suggesting a modification in the presentation of the fusion domain
(Fenouillet et al., 1993). These mutations also resulted in a non-glycosylated transmembrane
protein suggesting that the other two potential glycosylation sites are non-functional
(Fenouillet et al., 1993). Subsequent experiments with all three mutations showed that the
reduction in syncytia formation and gpl60 processing was due to the retention of gpl60 in the
rough E.R./ ris-Golgi compartments (Fenouillet and Jones, 1995). Since cleavage of gpl60
occurs in the rraws-Golgi (see section 1.8.2), the observed reduction in its processing can be
explained by its retention, and not by the reduction in glycosylation (Fenouillet and Jones,
1995).
The function of carbohydrate residues on the envelope proteins of MVV is not known,
although removal of sialic acid from the envelope glycoprotein of CAEV suggested that these
residues may be involved in protection from neutralizing antibodies and host cell proteases,
but were dispensable for the infectivity of the virus (Huso et al., 1988).
The existence of O-linked oligosaccharides has recently been demonstrated on HIV-1
gpl20 (Bernstein et al., 1994). O-linked glycosylation is less refined than N-linked
glycosylation. It is mediated by transfer of N-acetylgalactosamine to a serine or threonine
residue, followed by the addition of other sugar residues, such as fucose and sialic acid.
Treatment of gpl20 with neuraminidase followed by O-glycosidase resulted in a reduction in
molecular weight suggesting the presence of O-linked glycosylation, but the function of these
residues is not known (Bernstein et al., 1994). A prominence of O-linked oligosaccharides on
the surface of the envelope protein of CAEV has been proposed (Huso et al., 1988).
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1.8 Viral glycoprotein assembly into virions: oligomerization and proteolytic
cleavage
1.8.1 Oligomerization
Prior to transport to the Golgi apparatus, oligomerization of retroviral envelope proteins
occurs in the E.R.. The oligomerization of HIV-1 glycoproteins will be discussed as an
example of lentivirus oligomerization. Studies with HIV-1 showed that the transmembrane
protein gp41, existed as homomeric tetramers (Pinter et al., 1989). These oligomeric
complexes were stable under mild reducing conditions and were recognised by antibodies
present in patients sera (Pinter et al., 1989). Further investigation of the gp41 protein showed
that the ectodomain was required for gp41 oligomerization (Earl et al., 1990). This domain,
spanning amino acids 68-129, stabilised gpl60 tetramers in a noncovalent fashion (Earl et al.,
1990). The ectodomain overlaps with the predicted a-helical structure, which contains a
leucine-zipper motif. Leucine zippers within cellular proteins are well characterized as
forming dimers with transcription factors, and the proposed role of this motif in the
dimerisation of gpl60 was investigated. Initial reports suggested that this leucine-repeat motif
was not involved in oligomerization, since the substitution of leucine residues with proline to
disrupt the a-helix did not destabilise gpl60 oligomers (Chen et al., 1993). However, others
found that deletions in the N-terminus of the ectodomain resulted in the disruption of gp41
oligomers but not gpl60, whereas deletions in the C-terminus did not affect either gp41 or
gpl60 oligomerization (Poumbourios et al., 1995). Deletion in both these regions resulted in
monomelic gp41 and gpl60, indicating that both the N-terminus and other regions of gp41 are
required to maintain the oligomeric structure of gpl60 (Poumbourios et al., 1995). It is
suggested that gp41 oligomerization is less stable than that of gpl60.
The above studies demonstrated that both gpl60 and gp41 are able to form oligomers.
Studies with a truncated form of gpl60 demonstrated that gpl20 is also able to oligomerize in
the absence of gp41 (Hallenberger et al., 1993). This is consistent with data that cleavage of
gpl60 oligomers does not disrupt oligomerization but results in both gp41 and gpl20
oligomers (Weiss et al., 1990), and in fact oligomerization is a prerequisite for proteolyitc
cleavage (Gabuzda et al., 1992). Oligomerization of the transmembrane protein of CAEV has
been demonstrated (McGuire et al., 1992), but the absence of a leucine-zipper motif within
this protein means it may use different mechanisms for oligomerization than HIV-1.
In summary, it appears that the glycoproteins of HIV-1 exist as tetramers, and
oligomerization involves the leucine-zipper motif located in the ectodomain of gp41, as well as
other motifs not yet defined. Disulphide bond formation also occurs in the E.R., and thus
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correct folding, oligomerization and subsequent glycosylation are all required for the cleavage
of glycoproteins and assembly of virions.
1.8.2 Proteolytic cleavage of envelope precursors
The envelope precursors of lentiviruses must be cleaved for virus infectivity (McCune et al.,
1988). The proteolyitc cleavage of HIV-1 gpl60 results in the gpl20 surface protein and the
gp41 transmembrane protein (Willey et al., 1988). Mutations in the tryptic-cleavage site of
gpl60 resulted in a reduction in virus infectivity and syncytia formation (McCune et al.,
1988). This tryptic-like cleavage site, Arg-Gln-Lys-Arg, is conserved in all lentiviruses,
including MVV (Sonigo et al., 1985). Studies looking at post-translational processing of the
envelope proteins of FTV suggested the existence of two precursors (Verschoor et al., 1993). A
150kDa protein is initially seen in FIV-infected cells and this is replaced by a 130kDa protein,
which becomes cleaved into gplOO and gp35 (Verschoor et al., 1993). It is believed that the
150kDa precursor is cleaved to the 130kDa protein by removal of the signal peptide. Two
precursor species are also seen with MVV, a 150kDa species followed by a 135kDa protein
(Vigne et al., 1982). Nucleotide analysis of MVV predicts that the 135kDa protein is a
precursor and is cleaved to a gp90 and gp46 protein, although this has not been
experimentally proven (Sonigo et al., 1985). The existence of two precursor species has not
been described for HIV and it is suggested that the removal of the signal peptide of HIV-1
occurs co-translationally, presumably as the polypeptide is being translocated through the
lipid bilayer of the E.R.. The difference between these lentiviruses may be a consequence of
the difference in the length of N-terminal tail preceding the signal peptide (see 1.7.1).
The site within the cell where proteolytic cleavage occurs is debatable. In HIV-1, it is
understood that cleavage occurs after it has been translocated from the E.R. and thus is
dependent on the correct folding and oligomerization of the precursor, gpl60 (Dewar et al.,
1989). The use of transport inhibitors suggested that cleavage of HIV-1 gpl60 occurred in the
cis/medial-Golgi compartments (Dewar et al., 1989). A recent study with HIV-1 contradicts
this data since they demonstrated using low temperature incubations and membrane traffic
inhibitors that cleavage occurred post trans-Golgi (Kantanen et al., 1995).
Furin has been suggested as the protease responsible for cleaving the HIV-1 gpl60
precursor, since co-expression of furin and gpl60 in vaccinia viruses was required for gpl60
processing (Hallenberger et al., 1992). Inhibitors of furin prevented cleavage to HIV-1 gpl20
and gp41 (Hallenberger et al., 1992). Coexpression studies with baculovirus-derived HIV-1
glycoproteins and baculovirus-derived furin showed that this enzyme is also capable of
cleaving the V3 loop of gpl20 (Morikawa et al., 1993). The role of V3 loop cleavage is not
fully understood since the exposure of the cleavable domain in virion-associated gpl20 is not
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known (Morikawa et al., 1993).The role of fuiin in vivo is debatable since cleavage has been
shown to occur in cells not containing furin (Ohnishi et al., 1994).
1.8.3 Virus assembly
The assembly of MVV has not been widely studied. Following accumulation of the vims
envelope at the plasma membrane, vims assembly occurs. It is the gag proteins that are
responsible for vims assembly and budding, and only a brief overview will be presented below
in reference to HIV assembly.
The gag precursor assembles to an immature core structure which is then cleaved by
the vims protease, encoded by the pol gene, to the matrix (MA)(pl6), capsid (CA)(p30) and
nucleocapsid (NC)(pl4) proteins (reviewed by Wills and Craven, 1991). It is the matrix
protein that is thought to play a major role in vims assembly, since deletions in this protein
disrupts the formation of vims particles (Wills and Craven, 1991). Immuno electron
microscopy of HIV-1 particles reveals a spherical, sheet-like appearance locating the matrix
protein underneath the lipid envelope of the vims (Gelderblom et al., 1987). The gag
precursor of HIV, in common with other retrovimses (Schultz and Oroszlan, 1983), is
myristoylated at the amino terminal, which after cleavage results in the matrix protein
retaining this fatty acid tail. The function of this moiety is thought to be important for
quaternary structure and involvement in protein-protein or protein-lipid interactions.
Substitution of the N-terminal glycine residue, to which myristic acid is attached, with an
alanine residue resulted in the loss of myristic acid on the gag precursor and disrupted vims
assembly and formation of infectious particles (Bryant and Ratner, 1990). The noimal
processing of the gag precursor was impaired as was association with the lipid envelope,
indicating the importance of myristoylation in membrane targeting (Bryant and Ratner, 1993).
Due to the proximity of the matrix protein to the lipid envelope, an association with
viral glycoproteins is postulated, presumably with the the C-terminus of gp41 (see section
1.7.1). Studies involving deletions in the matrix protein of HIV-1 have shown that the N-
terminus of the matrix protein is required for a stable association of the envelope protein
within virions (Dorfman et al., 1994, Brody et al., 1992). There is an uncertainty as to which
portion of the envelope glycoprotein the matrix protein is associated. There are reports that the
cytoplasmic tail of gp41 is essential for vims budding (Dubay et al., 1992), whereas other
data has suggested that it is dispensable for vims assembly (Earl et al., 1991). It may be
possible that the matrix protein can form an association with the hydrophobic, transmembrane
portion of gp41. Deletions within other regions apart from that involved with myristoylation
have identified other domains in the matrix protein that are required for virus assembly
(Spearman et al., 1994). However, complete removal of the matrix protein, except for the
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residues involved in myristoylation and a few residues at the C-terminus, did not affect virus
assembly, but these studies did suggest an association of the matrix protein with envelope
proteins (Wang et al., 1993). The differences between the data produced by Wang et al.
(1993) and Spearman et al., (1994) probably lies in the experimental design such that the
effect of changing a few amino acid residues will have a more subtle effect on protein function
in vitro than complete deletion of the matrix protein.
By using recombinant vaccinia vectors, virus assembly can take place in the absence
of envelope proteins (Shioda and Shibuta, 1990). The presence of the pol gene is required for
the complete processing of the gag precursor, and this processing was shown to occur post-
assembly (Shioda and Shibuta, 1990). HTV has an additional regulatory protein, vpu, not
found in other retroviruses, that is expressed at the later stages of virus formation. It has been
shown to influence the gag precursor prior to its processing into the individual gag proteins
(Gottlinger et al., 1993). HTV-1 vpu was also shown to affect the processing of gag precursors
from related viruses, such as MVV, that do not encode a vpu-like protein. Since the matrix
protein of MVV is not myristoylated (Towler et al., 1987), the function of myristic acid in
virus assembly remains ambiguous. It is proposed that vpu may serve as a substitute of a host
cell factor in HTV-1 infection (Gottlinger et al., 1993).
Preliminary studies looking at the budding of HIV from polarized epithelial cells, indicated
that it is the envelope protein that governs the site of virus budding (Owens et al., 1991). In
the presence of envelope protein, budding occurred at the basolateral surface of epithelial
cells, whereas in its absence budding occurred both at the apical and basolateral surface
(Owens et al., 1991). The significance of this data in vivo may be through virus entry into the
host via the mucosal membrane, such that virus particles would then bud directly into the
blood stream for transport through the body.
1.9 Viral receptors
The entry of viruses into their host cells is mediated by their attachment to the surface of the
target cell. This is accomplished via a virus attachment protein (VAP) which forms the coat of
enveloped viruses or the capsid of non-enveloped viruses. The binding of the virus attachment
protein to its receptor brings the virus into close proximity to the cell surface providing the
opportunity for virus-cell fusion and infection. The virus receptor is defined as a host surface
component that participates in virus binding and facilitates virus infectioa The receptor also
determines the host range and the tissue tropism of the virus. For example, Epstein-Barr virus
infects B-lymphocytes and its receptor, C3d receptor CR2, is present on the surface of these
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cells (Fingeroth et al., 1984). However, in the case of the poliovirus which replicates only in
the gut and motor neurone cells, the tropism is not fully controlled by the distribution of its
receptor. In fact, the mRNA of its putative receptor, the lymphocyte homing receptor CD44
(Shepley and Racaniello, 1994), can be found in cells not infected by the virus. It is possible
that a post binding event is required to confer the host cell specificity and virus attachment
(Mendelsohn et al., 1989).
Recent identification of virus receptors has been facilitated by the use of recombinant
DNA technology and monoclonal antibodies. A panel of monoclonal antibodies against a
variety of cell surface markers can be used to initially screen for inhibition of infection, and
then the gene of the putative receptor can be transfected into a cell not normally expressing
this molecule and assessed for its ability to allow virus infection. This approach was used for
the identification of the receptor for HIV-1 as CD4 (Klatzmann et al., 1984, Dalgleish et al.,
1984, Maddon et al., 1986). Other methods are available for identifying a receptor molecule.
The virus overlay protein blot assay (VOPBA) is of some use (Boyle et al., 1987), but only
when receptor activity is expressed as a single polypeptide and interaction is not destroyed by
denaturation of the protein. Carbohydrate receptors can be identified by separating glycolipids
by thin layer chromatography and probing with virus, in a similar manner as a VOPBA.
Monoclonal antibodies to different carbohydrate moieties can be used for inhibition of
infection studies. One consideration when commencing these studies is that viruses from the
same families do not necessarily use the same type of receptors.
Virus receptors may be simple carbohydrate molecules or lipids, or more complicated
proteins that may function as recognition molecules on cells. Influenza viruses and
paramyxoviruses utilise sialic acid residues (Gottaschalk, 1958), and are thought to bind by
hydrogen bonding and van der Walls forces (Weiss et al., 1988). Phosphatidylserine and
phosphphatidylinositol are recognised by vesicular stomatitis virus (Mastromaiino et al.,
1987). The more complex polypeptide receptors include members of the immunoglobulin
superfamily, such as CD4, the receptor for HTV (Dalgleish et al., 1984, Klatzmann et al.,
1984), the intercellular adhesion molecule 1 (ICAM-1) for the ihinovirus (Greve et al., 1989,
Staunton et al., 1989) and aminopeptidase N (CD13) for human and porcine coronaviruses
(Yeager et al., 1992, Delmas et al., 1992). Other receptor protein molecules include hormone
receptors, such as the epidermal growth factor receptor for vaccinia virus (Eppstein et al.,
1985), and neurotransmitters, including the acetylcholine receptor for the rabies virus (Lentz
et al., 1982).
The CD4 receptor for HIV has been the most widely studied of the lentiviral receptors. Initial
observations that the CD4+ subset of T lymphocytes were the main target cells of HTV
infection lead to the confirmation of its identity (McDougal et al., 1985/1986). Monoclonal
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antibodies to CD4 blocked virus-induced syncytia formation (Klatzmann et al., 1984), gpl20
coprecipitated with CD4 (McDougal et al., 1986) and CD4 expressed in human CD4" T-cells
conferred the cells susceptible to HIV infection (Maddon et al., 1986).
CD4 is a 58kDa transmembrane glycoprotein belonging to the immunoglobulin gene
superfamily. The cytoplasmic portion is divided into four domain loop structures, D1 to D4
(Maddon et al., 1985). CD4 is predominantly expressed on the surface of T lymphocytes and
is also present on monocytes/macrophages, B cells and certain cells of the central nervous
system. The D1 domain has been shown to contain the gpl20 binding domain (Richardson et
al., 1988) and this has been further mapped to the complimentarity-detemiining region 2
(CDR2) loop (Landau et al., 1988, Arthos et al., 1989). Mutational studies revealed that
residues 42-49, within the CDR2 loop, were required for gpl20 binding (Petersen and Seed,
1988). The CDR3 region has also been implicated in HIV entry, although it lies on the
opposite face from the CDR2 loop. Initial studies with synthetic peptides indicated that it was
involved in the fusion process (Berger et al., 1991). However, further work revealed that this
interaction was not specific since these peptides could also disrupt the fusion activity of the
human T-cell leukaemia virus I (Repke et al., 1992). Thus the role of CDR3 in HIV binding is
ambiguous at present. There is some evidence that a flexible hinge situated between domains 2
and 3 may influence HIV entry since monoclonals to this region are able to block entry but do
not effect vims binding (Brady et al, 1993, Hearly et al., 1990).
The principal domain in gpl20 for CD4 binding has been mapped to the C-terminus
by mutational studies (Pollard et al., 1991, Pollard et al., 1992). A combination of monoclonal
antibody mapping and site-directed mutagenesis has finely defined 3 major regions for CD4
binding. These are residues 256-262 in the C2 domain, residues 368-389 in the C3 domain
and residues 421-457 in the C4 domain (Cordinnier et al., 1989, Lasky et al., 1987). Antibody
epitope mapping has also shown that C4 and C3 domains only are likely to be exposed on the
surface of gpl20, and thus these will directly interact with CD4 (Olshevsky et al., 1990,
Moore et al., 1994). Mutagenesis of single amino acids within these domains has indicated the
importance of these residues in retaining the structure of gpl20 required for CD4 interaction
(Cordonnier et al., 1989).
It has been observed that although expression of CD4 on mouse cells allows vims
binding, this is not sufficient for viral entry (Maddon et al., 1986). In fact, studies with
vaccinia-derived CD4 and gpl20 showed that only human cells expressing these proteins
could support fusion (Ashom et al., 1990). Therefore, the existence of accessory molecules to
CD4 have been implicated in vims entry (Stefano et al., 1993). The leukocyte functional
antigen 1 (LFA1) has been associated with HIV entry by the virtue that monoclonal antibodies
to this molecule inhibit vims fusion (Hildieth and Orentas, 1989). Presumably interaction of
LFA1 on the surface of T-cells with HIV-1 infected cells will bring CD4 and gpl20 into close
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proximity for interaction. The intracellular adhesion molecule 3 (ICAM3) has recently been
implicated in HIV entry since monoclonal antibodies to ICAM3 inhibited syncytia formation
and virus entry (Sommerfelt and Asjo, 1995). ICAM3 is present on the surface of lymphoid
cells, monocyte/macrophage cells and dendritic cells, and thus shares the host range of HIV
infection in vivo. There is evidence that Fc and complement receptors may enhance uptake of
opsonised virus (Homsy et al., 1989) such that anti-gpl20 antibodies bound to infected cells
interact with Fc receptors and increase the efficiency of virus entry. There is some controversy
as to whether this enhancement is dependent or independent on CD4 (McKeating et al., 1990,
Takeda et al., 1990). A cellular protease has been proposed as an accessory molecule to CD4
via cleavage of gpl20 (Morikawa et al., 1993). The V3 loop within gpl20 contains a
conserved motif which is a substrate to the dipeptidyl peptidase IV activity of the T cell
activation antigen, CD26 (Callebaut et al., 1993). Coexpression of CD4 and CD26 allows
virus entry and this is inhibited by monoclonal antibodies to this enzyme (Callebaut et al.,
1993). These results have been met with some scepticism, and other workers have been unable
to demonstrate a role for CD26 in HIV infection (Cohen, 1993, Wang et al., 1995).
HIV infection has been demonstrated in CD4" cells, particularly those of the central
nervous system (Harouse et al., 1989). The receptor was identified as galactosyl ceramide
since monoclonal antibodies to this molecule inhibited virus entry and gpl20 binds specifically
to galactosyl ceramide and no other glycolipid (Harouse et al., 1991, Bhat et al., 1991). A
combination of monoclonal mapping and thin layer chromatography to separate glycolipids
indicated that the V3 loop or sites within close proximity are involved in specific interaction
with galactosyl ceramide (Cook et al., 1994). Analysis of a CD4~/Gal-Ser+ cell line with
chimeric viruses, derived form a positive or negative infection phenotype, indicated that the
V3, V4 and V5 loops are all involved in binding of HIV gpl20 to galactosyl ceramide
(Harouse et al., 1995). HIV also infects cells of the placenta in a CD4-independent manner.
Probing a placental cDNA library, identified a membrane-associated mannose-binding lectin
to which gpl20 bound (Curtis et al., 1992).
The existence of two receptors for one virus is not unique to HIV. Herpes simplex vims
glycoprotein C binds to heparin sulphate, while the glycoprotein D binds to an unidentified
protein (Spear, 1993). The fibre protein of adenovims type 2 binds to an unknown receptor
and the penton base protein binds to integrins and 0^5 (Wickham et al., 1993). The
activity of the two receptors may be cofunctional such that these receptors will modulate each
other or act complementary. Alternatively, the receptors may act sequentially. This may be
explained by the relative binding affinity of each receptor for the vims. The binding of the
virus to the first receptor could be rapid followed by a stronger association with the second
receptor leading to vims entry. Thus the initial binding step may be weak enough to allow the
24
virus to 'browse' over the surface of the cell until it comes into contact with the second
receptor required for virus penetration (reviewed by Haywood, 1994).
Secondary binding has been shown to occur only at physiological temperatures, and is
usually irreversible committing the virus to penetration. Examples of viruses that show this
mechanism include the poliovirus and the herpes simplex virus. The initial binding of
poliovirus to the cells is followed by a temperature-sensitive step that is resistant to detergents
used to release the virus from cells (Lonberg-Holm, 1989). The binding of herpes simplex
virus to cells can be initially reversed with heparin, but this becomes irreversible on secondary
binding (Spear, 1993). Secondary binding may be brought about by changes in the
conformation of the VAP's or the receptor and thus increase binding affinity. Enveloped
viruses usually have their VAP's organised into clusters. The binding of one of the peptides to
the receptor may bring about a conformational change that allows stronger binding with the
remaining peptides within the multimeric VAP's. The spikes on the surface of HIV represent
oligomers of gpl20 associated with the transmembrane protein of gp41. The addition of
soluble CD4 results in the release of gpl20 from the cell only at 37°C, suggesting a strong
and stable interaction (Hart et al., 1991). Monoclonal mapping studies have shown that gpl20
undergoes a conformational change on binding to CD4 (Sattentau and Moore, 1991).
Rearrangements in the oligomeric spikes may influence membrane fusion by exposing the
fusion domains and rearranging the spike structure to allow the lipid bilayers to come into
close proximity for membrane fusion.
The identity of the receptor for MVV has not been fully characterized. VOPBA experiments
revealed that MVV binds to a 30kDa protein present in sheep choroid plexus cell and this
binding can be blocked by anti-sheep MHC classl! (Dalziel et al., 1991). Antisera to sheep
MHC classll was unable to block infection, although soluble MHC classll did block infection.
This suggested that MHC classll may only act as a co-receptor (Dalziel et al., 1991). The
existence of a secondary receptor is postulated since MVV does not infect all cells expressing
MHC classll in vivo, such as T lymphocytes. There have also been reports of a 50kDa protein
in goat synovium cells to which MVV binds (Crane et al., 1991a). These workers also
describe MVV binding to 15 and 30 kDa proteins (Crane et al., 1991a).
In summary, the study of virus receptors is of paramount importance for understanding the
initial stages of virus infection and viral tropism. With more refined DNA techniques, the use
of transgenic mice expressing a human receptor can be used to study viral pathogenesis, the
effects of antivirals and vaccines. The identification of the binding domains within the viral
receptor and the VAP's allows the potential for raising antivirals. These can be in the form of
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antibodies to these binding sites, anti-idiotype antibodies and ligands for blocking these
binding sites.
1.10 Virus Fusion
The entry of enveloped viruses into cells is mediated by attachment to the cellular receptor, as
discussed above, followed by virus fusion with the cellular membrane. Some enveloped
viruses utilise the receptor-mediated endocytosis pathway. Endocytosis is a common
physiological feature of cells and involves the ingestion of variable sized particles into the cell.
Receptor-mediated endocytosis allows the selection of specific molecules, such as hormones,
nutrients and growth factors. By binding to receptors on the cell surface, viruses will be
internalised into coated vesicles. These vesicles loose their coats to form endosomes. The
acidic environment of the endosome enables a conformational change in the envelope
glycoprotein which allows fusion with the endosomal membrane and release of the virus core
into the cytoplasm (reviewed by Marsh, 1984). Uncoating at various acidic pH's depends on
the virus. Semliki Forest virus uncoats at a pH close to neutral, whereas Influenza viruses
require a more acidic pH of 5 for uncoating. Membrane fusion and release of nucleocapsids is
completed before endosomes deliver their contents into lysosymes where enzymes will actively
degrade any viral or cellular components. The mechanism of fusion has been most widely
studied with influenza (Marsh and Helenius, 1989). It is thought to be mediated by
hydrophobic interactions between the fusion domain of the virus and the cellular membrane.
The close proximity of the two membranes leads to local dehydration and a change in lipid
configuration. This leads to fusion between virus and cellular membranes, and can occur at a
single site for the release of the nucleocapsid into the cell (reviewed by Marsh and Helenius,
1989). The fusion peptide of lentiviruses is also hydrophobic and thus the fusion mechanism is
likely to follow these events.
Retroviruses, including HIV, fuse to the cell at neutral pH (Stein et al., 1987, McClure et al.,
1988b, McClure et al., 1990), and entry occurs either by fusion with the plasma membrane or
by a pH-independent endosomal pathway. The fusion mechanism of HIV has been the most
thoroughly investigated of all lentiviruses. Various lines of evidence suggest that it is the
binding of gpl20 to CD4 that activates fusion. The addition of soluble CD4 to infected cells
results in the shedding of gpl20 (Hart et al., 1991), as discussed in section 1.9. The
physiological importance of this event is not fully understood, but it would appear that gpl20
shedding results in the exposure of the fusogenic domain. However, shedding has been shown
not to be paramount as long as the fusion domain is exposed (Sattentau and Moore, 1991). In
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contrast to this, increases in infectivity on binding to soluble CD4 are seen with HIV-2 and
SIV, but not with HIV-1 (Allan et al., 1990). HIV-2 can also be induced to infect CD4~ cells
by incubation with soluble CD4 (Talbot et al., 1994). The reasons for these differences
amongst the primate lentiviruses remain ambiguous, but the reason may lie in the relative
stability of the gp120 association with the transmembrane protein in vitro.
Cleavage of gpl20 prior to fusion has also been proposed as a method for promoting
virus entry. The existence of a substrate motif for proteases on the V3 loop has already been
discussed (section 1.8.2) (Clements et al., 1991). It is envisaged that following cleavage of the
V3 loop, gpl20 is displaced to expose the fusion domain (Sattentau and Moore, 1991).
Studies have shown that the binding of soluble CD4 to HIV is accompanied by the cleavage of
gpl20 (Moore et al., 1991). This cleavage can be blocked by monoclonal antibodies to the V3
loop (Moore et al., 1991), and it is proposed that on binding to CD4 a conformational change
occurs on gpl20 to expose the V3 loop to cleavage. Absence of protease activity in CD4+
cells renders these cells unsusceptible to HIV infection (Werner and Levy, 1993). The
interplay between gpl20 shedding and the cleavage of gp 120 to expose the fusion domain is
still not fully understood. It has been suggested that the conformational changes in gpl20,
gp41 and CD4 are sequential, and gpl20 shedding may occur at the later stages of vims
fusion or may not occur at the cell surface at all (Moore et al., 1991). The use of soluble CD4
in these studies is also unsatisfactory since it does not represent the tme conformational status
of this molecule in vivo.
Following the exposure of the fusion domain, the events leading to vims fusion are not well
understood. The fusion domain present at the amino terminus of HIV gp41 was identified by
analogy with that of paramyxoviruses (Gallaher, 1987). Hydrophobic amino acid substitutions
to charged amino acids within this domain affects fusion by disrupting its amphipathic a-
helical stmcture (Kowalski et al., 1991). The CI and C5 domains of gpl20 have been
associated with gp41 (Helseth et al., 1991), by providing a pocket in which the extracellular
loop of gp41 will sit (Schultz et al., 1992). Site-directed mutagenesis within the zipper motif
region located in this extracellular loop showed that C-terminus residues were involved in
gpl20 association (Chen, 1994). Kinetic studies with gp41 have shown that CD4 remains
attached during the fusion process, and the CDR-3 region of CD4 has a critical role in vims
fusion (Broder and Berger, 1993). In addition, the V3 and V4 regions of CD4 are also critical
for vims entry (Poulin et al., 1991), and this data suggests that CD4 attachment is required
for vims penetration as well as binding. Association of CD4 with the vims particle within the
cell may delay the release of the vims core into the cytoplasm, or retain the nucleocapsid at
the plasma membrane halting the release of the vims genome and subsequent viral
transcription. Whether this is a protective mechanism of the host cell, or whether this allows
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the cell to become physiologically prepared for virus infection is not known. However, there
would appear to be a sequence of related events from virus attachment to fusion to
nucleocapsid entry. In addition to the fusion peptide at the N-terminus of gp41, other regions
have been found to be functionally active. As well as providing the anchorage of gp41 in the
membrane, residues within the hydrophobic transmembrane region are important for
membrane fusion (Owens et al., 1994). The cytoplasmic domain of gp41 has been shown to
play a role in virus penetration and uncoating, which are both post-fusion events (Gabuzda et
al., 1992).
The fusion epitope of MVV has been located within the hydrophobic region at the N-terminus
of the transmembrane protein, gp46 (Crane et al., 1991b). A peptide encompassing this
hydrophobic region was tested for its ability to fuse goat synovial membrane cells. The fusion
ability of this peptide and the ability of anti-peptide sera to block fusion suggested that this
hydrophobic region contained a fusion epitope. The interaction of the transmembrane
glycoprotein with the external glycoprotein, and the conformational changes between these
two proteins leading to fusion is not known.
1.11 Functional domains of lentiviral glycoproteins
The regions of HIV-1 envelope glycoprotein involved in receptor binding and virus-cell fusion
have been discussed in sections 1.9 and 1.10 above. One of the most widely studied of the
epitopes present on gpl20 is the V3 loop. It was first characterized for its importance as a
neutralizing domain, and its mapping is described in detail in Chapter 4. The V3 loop spans
amino acids 308 to 322 on the external envelope protein of HTV-1. As well as its
neutralization properties, it has also been implicated in cell tropism and its ability to be
cleaved by host proteases has suggested its role in cell fusion (discussed in section 1.10).
Synthetic peptides to the V3 loop are able to block virus-cell fusion suggested its role in
gpl20 binding to CD4 (Rusche et al., 1988). A region of 8 to 15 amino acids within the V3
loop has been mapped as crucial for determining the efficiency with which HIV-1 infects T
cells (Nehete et al., 1993).
Different strains of HIV-1 vary in their ability to infect different cell types. Using recombinant
viruses with mutations in their envelope region, data has accumulated as to identify the region
within gpl20 that influences the tropism of a given strain for macrophages (O'Brien et al.,
1990, Shioda et al., 1991). A 159 amino acid region encompassing the VI, V2 and V3 loops
has been mapped which does not include the CD4 binding domain (Shioda et al., 1991), and
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suggests that gpl20 alone determines the host cell tropism. Finer mapping of this region has
narrowed the macrophage-tropic region to 94 amino acids which include the whole of the V3
loop, and only 2 amino acids from the CD4 binding domain (Westervelt et al., 1991). These
authors suggested that the tropism of some strains for macrophages may lie in the specificity
of the proteases on the surface of macrophages. By transferring the V3 loop from a
macrophage tropic virus to a non-macrophage tropic virus, an alteration in tropism was
induced (Cann et al., 1992). This proves that the 94 amino acid region is involved specifying
viral tropism. It should be noted that these studies use T cell and macrophage cell lines, which
are not true reflection on events in vivo. In fact, most of the mutants described in the above
studies are able to infect PBMC and primary macrophages.
As was mentioned above, the V3 loop is of particular importance in generating neutralizing
antibodies. This is not the only region of HIV-1 envelope that is involved in neutralization.
The second conserved region of gpl20 has been implicated in inhibition of virus infection (Ho
et al., 1988). Antisera were raised to synthetic peptides to this region and shown to neutralize
a wide range of HIV-1 strains. This antisera did not block binding of gpl20 to CD4,
suggesting it is involved in post binding events. The existence of anti-C2 antibodies in the host
is a rare event (Ho et al., 1988), but the authors suggest the importance in using these peptides
to this region by inhibiting virus infection in vivo. Other regions to which neutralizing
antibodies are raised include the CD4 binding domain (Lasky et al., 1987), the V2 domain (Ho
et al., 1991, see chapter 4) and a conserved domain in gp41 (Muster et al., 1993). The
carbohydrate moieties have also been implicated in raising neutralizing antibodies (Hansen et
al., 1991). The relevance of neutralizing antibodies in vivo is not understood. Antibodies
isolated from the serum of infected individuals are capable of neutralizing laboratory strains,
but usually are ineffective in neutralizing primary, autologous virus (Weiss et al., 1986). The
reason why this occurs is not understood, but has important implications when interpreting
results obtained in vitro systems to the situation in the host. It is also important to take into
consideration the conformation of a given epitope in the native protein when interpreting
results obtained using synthetic peptides.
No functional epitopes in MVV have been described. Due to the limited strains of virus
available, no sequence comparisons can be made to identify variable and conserved regions,
and thus use these as a basis for epitope mapping as has been done for HIV-1. The following
two sections will review the knowledge of envelope protein interaction with the immune
system and the generation of antigenic variants in the face of neutralizing antibodies.
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1.12 Interaction of MVV with the host immune system and the role of envelope
Following infection of the host with MVV, there is an active humoral response. Serum
antibody is detected within the first six months after infection and steadily rises over a period
of two years (Gudnadottir and Palsson, 1966). These antibodies are able to neutralize vims
infection in vitro, but despite this humoral response vims infection persists in vivo
(Gudnadottir and Palsson, 1966). A second longitudinal study involving intracranial injections
of sheep with MVV confirmed the presence of neutralizing antibodies 4 weeks post infection,
followed by an increase over the next three months when a steady state level was reached
(Griffin et al„ 1978). Neutralizing antibody first appeared in the serum, but was also present
in the cerebral spinal fluid at later stages of infection (Griffin et al., 1978). The
characterization of the neutralizing antibodies was further studied to assess their affect on
vims entry in vitro (Kennedy-Stoskopf and Narayan, 1986). Using a variety of vims binding
temperatures, it was shown that the rate of binding of vims to the surface of permissive
fibroblast cells was faster than the rate of neutralization. In contrast, transformed macrophage
cells showed an increase in vims binding in the presence of neutralizing antibodies and that
infectivity was blocked at the RNA transcription level. It is noted, however, that the
neutralizing sera used in these assays is hyperimmune, and in vivo the antibodies titres would
be even lower affinity, supported by the fact that development of neutralizing antibody in the
host is slow and titres are low. It was proposed that the ability of vims to bind to the target
cells in the presence of an active humoral response may be the mechanism by which the vims
is able to persist (Kennedy-Stoskopf and Narayan, 1986). This is supported by the fact that
neutralizing ability of sera in vitro requires a long incubation period of up to 1 hour at 37°C,
which would be inappropriate in vivo.
Antibodies against the major core antigen, p25, are the first to appear following
infection, followed by the appearance of anti-envelope antibodies and antibodies to other core
proteins 4-8 weeks post infection (Kajikawa et al., 1990). This study used two strains of
MVV, one which is highly lytic in culture and a second which shows minimal lysis. The
appearance of anti-matrix, pl4, antibodies appeared sooner with the lytic vims than with the
non-lytic strain, presumably since it will be exposed to the immune system sooner in a lytic-
type infection. There was no difference between the antibody responses to p24 and envelope
antigens between the two strains. This longitudinal study used new-bom lambs which will
progress to the disease state more rapidly than adults, and thus the appearance of pl4 in
lyrically infected sheep may not be of significance in the field (Kajikawa et al., 1990).
The use of recombinant proteins has allowed the development of more refined assays
for analyzing antibody titres. An ELISA assay has been developed for the detection of anti-
p25 antibodies using a yeast-derived recombinant protein (Reyburn et al., 1992). The
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detection of p25 levels is widely used as a measure of HIV replication during infection, and
this assay provides the sensitivity to use in the detection of MVV infection. Expression of a
variety of MVV antigens in the pGEX bacterial system has shown that the N-terminus of the
transmembrane antigen, gp41, is the immunodominant antibody in infected sheep (Kwang and
Cutlip, 1992 a and b). These bacterially-derived recombinant proteins have the potential to be
used in a screening assay similar to that described for the p25 antigen above (see also Chapter
5 of this thesis). The immunodominance of the transmembrane protein has been more fully
characterized in CAEV (McGuire et al., 1992). Expression of two antigenically distinct
strains of the envelope protein of CAEV in the vaccinia system showed that the neutralization
epitope is likely to be conserved (Lichtensteiger et al., 1991). The recombinant proteins were
able to inhibit heterologous neutralizing antibodies in goat sera, as well as homologous
antisera. This suggests that the neutralization epitope is conserved between strains but it is the
variation in adjacent amino acids that will alter the conformation and affect the interaction of
the epitope with the host immune serum. The location of this neutralization epitope within the
envelope protein is not identified in this study. Recent studies using a lambda-expression
library have identified four immunodominant epitopes (Bertoni et al., 1994). These epitopes
all lie in the external domain of the transmembrane envelope protein. One of these epitopes is
conserved in other lentiviruses, such as HIV. Three distinct regions of the external envelope to
which sheep mount an immune response have been identified, using yeast-derived recombinant
fragments of MVV envelope protein (Carey et al., 1993). To date, the identity of the principal
neutralization domain in MVV is not known.
The appearance of anti-envelope antibodies, present in the synovial fluid, in CAEV
infection has been correlated to the severity of inflammatory lesions in the joints of infected
goats (Knowles et al., 1990). There was no correlation with anti-p25 levels in the blood. This
epitope has been mapped to the transmembrane protein (Bertoni et al., 1994). No such
association has been described for MW infection.
The presence of complement-fixing antibodies has also been described in lentiviral infections.
In MVV, complement-fixing antibodies are the first to be raised on infection, approximately 1
to 2 months post infection (Gudnadottir and Palsson, 1966). A localised production of
complement-fixing antibodies in the central nervous system has also been described, and may
explain the clearance of virus in this environment (Petursson et al., 1976). The relevance of
these antibodies in vivo is disputable since the characterization used a laboratory test which
may not be significant in vivo. In HIV, complement activation has been implicated as being
important for clearing virus by lysing virus infected cells or cell-free virus. The V3 loop of
gpl20 has been demonstrated as an important region for activating complement-fixing
antibodies (Spear et al., 1993).
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The presence of enhancing antibodies in lentivinis infections has proved a hindrance when
developing potential vaccines. These have been particularly problematic when using
recombinant envelope proteins as vaccines followed by challenge with the whole virus (Wang
et al., 1994, Sieblink et al., 1995). It is possible that the conformation of the recombinant
proteins affect the nature of antibodies raised. However, enhancement has also been observed
when using inactivated virus, as with MVV and CAEV vaccine studies (McGuire et al., 1986,
Nathanson et al., 1981). The observation that neutralizing antibodies are unable to prevent
virus binding and uncoating on the surface of macrophages (Kennedy-Stoskopf and Narayan,
1986) has been investigated further. It was shown that this mechanism may be due to the
binding of the Fc portion of the antibody to the Fc receptor on the surface of the macrophage
resulting in the internalization of the virus and thus enhancement of infection (Jolly et al.,
1989). Antibody-dependent enhancement is defined as the ability of antibody to enhance the
infection of the virus in the presence of fresh compliment. This suggests the role of a
compliment receptor. In fact, enhancing antibodies can also work with inactivated
compliment, but loose their activity by removal of the Fc portion. It has been proposed that
the FcRin is required for enhancement through macrophages in HIV infection (Homsy et al.,
1989).
The cell-mediated response to MVV infection is only just beginning to be understood. Early
reports described the presence of cell-mediated immunity in peripheral blood leukocytes
(Griffin et al., 1978). Following intracerebral infection a response was detectable within one
week after virus infection, which peaked at 1 to 2 weeks and then returned to basal levels after
4 to 6 weeks. These stimulated cells were detected in the cerebral spinal fluid, the spleen and
the lymph node as well as the blood stream. Lymphoid tissue is the primary region were the
immune response is initiated, and by manipulating the cannulation procedure in sheep the
early immune event in the lymph node and its ducts have been studied (Blacklaws et al.,
1995a). Histological examination of the lymph node after subcutaneous infection of MVV
shows an active immune response by the presence of large activated lymphocytes in the T cell
rich zones and a large number of plasma cells in the medullary cords (Blacklaws et al.,
1995b). Analysis of the efferent lymph duct showed the presence of T lymphocytes which
express MHC class n but did not express the IL-2 receptor (Bird et al., 1993). These
lymphocytes were further characterized as part of a pool of CTL precursors (Blacklaws et al.,
1994). The CTL precursors appeared in the blood stream 3 weeks post infection and remained
for up to 3 months (Blacklaws et al., 1994). Similar data has been found with CAEV
infection. The subset of CTL precursors in the circulating blood stream were characterized as
CD8+ lymphocytes (Iichtensteiger et al., 1993). Studies within the lymph node showed that
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the release of CTL precursors was linked to viral replication. This acute immune response
occurrs between 10 to 14 days post infection, although viral replication is detectable before 10
days (Blacklaws et al., 1995b). This indicates that this delay in the immune response may
allow the virus to establish persistence. Once the immune response is detected the number of
infected cells decrease followed by a drop in the number of T cells (Blacklaws et al., 1995b).
Thus it appears in the absence of viral antigen T cell proliferation decreases. The viral
proteins responsible for inducing a cell-mediated response are not known at present The cell-
mediated response of HTV infection has been more widely studied. This response however is
further complicated since the vims infects CD4 lymphocytes, and will not be reported here.
1.13 Antigenic variation of MW envelope glycoproteins
As was highlighted above, MW is able to persist in the host despite an active immune
response. The ability of the virus to escape immune surveillance has been partly attributed to
antigenic variation. Evidence for antigenic variation was gained through longitudinal studies
of experimentally infected sheep. Sheep infected with a given strain of MW all generated
neutralizing antibodies within the first six months, but these antibodies were unable to
neutralize a different strain (Narayan et al., 1977). After a 22 month period the virus isolates
were no longer susceptible to neutralization by the original serum, indicating the existence of
mutants. These mutants could be passaged in vitro without loss of the change in neutralization
properties suggesting they were stable mutants (Narayan et al., 1977). This study was
extended over a period of 3.5 years, where virus and serum samples were taken at various
time points (Narayan et al., 1978). The viruses isolated after 22 months were poorly
recognised by the original neutralization sera, as was seen in the earlier study. By looking at
the neutralization patterns over the three years the various virus isolates could be grouped into
three types. However, one of the variants was antigemcally similar to the original strain
suggesting the co-existence of the original strain and the variants. Alternatively the virus may
have mutated back to its original form. From this study it was claimed that antigenic mutants
were raised after the generation of neutralizing antibodies. The sheep eventually mounted
neutralizing antibodies against the variant strain (Narayan et al., 1978). The studies described
above have characterized MW mutants on neutralization properties. This work relies on the
fact that the original stock of virus was clonal. Data generated in a subsequent paper puts this
claim into dispute (Crane et al., 1988). This experiment involved the hyperimmunization of a
sheep with the original 1514 'clonal' strain of MW, and this resulted in the generation of
antibodies that were able to neutralize both the original virus and a variant, isolated from the
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earlier study (Narayan et al., 1978). This data suggests that the original virus was not clonal,
and this sheds doubt on the relevance of their earlier work.
Peptide mapping was carried out to ascertain which viral antigen was involved in
antigenic variation (Scott et al., 1979). Minor differences were seen in the envelope protein
only and not in the capsid proteins. Since these changes were small, it was postulated that the
variants had arisen from point mutations rather than recombination. To analyse where on the
viral genome mutants were occurring, RNaseTl oligonucleotide fingerprinting was carried out
on viral RNA of the antigenic variants. Small differences were seen in the 3' end of RNA,
which corresponds to the envelope region of the genome (Clements et al., 1980). Further
studies using a greater number of variants confirmed these results, and demonstrated that
these changes were commonly the same point mutation (Clements et al., 1982). These studies
also indicated that the variants rose from gradual point mutations in the original strain, and
were thus progressive. It should also be noted that these RNA fingerprinting studies were
crude and thus results can only be interpreted with caution.
Further evidence for antigenic variation being confined to the envelope region came
from studies using a panel of monoclonal antibodies (Stanley et al., 1987). By screening the
original parent strain and the subsequent mutant viruses from the earlier study (Narayan et al.,
1978), five epitopes were characterized that were implicated in antigenic variation. Three of
these epitopes were present on the original virus, and replaced on mutants by other epitopes
(Stanley et al., 1987). No similar changes were observed in the core protein. These
monoclonal antibodies were unable to neutralize the vims, and the authors claimed the
involvement of both neutralizing and non-neutralizing epitopes in antigenic variation. They
also claimed that earlier studies using polyclonal serum were unable to detect minor changes
in the envelope protein, and thus variation was probably are more frequent event than was
reported in other studies (Thormar et al., 1983). They suggest that single point mutations
within the envelope gene may have a significant effect on the three-dimensional structure of
the envelope, and this will result in the marked change in antigenicity of the protein (Stanley et
al., 1987).
Sequence comparisons of different strains of MVV have shown that the majority of
variation occurs within the env gene (Braun et al., 1987, Querat et al., 1990, Sargan et al.,
1991). Sequence comparisons between two strains of the 1514 isolate of MVV showed a
hypervariable region within the envelope protein (Braun et al., 1987), but it has not been
formally proved whether neutralizing antibodies are directed to this site. The role of
neutralizing antibodies in generating mutants is debatable. The fact that they are ineffective in
clearing vims from the host would indicate that their role in vivo is minor. Sequence
comparison of the EV1 strain propagated in vitro has shown that variation in the env gene can
arise in the absence of neutralizing antibodies (Carey and Dalziel, 1994).
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Antigenic variation has been described in a variety of viruses, most notably the Influenza
viruses. Mutations are seen in the haemaglutinin and neuraminidase proteins (Webster et al.,
1982). Of the lentiviruses, it is EIAV that shows the most marked variation. Its disease
progression differs from other lentiviruses, in that there are recurrent cycles of viraemia
followed by chronic disease episodes. This has been attributed to the constant emergence of
antigenic variants, followed by the response by the immune system (Montelaro et al., 1984).
The emergence ofvariation within the genome of lentiviruses may be expected due to the error
prone reverse transcriptase (Clements et al., 1988). Several other studies looking at the
emergence of variants and their potential role in pathogenesis has suggested that antigenic
variants may not be significant (Lutley et al., 1983, Thormar et al., 1983). These longitudinal
studies found that antigenic variation was a rare and random event, and that the original virus
co-existed with the antigenic variant They did not observe any correlation with the
development of antigenic variants and the severity of disease (Lutley et al., 1983). In
summary, it would appear that the role of neutralizing antibodies in generating antigenic
variants is debatable.
1.12 Aim of research project
The role of lentiviral envelope glycoproteins in the virus life cycle has been reviewed with
particular attention to HIY-1. In contrast, the functional epitopes within the envelope
glycoprotein of MVV are not known. It is understood to be a major target for neutralizing
antibodies, but the significance of this in vivo is not understood. The major epitopes to which
the neutralizing response is raised are not known. By analogy with HIV, the envelope
glycoprotein of MW would be expected to interact with the host cell receptor, and thus
influence the tropism of the virus. The regions of the envelope which are involved in
interaction with its receptor are not known.
To begin to address these questions, expression of the external glycoprotein (referred to as
gpl35 throughout the thesis) of MW as a recombinant protein was undertakea A source of
recombinant envelope would be of use both in functional studies and as an immunogea
Studies were undertaken to generate monospecific serum using the bacterial recombinants and
lectin-purified envelope from virions as sources of antigea The use of baculovirus derived
envelope to characterize the host cell receptor was also investigated
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CHAPTER 2: MATERIALS AND METHODS
2.1 MATERIALS
All chemicals were supplied by Sigma Chemical Co., Poole, Dorset, England, or Fisons
Scientific Equipment, Loughborough, England, unless stated otherwise. All enzymes used in
molecular biology were supplied by Northumbria Biologicals Ltd. (NBL), Cramlington, U.K..
Tissue culture reagents were purchased from GIBCO, Glasgow, U.K. and tissue culture
plastic ware was supplied by Nunclon, Denmark. Recipes for frequently used solutions are
given in Appendix 2.
2.2 METHODS
2.2.1 Tissue culture
2.2.1 i Mammalian cell culture
a] Establishing sheep fibroblast cell lines
Sheep fibroblast cell lines were derived from skin biopsies as described in Rheinwald and
Green (1977) and were a kind gift from Dr.B.Blacklaws, Department of Veterinary Pathology,
University of Cambridge. Cells were stored in liquid nitrogen at a concentration of
lxl06cells/ml in 90%FCS(v/v)/10%DMSO(v/v). Cells were resuscitated by thawing quickly
at 37°C and washing out the DMSO in 10%FCS(v/v)/DMEM(v/v). They were grown up as
monolayers in a T25 tissue culture flask at 37°C in the presence of 5%CC>2.
Cells were routinely grown in T150 tissue culture flasks with 10%FCS/DMEM. All medium
contained penicillin/streptavidin and L-glutamine, unless otherwise stated. When the
monolayer was approximately 90% confluent, medium was removed and cells washed twice
with versene followed by incubation with 2-3mls trypsin/versene at room temperature until
cells were no longer adherent. lOmls of 10%FCS/DMEM was added and cells split 1:3.
b] Visna Virus Strains
All experiments used the EV1 isolate of Maedi-Visna virus (Sargan et al., 1991).
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cj Preparation of virus stocks
Skin fibroblasts were grown to 80% confluency in T150 flasks. Medium was removed and
virus was added at a m.o.i. of 0.1 in 10ml 2%FCS/DMEM. Cells were incubated with virus at
37°C for 60 minutes with gentle agitation every 15 minutes to prevent cells drying out. A
further 20mls 2%FCS/DMEM was added and cells left for 6 to 8 days until approximately
50% c.p.e. was apparent. Medium was removed and clarified by centrifugation at 2 500xg for
5 minutes at 18°C. Supernatant was stored in l-5ml aliquots at -70°C and viral titration
performed as described below.
d] Titration of virus
96 well flat-bottomed tissue culture plates were seeded with lxl04cells per well in 100|fi
10%FCS/DMEM and left to grow overnight. 10-fold virus dilutions were made in
2%FCS/DMEM, medium removed from the inside 60 wells and virus dilutions added across
the plate, 50ul/well, six wells for each dilution. The 10th column was reserved for medium
only as a mock infection. Cells were incubated for 2-3 hours after which medium was
removed and cells were fed with 50|i.l 2%FCS/DMEM/well. The plate was fed with an
additional 50pl 2%FCS/DMEM/well 4 days later. After another 3 days cells were stained
with Giemsa stain as follows.
After removal of medium, cells were fixed in ice-cold acetone:methanol (1:1), 100|il/well, for
5 minutes, removed and air dried for 5 minutes. Cells were then incubated for 30 minutes with
1% potassium dichromate(w/v), 100(il/well. This was removed and cells fixed in
acetone:methanol as before. Giemsa stain was freshly diluted in water (1:1), and added to
cells, 100pl/well, for 5 minutes. Cells were washed in excess water and destained in water.
The plate was air dried and wells examined for presence of syncytia. The 50% tissue culture
infectious dose (TCIDso/ml) was calculated by the method of Reed-Meunch (1937).
e] Virus neutralization assay
96 well plates were seeded with lxl04cells/well in 10%FCS/DMEM and grown overnight.
Serial dilutions of heat inactivated sera (56°C for 30 minutes to inactivate compliment) were
incubated with 500 TCID50 visna virus overnight at 4°C. The next day medium was removed
from the inside 60 wells and virus/sera mixtures (50pl/well) were added to the first row and
doubling dilutions made across the plate using 2%FCS/DMEM containing appropriate
dilution of heat inactivated serum. After a 2 hour incubation, medium was removed and wells
were fed with lOOpl 2%FCS/DMEM. 7 days later cells were fixed and Giemsa stained as
described above. Neutralization was determined by decrease in virus titre, where antibody
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litres were defined as greatest dilution of sera which gave 50% reduction in virus titre
compared to controls.
2.2.1ii Insect cell culture
a] Establishing insect cell lines SF21 and H5 in monolayers.
The insect cell line SF21, supplied by CLONTECH, is derived from the ovarian tissue of the
fall army woim, Spodoptera frugiperda (Vaughn et al., 1977). Cells were grown in TC100
medium supplemented with 10%FCS and penicillin/streptomycin. H5 cells are derived from
the eggs of the cabbage looper, Trichoplusia ni, the natural host of Autographa californica
multiple nuclear polyhedrosis virus (AcMNPV) (Davis et al., 1993). Cells were grown in
serum-free medium, SF900.
Insect cells will survive at a pH 6.2-6.4, they grow reasonably well at any temperature from
room temperature to 30°C and do not require CO2. Cells were maintained at 27°C for
optimum growth giving a doubling time of 20-24 hours.
Insect cells were resuscitated by thawing at 37°C and adding 5mls of appropriate medium
which had been pre-cooled to 4°C. Cells were allowed to attach to T25 flask for 1-2 hours
and then medium was replaced with fresh medium. Medium was changed daily on H5 cells
until they reached confluence. Cells were passaged when 80-90% confluent by removing
medium and adding 5-10mls of fresh medium. Cells were harvested by knocking the flask
several times to dislodge the cells and split 1 in 4. Insect cells were maintained in T150 tissue
culture flasks.
b] Storage of insect cells in liquid nitrogen
Cells were harvested as described above. Cell viability was assessed using trypan-blue
exclusion (dead cells take up the stain). Cells that were at least 90% viable only were used to
make stocks. SF21 cells were adjusted to a cell density of 4xl06cells/ml in TC100/FCS
medium and chilled to 4°C. Cells were mixed with an equal volume of chilled TC100/FCS
containing 20% DMSO(v/v). 1ml aliquots in cryogenic vials were placed at -20°C for 1 hour,
followed by overnight storage in -70°C. They were transferred to liquid nitrogen the next day.
H5 cells were cryopreserved at a concentration of 3xl06cells/ml in ice cold medium consisting
of 45% conditioned medium(v/v) (medium removed from flask of growing cells)/45% fresh
medium(v/v)/10% DMSO(v/v). Cells were then placed at -20°C for 1 hour, at -70°C for 24
hours and then transferred to liquid nitrogen.
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c] Growing insect ceil lines as suspension cultures
Suspension cultures are useful for large scale preparation of recombinant proteins and
preparations of virus stocks. Healthy insect cells were seeded into 100ml of appropriate
medium at a density of 2xl05cells/ml and grown to the required cell density. Cells were grown
in a sterile Techne biological spinner (100ml) and cells were stirred gently using a magnetic
stirrer (model-IKA-combimag reo, Drehzahl electronic), specifically designed for tissue
culture to prevent heating of the plate and thus destruction of cells.
d] Propagation of baculovirus virus stocks
SF21 cells were seeded into a 100ml spinner culture at lxl05cells/ml and grown to a cell
density of 4xl05cells/ml (approx. 2 days). Cells were infected with baculovirus at a m.o.i. of
0.1 pfu/cell, by addition of calculated volume to spinner culture and grown for a further 4-5
days. Cell suspension was harvested into sterile 50ml tubes (Corning) and centrifuged at
lOOOxg for 5 minutes at 18°C to remove cells and debris. Supernatant was transferred to
sterile 15ml tubes and/or 1ml screw-top microfuge tubes and stored either at 4°C for short
term storage or at -70°C for longer term storage. The titre of the virus stock was determined
by plaque assay.
e] Baculovirus plaque assay
Plaque assays were used to isolate recombinant viruses and to titre virus. 35mm tissue culture
petri dishes were seeded with lxl06cells/1.5ml/dish and grown overnight or seeded with
1.5xl06cells/1.5ml/dish and incubated for 1-4 hours to use on the same day. Dilutions of virus
were made; 10 4,10"5 and 10"6. lOOpl of each dilution was used to infect a single petri dish, 2-
3 dishes per dilution. An appropriate dilution of BacPAK6 (Clontech), between 10"5 and 10"6,
and medium only were used as controls. Petri dishes were incubated for 1 hour at room
temperature after which the virus inoculum was removed. The cells were overlaid with 1.5ml
of 1% SeaPlaque agarose(w/v)(FMC Bioproducts)/10% FCS/TC100 pre-waimed to 37°C to
prevent agarose setting. The agarose was allowed to set and 1.5ml TClOO/FCS/dish
containing 450(il X-galactose (X-Gal, 25mg/ml stock in DMF, stored at -20°C)(Northumbria
Biologicals, U.K.) was added. Dishes were incubated at 27°C for 4-5 days. 1ml of 0.03%
neutral red/PBS (0.33%(w/v) neutral red/PBS stock, filter sterilised and stored in dark at
room temperature) was added to each dish and incubated at 27°C for 2-3 hours. Stain was
removed and dishes stored upside down overnight in the dark to allow the colour to develop.
Neutral red is taken up by healthy cells so that virus infected cells can been seen and counted
as clear plaques. Dishes infected with positive control virus, i.e. BacPAK6, will give blue
plaques in the presence of X-gal.
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Calculation ofvirus titre:
Plaques were counted from dishes giving a reasonable number of plaques (10-30 plaques).
The titre of the vims stock (pfu/ml) was calculated as;
average number ofplaques/dish x 10 x (dilution factor)"1
2.2.2 Molecular biology
2.2.2i Bacterial culture
a] Bacterial medium and agar plates
Bacteria were routinely grown in Luria Bertoni (LB) broth containing fresh ampicillin
(100|ig/ml) to select for ampicillin resistant bacteria since all plasmids used in this thesis
contained an ampicillin resistance gene. LB/agar plates were prepared by melting 1.5%
bacteriological agar(w/v) (Oxoid, U.K.) in L-Broth, cooling to 42°C and adding ampicillin
(lOOpg/ml). For the blue/white colony selection of pCRU™(kivitrogen, USA), agar/amp
plates were coated with 25pi X-Gal (40mg/ml stock in DMF) and incubated at 37°C for 1
hour before use.
b] Bacterial strains, growth and storage
Bacterial strains used in this project were competent E.coli JM101 (Yannish Perron et al.,
1985), DH5a™ (GIBCO, BRL) and INVa-F™ (Invitrogen, USA). Transformed bacteria
were streaked onto agar plates and stocks made from single colonies grown up in 10ml L-
Broth/ampicillin for 16-18 hours. Bacteria were stored in 20% glycerol(v/v) at -70°C.
c] Transformation of Competent Bacteria
Transformation of INVa-F™ cells was carried out as manufacturer's instructions using p-
mercaptoethanol to prepare bacterial cells for uptake of plasmids. The protocol is a
modification of the following basic method used for bacterial strains JM101 and DH5-a.
Bacterial cells were thawed out on ice and aliquoted into suitable quantities, usually lOOpl.
Plasmid DNA was added to the cells for a 30 minute incubation on ice followed by heat shock
at 42°C for 90 seconds to allow uptake of plasmid. 900pl L-Broth added and cells grown up
for 60 minutes to allow for the expression of ampicillin resistance gene. Cells were then plated
out onto agar plates. Transformation of bacteria with pCRII used "One-Shot" cells provided




a] Restriction enzyme digestion
DNA was digested for the purposes of checking DNA or for sub cloning fragments into
plasmids. DNA was digested in a maximum volume of 25|il using approximately 1 unit of
enzyme/|Xg of enzyme site. Restriction enzymes were supplied by Pharmacia, U.K. and
Northumbria Biologicals, U.K.. Digestions were carried out for a minimum of 1 hour at 37°C
in the manufacturer's buffer and then analysed by gel electrophoresis using uncut samples as
controls.
b] Preparation of linearised plasmid for cloning
Prior to ligation, it was necessary to remove 5' terminal phosphate groups from the digested
plasmid to prevent self ligation. A Shrimp Alkaline Phosphatase (SAP) (United States
Biochemical, USA) was used as an alternative to more commonly used Calf Intestinal
Phosphatase (CIP) since it is irreversibly deactivated at 65°C and is active in most restriction
enzyme buffers allowing it to be added directly to restriction digest mixture. 0.1 unit of SAP
was added per lpmol DNA termini (2.5pg of 3kb plasmid) for 1 hour at 37°C followed by a
15 minute deactivation at 65°C. To ensure the removal of protein contamination the DNA
sample was phenokchloroform extracted, ran on a 1% agarose gel and DNA purified as
described in section 2.2.2iii.
c] Ligations
lOOng of dephosphorylated plasmid was routinely ligated to an equal or excess molar ratio of
insert which had been cut with the same restriction enzymes. Ligation reactions were carried
out in 10|il volumes using 5 units of T4 DNA ligase and the manufacturer's ligation buffer.
Reactions were incubated for 16-18 hours at 12°C and appropriate controls were included to
ensure the efficiency of T4 ligase, SAP and transformation.
2.2.2iii DNA preparation, purification and analysis
a] Preparation of plasmid DNA
DNA preparations were carried out using the Qiagen purification method (Qiagen Inc., USA)
following the manufacturer's protocol. Minipreparations were made using Qiagen-Spin
columns (Qiagen Inc., USA) starting with 5ml bacterial culture grown from a single colony
for 16-18 hours. Maxipreparations were done using Qiagen tip-500 using 500ml culture of a
low copy number plasmid or 150ml culture of a high copy number plasmid. Essentially
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bacterial cells are lysed and DNA is denatured by alkali for a limited time. Chromosomal
DNA and protein are precipitated using potassium acetate, pH5.5 leaving the smaller plasmid
DNA in solution. After centrifugation the supernatant is put through the Qiagen column.
Qiagen columns are made from an anion exchange resin that allows binding of DNA which
can then be eluted by increasing the salt concentration and pH. Following elution from Qiagen
tip-500 it was necessary to precipitate the plasmid DNA using isopropanol to prevent
coprecipitation of salt. Plasmid DNA was resuspended in TE, pH8.0 and stored at -20°C.
b] Phenohchloroform extraction
This was carried out to remove contaminating protein from DNA samples. DNA samples were
extracted using phenol:chloroform:isoamylalcohol (25:24:1) twice followed by a single
chloroform extraction. DNA was then ethanol precipitated on dry ice for a minimum of 15
minutes using 2 volumes of ethanol and l/10th volume 0.3M sodium acetate, pH5.5. DNA
was pelleted 9 OOOxg for 10 minutes at 4°C, washed with 70% ethanol, air dried and
resuspended in TE, pH8.0.
c] DNA gel electrophoresis
DNA samples were analysed on a 1% agarose(w/v)/TAE gel containing lpg/ml of ethidium
bromide. DNA samples were prepared before loading by mixing them with DNA loading
buffer in a ratio of 1:2 loading buffer to sample. Gels were run at a constant voltage of 85-
lOOmV for 60-90 minutes and visualised by UV illumination of ethidium bromide.
EcoRI/Hindlll ADNA digests markers (Northumbria Biologicals Ltd., U.K.) were run
alongside the samples.
d] DNA extraction from agarose
DNA was run on a 1% low melting point agarose (SIGMA)(w/v) gel made up in TAE buffer
containing lpg/ml of ethidium bromide. TAE was used preferentially to TBE buffer since
agarose extraction by Genecleanll (Stratech Sci.) is more efficient using TAE buffer. The
agarose gel was run at 4°C at a constant voltage of 40mV to prevent melting of the agarose.
DNA was visualised by UV illumination and the required fragment cut out of the gel. DNA
was extracted and purified following the manufacturer's instructions for the Geneclean II kit
(Stratech Sci.) which uses a silica matrix for binding and purifying DNA.
e] Determination of DNA concentration
For small amounts of DNA (pg-ng) estimates were taken by visualising the intensity of
fluorescence under UV illumination compared to DNA markers of known concentration.
Larger quantities of DNA were measured by reading the absorbance at wavelength 260nm on
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a spectrophotometer. An O.D.260 of 1.0 is equivalent to 50pg/ml double stranded DNA
or 40pg/ml of single stranded DNA. Purity of the DNA was measured by calculating the ratio
O.D.260/28O where a ratio of 1.8-2.0 represents a sample clean from protein/phenol
contamination (Sambrook et al., 1989).
2.2.2iv Analysis of DNA sequences by blotting and hybridisation
a] Southern blotting by alkali method
Digested DNA samples were run on a 0.8% agarose(w/v)/TBE gel containing lpg/ml of
ethidium bromide for 16-18 hours at a constant voltage of 40mV. The gel was examined under
UV light to visualise DNA and photographed alongside a ruler to determine position of DNA
fragments. The gel was cut to size removing areas of gel that did not contain DNA and
transferred onto an uncharged nylon membrane using a modification to the method first
described by Southern (1975). The DNA was denatured by shaking the gel in 0.25M HC1 for
30 minutes, washed in distilled water and shaken for a further 20 minutes in 0.25M NaOH to
neutralize the DNA. Transfer was carried out onto a nylon membrane (Hybond-N,
Amersham) using 0.25M NaOH/1.5M NaCl as the transfer solution. The membrane was
prewetted in distilled water for 5 minutes prior to assembly of the transfer pyramid set up
using the Whatmann 3mm filter paper wick method described by Sambrook et al. (1989). The
transfer was carried out for a minimum of 2 hours after which the filter was washed in 2xSSC
and air dried. The DNA was immobilised by baking for 2 hours in a 80°C vacuum oven
between two sheets of Whatmann 3mm paper. The membrane was stored at 4°C until required
for hybridisation.
b] Slot blotting
Slot blotting was performed using undigested samples of DNA. Nitrocellulose strips (Hybond-
C, Amersham) were cut to the size of the slot blot manifold and soaked in dH20. The
manifold was assembled with the nitrocellulose paper and attached to a vacuum pump. 100-
200pl of the DNA sample was added to each slot and allowed to be sucked through the
apparatus. The blot was then soaked as follows: 5-10 minutes in 0.5M NaOH, 5-10 minutes
in 1M Tris-HCl, pH7.5 and 5-10 minutes in 2xSSC. The blot was placed on a piece of 3mm
Whatmann paper that had been soaked in 2xSSC and baked as described above. The blot was
air dried and stored at 4°C until ready for hybridisation.
c] Colony Hybridisation
Single colonies were transferred to agar/amp plates and allowed to grow for 16 hours at 37°C,
after which they were transferred to nylon filters (Hybond-N Nylon, 0.45u, 82mm diameter,
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Amersham UK). The filters were processed by a modification of the method first described by
Buluwela et al. (1989). The filters were placed on 3mm Whatmann paper that was pre-soaked
in 2xSSC/5% SDS(w/v) for 2 minutes and then microwaved at full power for 2.5 minutes in a
650W Matsui microwave oven. The filters were then rehydrated briefly in 2xSSC/0.1%
SDS(w/v) and then prehybridised in aqueous prehybridisation buffer for up to 6 hours at
65°C, followed by hybridisation for 16 hours at 65°C with 32P-labelled probe. The filters
were washed as described below and exposed to film (Kodak X-omat S). Colonies that were
recognised by the probe were picked and grown up into lOmls L-Broth/amp and analysed as
required.
d] Preparation of 32P-labelled probes
DNA fragments were purified from an agarose gel using the Geneclean II kit and labelled as
follows. 30ng of DNA fragment was mixed with 6jil of oligonucleotide labelling buffer and
made up to 28|il with distilled water. The mixture was boiled for 3 minutes to denature the
DNA and cooled slowly to room temperature preventing the DNA from reannealing. lOpCi
dCTP-a32P (Amersham, U.K., specific activity 400Ci/mmol) and lpl Klenow DNA
polymerase was added and the reaction carried out for 1-2 hours at 37°C. The reaction was
stopped with 170|Jl of lOxTE, pH8.0. Efficiency of labelling was calculated by removing
unincorporated nucleotide by acid precipitation with ice-cold 5% trichloracetic acid(v/v) on
glass fibre discs (Whatmann) (Sambrook et al., 1989). Discs were dried and counted on a
Beta counter (model 1450 Microbeta PLUS-Liquid scintillation counter, Wallac) in 1ml of
'Optiscint' Hisafe (LKB Scintillation products, Pharmacia Wallac, U.K.). The specific
activity was calculated and incorporation was usually between 10-15%, that is a specific
activity of 4xl07cpm/ug DNA. Immediately prior to hybridisation the labelled probe was
denatured by boiling for 5 minutes and quenching on ice.
e] Hybridisation of DNA blots
Blots were rehydrated in 6xSSC prior to hybridisation which was carried out in glass tubes in
a hybridisation oven. Blots were prehybridised in aqueous prehybridisation solution (APH,
lmlAPH/cm2 membrane) for 1-4 hours at 68°C. Labelled probe was added to fresh
prewarmed APH and blots hybridised at 68°C for 16-18 hours. Blots were washed twice in a
low stringency wash, 2xSSC/0.1%(w/v) SDS at 68°C, 30 minutes per wash followed by a
further two 30 minute washes in high stringency wash, 0.2xSSC/0.1%(w/v) SDS, at 68°C.
Blots were dried between two sheets of Whatmann 3mm paper and placed under film (Kodak-
Biomax MR) with an intensifying screen for 3-10 days at -70°C until bands were visible.
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2.2.2v DNA sequencing
Sequencing was performed using dideoxy chain termination that was a modification of the
basic method first described by Sanger (1977). Sequencing was carried out manually using
a-35S-dATP (Amersham: Specific activity 400Ci/mmol) or on an automated sequencer (DNA
sequencer model 4000L, Li-COR) using IRD41 labelled primers. Fig.2.1A lists the primers
used. Primers 193L and 415H were used in manual sequencing, and primers 124 and 125
were used in automated sequencing.
a] Preparation of DNA prior to sequencing
Mini preparations of DNA were carried out using Qiagen-Spin columns. DNA prepared by
this method gave sufficiently pure DNA to use in sequencing reactions and yields were in the
range of 3-5pg/ml bacterial culture. Prior to performing sequencing reactions using IR-Dye
labelled primers it was necessary to denature the DNA. Approximately 5-10pmol DNA was
made up to 18pl with distilled water and 2pl of freshly prepared denaturing buffer (2M
NaOH/2mM EDTA) was added. After a 5 minute incubation at 18°C the sample was
neutralized with 3pl of 3M sodium acetate, pH5.0 and 7ul of distilled water. DNA was
precipitated with 75 pi 100% ethanol for 15 minutes at -70°C, pelleted at 13 OOOxg for 15
minutes at 4°C in a microcentrifuge, washed with 70% ethanol and air dried. Sequencing
reactions were immediately carried out.
b] Sequencing with automated sequencer
i) Sequencing reactions
The sequenase V2.0 T7 DNA polymerase sequencing kit (USB, USA) was used to carry out
sequencing reactions and labelling was performed using the protocol supplied by the
automated sequencer model 4000 using IR-dye labelled primers 124 and 125.
ii) Sequencing gel electrophoresis
Gel electrophoresis was performed according to the protocol in the manufacturer's handbook.
TM
Long Ranger (AT Biochem, Malvern, USA) acrylamide was used to make up the gels in
TBE buffer.
c] Sequencing by manual methods
i) Sequencing reactions
TM
Thermal cycle DNA sequencing was performed using the Circumvent Thermal Cycle DNA
sequencing kit ( New England Biolabs., USA). It was not necessary to denature the DNA
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prior to carrying out sequencing reactions. Primers used are listed in Fig.2.1A and reactions
were carried out using a-35S dATP incorporation. Cycling conditions were 20 cycles of 20
seconds at 95°C, 20 seconds at 55°C and 20 seconds at 72°C using a Techne Programmable
Dri Block PHC-1 model.
ii) Sequencing gel electrophoresis.
Electrophoresis was carried out using a Bio-Rad Sequi-Gen apparatus. Gels were made up
with 6% acrylamide(w/v)(acrylamide:N,N'-methylbisacrylamide, ratio 19:1, Biorad)
containing 8M urea (Sigma, molecular biology grade) in 0.5xTBE buffer. Plates were sealed
at the base with 60ml acrylamide, 200pl TEMED and 400pi 25%AP(w/v) (Biorad). 120mls
of acrylamide was degassed and filtered through a 0.45pm filter and 100pi TEMED and 400p.
1 of 25% AP(w/v) added prior to pouring the gel. Gels were run in 0.5xTBE.
Prior to loading the gel, samples were heated to 75°C for 2 minutes and loaded into wells that
had been prewashed to remove traces of urea. Gels were prerun for 60-90 minutes until they
reached a temperature of 45°-50°C. Electrophoresis was carried out at 60 watts for 3-6
hours, dried down onto Whatmann 3mm paper at 80°C under vacuum (Biorad model 583 gel
drier) and put down under film (Kodak X-OMAT R film) for 16-18 hours at -70°C.
222\i Polymerase chain reaction
a] Primers and Template DNA
Primers used in this thesis are shown in Fig.2.1B. Various considerations were taken when
designing primers. Primers were made between 18-34 nucleotides long, were at least 50% GC
rich and contained no palindromic sequences to prevent formation of hairpin structures. It was
usual to end primers with a G or C residue at the 3' end. The primers were synthesised by
Oswell DNA Service (Department of Chemistry, Kings Buildings, West Mains Road,
Edinburgh, EH9 3JJ). Primer concentrations were approximately 0.05mmolar.
Unless stated otherwise, the template DNA was taken from a clone containing the whole env





Primers shown are annotated with the sequence to which they bind and the nucleotide position
in that sequence is also indicated.
Nucleotide positions for the MVV EV1 primers are from Sargan et al., 1991.
B. PCR Primers
Primers 1 and 2 were used to generate the envA fragment of gpl35 (see Chapter 3).
Primers 4975 and 4976 were used to generate the external portion of the envelope gene of
MVV (see Chapter 5).
Primers 27IP and 272P were used as control primers for amplifying the whole env gene of
MVV.
The appropriate restriction enzyme site are underlined for each primer.
The terminal codon of the MVV genome is shown in bold typing and the corresponding amino
acid for which it codes is given.
The nucleotide position of the terminal base of the MVV genome is also stated.





MVVEV1 nt 7135 nt7119
Primer 415H (reverse)
(5')- CCCACTGTTTATATTATGTCT -(3')


































40ng of DNA template and 25-50pmoles of each primer were used per reaction. Reactions
were made up as follows: lOOpl of reaction buffer (50mM KCl/lOmM Tris-HCl, pH8.8,
1.5mM MgCU, 3mM dithiothreitol (DTT)) (Ohara et al„ 1989), 0.17pg/ml of bovine serum
albumin, lOOpM of each dNTP (Pharmacia, UK) and 1.7 units of Thermus aquatus (Taq)
DNA polymerase (GIBCO, 5units/|il). Reactions were made up in 0.5ml microcentrifuge
tubes under sterile conditions and wearing gloves to prevent contamination. Before running the
reactions, samples were overlaid with lOOpl mineral oil to prevent evaporation. PCR cycles
were carried out using a Techne Programmable Dri Block PHC-1. Thirty cycles were run:
denaturation at 95°C for 0.6 minutes: annealing at 55°C for 2 minutes, extension at 72°C for
2.5 minutes, final extension for 7.5 minutes.
Pilot reactions were carried out using varying concentrations of DMSO, typically 0-10%
(v/v). DMSO is a denaturant that reduces secondary structure in the DNA template and is
thought to increase the efficiency of PCR (Pomp and Medrano, 1991, Roffs at al., 1992).
10% of the sample was analysed on a gel and the remaining 90% was cloned into pCRII™
plasmid using the TA cloning kit (Invitrogen, USA) following the manufacturer's instructions.
2.2.3 Protein analysis
2.2Ji Quantitation
To determine the amount of protein in a sample the BIO-RAD protein assay was used (Bio-
Rad, Germany). The assay utilises the shift in the absorbance maximum of acidic Coomassie
Brilliant Blue G-250 from 465nm to 595nm in the presence of protein. Protein concentration
was determined following the manufacturer's instructions using BSA made up in PBS(w/v) as
a standard. When proteins were not in a form suitable for using in this assay, such as when
bound onto glutathione beads, protein was concentration was estimated on a stained SDS-
PAGE gel.
2.2Jii One-Dimensional Gel electrophoresis of proteins
Proteins were separated by gel electrophoresis following the method described by Laemmli
(1970) using the Bio-Rad Mini Protean II slab gel apparatus with 0.75mm spacers. SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) used either a single concentration or a
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gradient of separating gel, using a stock solution of 30% acrylamide(w/v)/0.8%
bisacrylamide(w/v) and a final concentration of 0.38M Tris-HCl, pH8.7/0.1% SDS(w/v).
Acrylamide was polymerised using 0.05% AP(w/v) and 0.05% TEMED(v/v). The stacking
gel contained 3.48%acrylamide(w/v)/0.093%bisacrylamide(w/v)/0.145MTrisHCl,pH6.8/
0.12% SDS(w/v) and was polymerised with 0.05% AP(w/v) and 0.1% TEMED(v/v). Before
loading, samples were mixed in a ratio 1:1 with 2x SDS-reducing buffer and boiled for 3
minutes to denature the proteins. Electrophoresis was carried out in running buffer (0.05M
Tris-HCl/0.1% SDS(w/v)/0.37M glycine)for 40-50 minutes at a constant voltage of 200V.
Protein standard molecular weight markers were always run alongside the samples (Broad-
Range 200-6 kDa, Bio-Rad, Germany).
2.2.3iii Protein Detection
a] Coomassie Brilliant Blue staining
Gels were routinely fixed and stained in 0.25% Coomassie Brilliant blue R250(w/v) in 40%
methanol(v/v)/15% acetic acid(v/v) for 30 minutes followed by several destain washes in 20%
methanol(v/v)/5% acetic acid(v/v).
b] Silver Staining
This was used when amounts of protein in samples were too low to be detected by Coomassie
blue staining, typically 2 to 5 ng/protein band, using the protocol first described by Oekley et
al. (1980). Gels were prefixed in 50% methanol(v/v)/10% acetic acid(v/v) for 30 minutes
followed by 20 minutes in 5% methanol(v/v)/7% acetic acid(v/v). Gels were then fixed in 10%
glutaraldehyde(v/v) for 20 minutes and washed in distilled water extensively over 16 hours.
Proteins were detected by incubating gels in 0.1% silver nitrate(w/v) for 15 minutes. Bands
were developed using a 0.28M Na2C03 solution containing 0.05% formaldehyde(v/v). Once
the desired level of staining had been reached the reaction was stopped using solid citric acid.
A permanent record of the gels was taken by photographing the gel using a commercial gel
documentation apparatus (The Imager). Gels were also dried down for 1 hour under vacuum
at 80°C on a Bio-Rad model 583 Gel dryer.
c] Immunoblotting
Proteins were separated by SDS-PAGE and then transferred onto nitrocellulose membranes
(Hybond-C, 45u, Amersham, U.K.) using an Ancos semi dry electroblotter A (Harlow and
Lane, 1988). Gel, nitrocellulose and paper were pre-soaked in transfer buffer (25mM Tris-
HCl/20% methanol(v/v)). The gel was placed on top of the nitrocellulose and these were
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sandwiched between 6 sheets of 3mm Whatmann paper and electrophoretically transferred at a
constant current of 120mA. Following transfer the protein markers were cut off and stained in
5% Amido-Black(w/v) in 50% methanol(vA')/5% acetic acid(v/v)and destained in 50%
methanol(v/v)/5% acetic acid(v/v).
The nitrocellulose containing proteins of interest was blocked in 5% "Blotto" (5% milk
powder (Marvel)(w/v)/0.2% Tween20(v/v)/PBS) for 1 hour at 18°C. Primary antibodies were
diluted appropriately in 1% "Blotto" (1% milk powder(w/v)/0.1% Tween20(v/v)/PBS) and
membranes were incubated for 16 hours at 4°C. Membranes were washed 5 times in 0.1%
Tween20(vAO/PBS and incubated for 1 hour at 18°C in the presence of alkaline-phosphatase-
conjugated secondary antibody diluted in 1% "Blotto" followed by a washing step as before.
In some experiments an additional step was added to increase the intensity of staining. This
involved using a biotinylated secondary antibody followed by alkaline-phosphatase linked to
extravidin. Blots were developed by washing twice in 0.1M Tris-HCl, pH9.5 and using the
NBT western blot development solution. Once bands were visible and of suitable intensity
compared to background development was stopped by washing the blots in distilled water.
Blots were air dried and kept in the dark.
2.2Jiv Immunodetection
a] Enzyme-Linked Immunosorbent Assay (ELISA)
Immulon II or IV (Dynatech, USA) 96-well plates were used for ELISAs. Plates were coated
with antigen diluted in PBS (lOOul/well) and incubated either for 1 hour at 18°C or overnight
at 4°C. Plates were washed five times in 0.1% Tween20(v/v)/PBS with 1 minute soak
between each wash. This was followed by a blocking step using 2% BSA(w/v)/PBS
with 200pl/well for 30 minutes at 18°C. Antibody was diluted in the blocking buffer and
added to plates for up to 1 hour at 18°C, 100pl/well. Plates were washed as before and
alkaline phosphatase-conjugated secondary antibody added, 100pl/well, diluted in blocking
buffer and incubated for 1 hour at 18°C in the dark. Plates were washed and developed in
phosphatase substrate for up to 2 hours at 37°C and read on an ELISA counter (Titertek
Multiscan) with a 405nm filter.
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b] Immunoflourescence
i) Preparation of cell monolayers
Sterile 13mm round, glass cover slips were placed into wells of a 24-well tissue culture plate
(Nunclon) and lxl05cells/well were added, in a total volume of 0.5ml/well. Cells were
incubated at 37°C for 16 hours to allow cells to adhere to plastic. Fixing was carried out with
ice-cold 0.15M NaCl/ 80% acetone(v/v) for 10 minutes. The coverslips were dried and stored
in fresh wells at -20°C.
ii) Immunoflourescent staining
Cells were thawed out at 18°C for a minimum of 45 minutes and blocked in 250|il of
10%normal species serum(v/v)/0.01%Tween80(v/v)/SPBS for 30 minutes at 18°C (normal
species serum is that in which the conjugated antibody is raised). Blocking solution was
removed and cells incubated for 1 hour at 18°C in 250|il of antiserum, diluted in 2%normal
species serum(v/v)/0.01%Tween80(v/v)/SPBS. Cells were washed five times in
0.01%Tween80(v/v)/PBS and incubated in 250|il of FITC-labelled anti-species antibody,
diluted as above for lhour at 18°C in the dark. Cells were washed three times and mounted in
2-3pi of Citiflour. Slides were stored in the dark at 4°C and examined by a Leitz Ortholux II
microscope.
c] FACS staining
For single colour immunoflourescent staining, fibroblast cells were resuspended to a
concentration of 2xl06cells/ml in PBA (PBS/0.5%BSA(w/v)/0.04%azide(w/v)). 106cells were
taken as a single aliquot and 50pl of primary antibody, diluted appropriately in PBA, was
added for a 30 minute incubation at 4°C. Cells were washed three times in PBA and 50pl of
FTTC-labelled secondary antibody added with the same incubation conditions. Samples were
kept in the dark during this incubation. Cells were again washed and reuspended in 250pl of
PBA (with or without 250pl of 1% paraformaldehyde).
Fluorescent analysis was carried out using a Bacton Dickinson FACScan cell analyzer. The
fluorescent profile is presented as a histogram of fluorescent intensity versus relative cell
number.
2.2Jv Preparation and purification of MVV proteins
a] Preparation of MVV-infected cell lysates
Sheep skin fibroblasts were grown to 90% confluency in T150 tissue culture flasks and
infected with a low m.o.i. of MVV, between 0.1-0.5 m.o.i./cell, in lOmls of 2%FCS/DMEM
for 1 hour. A further 20mls of 2%FCS/DMEM was added. When cells showed extensive
c.p.e. sterile glass balls were added to dislodge infected cells. Cell debris was spun down at
10 OOOxg for 16 hours at 4°C in a Beckman JA-20 centrifuge. The pellet was resuspended in
a minimum volume of sterile PBS and stored at -70°C. Viral antigens were titrated out and
analysed by western blot using MVV-infected sheep serum. Mock preparations of antigen
were made by the same method adding only 2%FCS/DMEM to the cell monolayers.
b] Purification of gpl35 using a lectin affinity column
Sheep fibroblasts were grown up in 8L tissue culture bottles (Corning) in 10%FCS/DMEM
containing 25mM Hepes until cells were 80% confluent Cells were infected as above with a
low m.o.i. of MVV and cells monitored for c.p.e.. Medium was removed and clarified at
200xg for 10 minutes at 16°C. The virus was then pelleted in an ultracentrifuge at 120 OOOxg
for 3 hours at 4°C. The pellet was resuspended in 2mls of ice-cold resuspending buffer (0.1M
NaCl, ImM EDTA, 20mM Tris-HCl, pH7.4) and this was then disrupted in an equal volume
of 2xdisruption buffer (20mM Tris-HCl, pH7.4, 0.15M NaCl, ImM CaCl2, ImM MnCl2, 1%
Chaps(w/v), 0.1%TritonX-100(v/v), 60mM DTT). The disrupted pellet was kept on ice at all
times. The sample was circulated through a lentil lectin-Sepharose 4B (Pharmacia) column for
3 hours at 4°C, which had been set up and equilibrated according to the manufacturer's
instructions. The sample was collected and column washed in 30 column volumes of wash
buffer (0.1% Chaps(w/v),0.15M NaCl, 0.02M Tris-HCl, pH7.4, ImM MnCl2, ImM CaCk).
Glycoproteins were eluted using 0.2M methyl-a-D-mannopyranoside in wash buffer. 200pl
samples were collected and analysed by western blot. The aliquots containing purified protein
were pooled and stored at -70°C.
2.2.3vi Acetone precipitation
To concentrate protein samples, 5 volumes of ice-cold acetone was added and incubated at
-20°C for 16 hours. Precipitated protein was then pelleted by centrifugation at 13 OOOxg for
10 minutes at 4°C. The pellet was resuspended in the required buffer.
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2.2Jvii Preparation of peptides for immunisation
Peptides were synthesised commercially. Peptides were supplied in a lyophilised state that had
been desalted but were not HPLC pure. Peptides were reconstituted in 0.01M HC1 (5mg
peptide/ml HC1) and extracted in 40mls of ether. The aqueous layer was removed, excess ether
was allowed to evaporate in a fume hood and peptides stored at -20°C. lOOpl of 0.1M
phosphate buffer, pH7.0 was added per ml of peptide immediately before crosslinking.
Prior to immunisation it was necessary to link the peptide to a carrier molecule. Ovalbumin
was used as a carrier protein and peptides linked via N-succinyl-3-(2-pyridyldithio)
proprionate (SPDP) which provides the thiol groups for crosslinking with cysteine residues at
the amino terminal of the peptide. lOmg ovalbumin was dissolved in 1ml PBS. 173pl of
40mM SPDP (dissolved in ethanol), equivalent to 30 molar excess of ovalbumin, was added
dropwise to the ovalbumin and incubated at 23°C for 30 minutes. Unlinked ovalbumin was
separated from linked by passing through a PD-10 column (Pharmacia) according to the
manufacturer's instructions. The linked protein was eluted first followed by the unlinked
ovalbumin. To ensure that 2-thiopyridial groups had been introduced onto the amino groups in
ovalbumin, 0.01M DTT was added to an aliquot of linked ovalbumin and the release of
pyiidine-2-thione was measured on a spectrophotometer at an absorbance of 343nm and
compared to a non-reduced and an unlinked sample. Linked ovalbumin was stored at -70°C
until required.
To link the peptide to its carrier molecule, 30 molar excess of peptide was added dropwise to
2 mg of linked ovalbumin and incubated at 23°C for 1-2 hours. The linking reaction was
monitored by measuring the absorbance at 343nm every 30 minutes to measure the release of
pyridine-2-thione. When the absorbance readings were constant it was assumed that all 2-
pyridial disulphide sites had been reduced by substitution of pyridine-2-thiol with a peptide
molecule. A summary of reactions is shown in Fig. 2.2.
2.2.4 Preparation of polyclonal and monoclonal antibodies
2.2.4i Animals
Rabbits used in these studies were either from our own breeding colony or were from a Dutch
colony, female only, supplied in the Department of Medical Microbiology, University of
Edinburgh. All mice used were 6-8 week old Balb/C females.
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Figure 2.2: Coupling of the carrier molecule to peptides via crosslinking with N-succinyl
3-(2-pyridylthio) proprionate(SPDP)
i) Structure of SPDP
ii) Introduction of 2-pyridiaI disulphide structures into ovalbumin (ova)
iii) Conjugation of peptide (pep) to ovalbumin (ova) and release of pyridine-2-thione
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22AW Immunisations
Titre-Max™(Vaxcel™, Narcross, GA, USA)was used as an adjuvant for all primary
immunisations. The antigen was diluted to the appropriate concentration in PBS. An equal
volume of Titre-Max™ was taken and an emulsion prepared using 2x2ml syringes linked by a
double ended locking connector. Contents of the syringes were transferred from 1 syringe to
the other for 5 minutes, starting with transfer of antigen to the adjuvant, until an emulsion had
formed. Rabbits were given 2x0.5ml injections subcutaneously in their back limbs and mice
were given 2x200|il injections subcutaneously. Booster immunisations were done using either
antigen emulsified in Incomplete Freund's adjuvant or in PBS only in the same quantities as
above. Rabbits were given subcutaneous booster injections and mice given booster injections
intraperitoneally. Three days prior to fusion mice were given a final immunisation
intravenously into the tail vein in PBS only.
Blood samples were taken for analysis from the ear vein in rabbits and the tail tip in mice.
Blood was allowed to clot for 16 hours at 4°C, serum removed and stored at -20°C.
2J2.4iii Preparation of monoclonal antibodies
a] Preparation of myeloma cells
SP2/0 murine myeloma cells were used for fusion. 1 week prior to fusion, myeloma cells were
recovered from liquid nitrogen into a T25 tissue culture flask in 15%FCS/RPMI medium
supplemented with L-Gln and sodium pyruvate. Cells were grown in 5%C02 , expanded into
T150 tissue culture flasks and gradually weaned to 5%FCS/RPMI 1640 medium.
On the day of fusion myeloma cells were harvested, resuspended in unsupplemented RPMI,
counted and cell viability tested by Trypan-Blue exclusion. Cells were chosen for fusion only
if cell viability was greater than 95%.
b] Preparation of mouse feeder cells
On the day prior to fusion, feeder cells were prepared. One Balb/C mouse was sacrificed and
the spleen was removed under aseptic conditions. The spleen cells were separated by passing
the spleen through a sterile sieve into 15%FCS/RPMI, the clumps were allowed to settle and
cell suspension was poured into a fresh universal. Cells were spun down at 200xg for 5
minutes at 16°C and cells resuspended into 7mls 15%FCS/RPMI. Cells were counted in white
blood cell counting mix and irradiated.
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Cells were adjusted to 5xlCPcells/ml and plated out onto 96 well plates, lOOpl/well, and
incubated overnight at 37°C in a CO2 incubator.
c] Fusion of myeloma cells with immune spleen cells
The fusion protocol used is an adaptation of that described by Galfre et al. (1977).One
immunised mouse was sacrificed and spleen removed as above. Cells were extracted into
unsupplemented RPMI, washed and resuspended in lOmls RPMI. 0.5mls of cells were
removed at this stage and fully supplemented medium was added to these cells which would
act as a background control. Spleen cells and SP2 cells were mixed ratios of 3:1 to 8:1 and
pelleted at 200xg for 5 minutes. As much medium as possible was removed to leave the pellet
dry. 1ml of prewarmed 50% PEG1500(w/v) (Boeringher Mannheim) (at 37°C) was added
slowly to the pellet, 50pl at a time over a 5 minute period whilst keeping the pellet warm in a
beaker of water at 37°C. The cell suspension was allowed to sit for 3 minutes at 37°C and
PEG was then diluted out slowly by adding 1ml RPMI over 5 minutes, followed by 2mls over
2 minutes, followed by 20mls over 4 minutes. Fused cells were spun down gently at 200xg for
5 minutes and carefully resuspended in 20mls of 15%FCS/RPMI. Cells were plated out onto
the inner 60 wells of preprepared 96-well plates, 50pl/well. An extra row was plated out with
the unfused spleen cells that had been retained at the beginning of the fusion experiment. 24
hours later cells were fed with 15%FCS/RPMI containing
4%hypoxanthine/aminopterin/thymidine (HAT), 50pl/well.
d] Monitoring hybridoma cell lines
10 days post fusion all the wells were examined for clones and scored appropriately. Cells
were fed with 15%FCS/RPMI/l%HAT(v/v). When the wells were 50-80% confluent 100pi
supernatant was removed and screened. Positive wells were then grown up into 24-well plates
by dispersing cells with a Pasteur pipette and transferring to a single well in a 24-well plate
that had been preincubated with 15%FCS/RPMI/l%HAT(v/v) medium. Backup wells were
grown and duplicate stocks of cells from individual wells were frozen down in 1ml
10%DMSO(v/v)/90%FCS(v/v) and stored in liquid nitrogen.
e] Cloning hybridoma cell lines by agar cloning
When all the original wells containing hybridomas had been tested, up to 4 clones were
selected for cloning at one time. Cells were maintained in 24 wells and weaned off HAT
medium into HT medium. Agar plates were prepared with 0.5% bacto agar(w/v)(Difco)/20%
FCS(v/v)/l% HT(v/v)/RPMI medium supplemented with L-Gln and sodium pyruvate. 90mm
dishes were used with 8mls of agar medium/dish, agar was allowed to set and incubated in the
CO2 incubator for 2 hours. Cell dilutions were made in 1ml of 20%FCS/RPMI as 1/5, 1/25,
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1/50 and 1/125 dilutions and an equal volume of agar medium was added. The cell
preparation was added to the agar plates and maintained in CO2 incubator for 1-2 weeks.
When clones were large enough to be seen by a naked eye they were removed with a Pasteur
pipette and transferred to a well in a 24-well plate that had been preincubated with
20%FCS/RPMI. Two rounds of agar cloning was done to obtain a single hybridoma cell line.
2.2.4iv IgG purification of polyclonal serum
This was carried out using a protein G sepharose 4 FF column (Pharmacia, USA). 5mls of
serum was clarified at 10 OOOxg for 10 minutes and passed through a 0.2pm filter. The
sample was then diluted 1:1 with binding buffer (supplied by the manufacturer) and IgG
purified following the manufacturer's instructions.
2.2.5 Preparation and purification of recombinant proteins
2.2Ji Expression and purification of bacterial glutathione-S-transferase fusion proteins
a] Analyzing transformations by "miniscale" protein preparation
Analysis of transformed bacteria containing cloned pGEX plasmid was carried out as follows.
Bacteria were streaked out onto agar/ampicillin plates and colonies grown up over 16 hours at
37°C. Several colonies were picked and grown in 2mls L-Broth/amp for 3-4 hours until the
medium was turbid. The culture was induced with O.lmM isopropyl-(3-D-
thiogalactopyranoside (IPTG) for 1-2 hours. Cells were harvested by centrifugation at
13 OOOxg for 5 seconds and the pellet was resuspended in 300pl of ice-cold PBS. lOpl was
retained for analysis. Cells were lysed with a 2mm probe sonicator (Ultrasonic generator,
Dawe instruments Ltd.) for 10 seconds with sufficient power to lyse the cells but prevent
frothing. Cell debris was removed by centrifugation at 13 OOOxg for 5 minutes and
supernatant removed. 50pl of 50% glutathione-agarose bead(v/v)/PBS slurry was added to the
supernatant and mixed for 2 or more minutes at 18°C. The beads were washed twice in PBS
and resuspended in 50pl 2xSDS-reducing buffer, boiled for three minutes and analysed by
SDS-PAGE. Bacteria transformed with the native pGEX plasmid was always included as a
positive control.
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b] Preparation of recombinant fusion protein on a medium/large scale
Medium preparations were made from 100ml cultures and large scale preparations from 1L
cultures. Precultures were set up as 10ml or 100ml for medium and large scale preparations,
respectively by inoculating the appropriately sized culture with a single colony pick and
growing up the cultures for 16 hours. Cultures were diluted 1:10, grown to the required cell
density as determined spectrophoretically by absorbance at 600nm and induced with O.lmM
IPTG for a predetermined time. Cells were harvested by centrifugation at 300xg for 5 minutes
or for 10 minutes at 4640xg for 10 minutes at 4°C in a JA-20 centrifuge for a medium or
large scale preparation, respectively. Cell pellets were resuspended in l/100th of the volume
of the original culture in ice-cold PBS and lysed using an ultrasonic probe described in the
above section. Medium scale preparations were given 3xlminute pulses with 1 minute on ice
in between, and large scale preparations were given 3x3 minute pulses with 3 minute intervals
on ice. 1% TritonX-100(v/v)/PB S was added and cells were pelleted by centrifugation at
300xg for 5 minutes at 4°C. The supernatant was removed and incubated for 30 minutes at
18°C with 100pl or 1ml of 50% glutathione-agarose slurry for medium or large scale,
respectively. Beads were washed 3 times in ice-cold PBS and resuspended in PBS, in the same
volume as beads that were added. An aliquot was analysed by SDS-PAGE.
c] Elution of fusion protein from glutathione beads
Beads were pelleted gently in a bench centrifuge for 10 seconds and PBS removed. An equal
volume of lOmM reduced glutathione/5OmM Tris-HCl, pH8.0 was added and mixed for 2
minutes at 18°C. Beads were collected as before, supernatant was retained and elution
repeated twice more. Eluted samples were stored at -70°C and analysed by SDS-PAGE .
2.2.5ii Expression and purification of a recombinant protein in the baculovirus system
Expression of a recombinant protein in the Baculovirus system was carried out using the
CLONTECH BacPAK™ Baculovirus expression system. Described below are the methods
used for production of a recombinant vims.
a] Cotransfection of baculovirus expression vector and baculoviral DNA
SF21 cells were seeded into 35mm dishes at a 1.5xl06cells/1.5ml/dish for 1-4 hours or
lxl06cells/l .5ml/dish with overnight incubation. Medium was removed, cells washed with
unsupplemented TCI00 and a further 2ml TCI00 medium added for 30 minutes. It was
necessary to exclude FCS since a component of serum inhibits lipofectin mediated
transfection. Lipofectin-DNA complexes were made up by mixing the appropriate amounts of
plasmid DNA and viral DNA made up to a total volume of 50pl with SDW. 50pl Lipofectin
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was added to each sample and Lipofectin-DNA complexes were allowed to form over a 15
minute incubation at room temperature. Lipofectin is a complex of positively charged lipids
that binds to nucleic acids allowing uptake by fusion with the plasma membrane. Preparations
were made up in sterile polystyrene tubes (Nunclon) since lipofectin sticks to polypropylene.
pBacPAK8-GUS was used as a positive control and its plasmid map is shown in appendix 1.
The plasmid contains an E.coli p-glucorinidase gene down stream of the polyhedron promoter.
Recombination with BacPAK6 viral DNA will result in a recombinant virus that expresses (3-
glucoronidase. This can be detected by a blue colour in the presence of 5-bromo-4cloro-3-
indolyl-P-D-glucorinic acid (X-Gluc, 25mg/ml stock in DMSO, CLONTECH).
After preparation of lipofectin-DNA complexes, medium was removed from dishes and 1.5ml
of fresh serum-free medium was added to each dish. Lipofectin-DNA complexes were added
to each dish, dropwise and gently swirled. After a 5 hour incubation medium was removed and
1.5ml of supplemented medium was added containing 12jil/ml X-gluc. 72 hours post
transfection medium containing recombinant vimses was harvested and stored at 4°C.
b] Isolation of recombinant viruses
To isolate a single clone of recombinant virus from the supernatant of the cotransfection
experiment, a virus plaque assay was performed. 10-fold serial dilutions of the cotransfection
supernatant were made; 104, 10~2 and 10~3. A plaque assay was set up using 2-3 dishes per
dilution. Control dishes were included using an appropriate dilution of BacPak6™ as a
positive control and 10%FCS/TC100 medium as a negative control. Plaque assays were
stained with 0.33% neutral-red and X-gal. Plaques were circled and examined under a light
microscope to ensure that the plaques contained vims-infected cells, i.e. unstained. Using a
pasteur pipette the plaque was gently sucked up including the agar overlay, added to 0.5ml
10%FCS/TC100 medium in a sterile microcentrifuge tube, and allowed to diffuse for 16 hours
at 4°C.
To prepare a primary stock of recombinant vims, lOOpl of the "plaque pick" was used to
infect a 35mm dish seeded with 5xl05SF21 cells. 3-4 days post infection the medium was
removed and this was stored at -70°C as the primary stock of recombinant vims.
c] Preparation of baculovirus DNA
Virus DNA was extracted from infected cells for the purpose of analysing recombinant
vimses by southern blot hybridisation. An infection was set up in 35mm petri dishes as
described above and cells were harvested 3-4 days post infection. 1ml PBS was added to the
infected-cell monolayer and cells scraped off into a 1.5ml eppendorf tube. Cells were pelleted
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at 200xg for 1 minute at 16°C. The supernatant was removed and cells washed again in 0.5ml
PBS, repelleted and resuspended in 250)0.1 TE buffer. To the cells 250pl lysis buffer (50mM
Tris-HCl, pH8.0, lOmM EDTA, 5% (i-mercaptoethanol(v/v), 0.4% SDS(w/v)), 12.5pi
lQmg/ml proteinase-K and 2pi lQmg/ml RNase was added and incubated for 30 minutes at
37°C. Protein contaminants were removed by extracting with phenohchlorofoim (50:50) three
times, the sample was mixed for 5 minutes by inversion and microcentrifuged for 3 minutes to
separate the phases. It was important not to vortex the sample since Baculovirus DNA is large
and susceptible to shearing. DNA was precipitated with l/10th volume of 3M sodium acetate
and 2 volumes of ethanol. The pellet was soaked in 50pl TE buffer for 16 hours at 4°C since
baculovirus DNA solubilises slowly. The DNA was gently resuspended and stored at -20°C.
d] Purification of recombinant protein
Table 2.1 indicates the seeding densities and volume of reagents required for the preparation
and purification of recombinant protein.
Two methods were used to purify recombinant protein which was expressed as a protein fused
to glutathione-S-transferase.
Method 1: Cell-associated recombinant protein
Protein was extracted from infected cells grown in 35mm dishes. 1ml PBS was added to the
cell monolayer and cells scraped off. Cells were pelleted and resuspended in 100pi PBS/0.1%
TritonX-100(v/v) and centrifuged at 9 OOOxg for 10 minutes at 4°C. The supernatant was
removed and 50pl of 50% glutathione-agarose beads were added for 30 minutes at 4°C.
Beads were washed twice in PBS and resuspended in an equal volume of PBS.
Method 2: Secreted recombinant protein
2-3 days post infection the medium was collected from infected cells and clarified by
centrifugation at 200xg for 5 minutes at 18°C. The supernatant containing recombinant
protein was dialysed against 1-2 litres PBS for 16 hours at 4°C. The supernatant was
removed and an appropriate volume of 50% glutathione-agarose(v/v)/PBS bead slurry was
added and mixed for 30 minutes at 4°C. The beads were washed twice in ice-cold PBS and
resuspended in same volume as beads.
To elute recombinant protein from the beads, the required volume of elution buffer (50mM
Tris-HCl, pH8.0/10mM reduced glutathione) was added and sample mixed for 2 minutes at
4°C. The elution was repeated and samples stored at -70°C.
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35mm dish 1.5xl06 l.OxlO6 0.1-0.5ml 1.5-2.0ml 50pl n/d
25cm2flask 2.0x106 1.5xl06 0.4-1.0ml 3.0-5.0ml lOOpl 200ul
150cm2flask 12.0xl06 8.0xl06 2.0-6.0ml 20-30ml 600pl 1ml
spinner lxl06/ml 2xl05/ml
(48hrs)
<10ml 100ml 2ml 4ml
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CHAPTER 3: THE EXPRESSION AND CHARACTERIZATION OF GP135
EXPRESSED IN pGEX BACTERIAL SYSTEM
3.1 INTRODUCTION
Little is understood as to the identity of functional epitopes on the envelope glycoproteins of
MVV, such as their role in receptor binding and induction of host neutralizing antibodies. To
carry out studies to delineate functional epitopes within the external glycoprotein, gpl35, of
MVV, attempts were made at expressing it as a recombinant protein. This would provide a
reliable source of gpl35 that could be used as an immunogen and also in functional studies.
Previous attempts had been made to express gpl35 as three overlapping fragments in the yeast
Ty-system (Carey et al., 1993). Problems encountered in this system included low yields due
to toxicity of gpl35 fragments and high contaminatioa
An alternative approach was taken to express these fragments in a simpler bacterial system
and the pGEX expression system was chosen (Smith and Johnson, 1988). Bacteria are the
ideal system of choice when expressing recombinant proteins. They are easy to manipulate
and can be grown in large cultures in the laboratory, up to 5 litres, without high costs. The
main disadvantage of using a prokaryotic expression system is that proteins are not
glycosylated. However, this was not a foreseen problem since work with gpl20, the external
glycoprotein of HIV-1, has shown that sera from infected patients are able to recognise
recombinant protein expressed in bacteria and these proteins can be used to raise neutralizing
antisera (Putney et al., 1986, Crowl et al., 1985, Lasky et al., 1986).
The pGEX system allows foreign polypeptides to be expressed as recombinant proteins fused
to glutathione-S-transferase, GST. GST is a 27kDa cytoplasmic protein, belonging to a family
of isoenzymes that detoxify a variety of xenobiotics by catalyzing the interaction of reduced
glutathione with these molecules. It was originally isolated by Smith et al. (1986) from the
parasitic helminth, Schistosoma japonicum (Sj26) and was subsequently expressed as a
recombinant protein in bacteria (Smith et al., 1988). This led to its manipulation as a fusion
partner for production of foreign polypeptides in bacteria (Smith and Johnson, 1988). Proteins
produced are usually soluble and can be purified under non-denaturing conditions by affinity
absorption onto glutathione-agarose beads, thus allowing recombinant protein to retain
functional activity and antigenicity (Smith and Johnson, 1988). The main advantage of the
GST carrier is that it is relatively small compared to other carrier species, for example (3-
galactosidase, and thus is not likely to interfere with the immunogenicity of the foreign
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polypeptide. It also lacks immunological complications as seen when protein A is used as a
fusion partner which can interact with a wide variety of antibodies. The GST moiety is under
the control of a strong tac promoter. The tac promoter is derived form the lacUV5 promoter
and the trp promoter, which are combined to give a hybrid promoter that is repressed by the
lac repressor (Amann et al., 1983). By inducing transformed bacterial cells with IPTG, the lac
repressor protein is lilted resulting in expression of fusion protein. Bacterial cells are then
lysed and fusion proteins are purified. Recombinant proteins can be recovered from the beads
by elution with free reduced glutathione at neutral pH.
Cloning is performed by ligating the DNA fragment encoding the polypeptide of interest into
one of three vectors available and transforming into competent E. coli cells. The expression
vectors contain an open reading frame with GST followed by a multiple cloning site
containing BamHI, Smal and EcoRI restriction sites and a termination codon set in all three
frames (see Fig.3.1). Vectors pGEX2T and pGEX3X also have a thrombin and blood
coagulation factor Xa cleavage site, respectively, for the removal of the GST carrier if
required. This bacterial expression system has been highly successful for the production of
many recombinant proteins. However difficulties can be encountered with foreign proteins
>50kDa and with proteins containing large hydrophobic or highly charged regions.
Recombinant proteins can be used in a variety of studies. These include the use of proteins for
detecting antibodies from immune sera either for diagnostic means or for analysing
neutralizing antibody response (Frosch et al., 1991, Iwayama et al., 1991, Frorath et al.,
1991). Since this system allows for the production of large amounts of protein of interest, it is
very useful for production of antibodies. Animals can be immunised by a variety of means, for
example with eluted protein, with protein immobilised on glutathione-agarose beads or with
crushed gel extracts containing the protein of interest (Oettinger et al., 1992). Recombinant
proteins have also been used for assessing cellular immune responses in the host as well as
detecting a humoral response (Tetzlaff et al., 1992). This system is applicable to construction
of cDNA expression libraries which can be adapted to epitope map a panel of monoclonal
antibodies (Rizzo and Gray, 1992). Proteins expressed in the pGEX system retain functional
activity, demonstrated by large scale expression of a glycoprotein hormone, leukaemia
inhibitory factor (LIF) and its use to maintain embryonic stem cells in culture. It should be
noted that to retain biological activity it was necessary to cleave LIF from GST via a thrombin
cleavage site (Gearing et al., 1989).
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Figure 3.1: The structure of pGEX plasmid vector (adapted from Current Protocols, 1990)
The map shows the location of the GST cassette in relation to the multiple cloning site,
comprising of BamHI, Smal and EcoRI restriction enzyme sites. The reading frames of all
three pGEX fusion vectors are shown, including protease cleavage sites and the termination
codon.
ampr represents the (3-lactamase gene responsible for ampicillin resistance,
ori is the origin of replication.
lacl^ represents the lac repressor gene whose product bind to the fusion protein promoter,
Ptac. This repression is lifted in the presence of DPTG.
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Pro Lys Ser Asp Pro Arg Glu Phe lie Val Thr Asp STOP
pGEX1 CCA AAA TCG GAT CCC CGG GAA TTC ATC GTC ACT GAC TGA CGA TCT G




Pro Lys Ser Asp Leu Val Pro Arg-^-Gly Ser ' Pro Gly lie His Arg Asd STOP
pGEX2T CCA AAA TCG GAT CTG GTT CCG CGT GGA TCC CCG GGA ATT CAT CGT GAC TGA CTG1 n! !n 1
SamHI Sma I EcoRI
factor Xa
Pro Lys Ser Asp Leu' lie Glu Gly ArgJ'Gly lie Pro Gly Asn Ser Ser STOP
pGEX3X CCA AAA TCG GAT CTG ATC GAA GGT CGT GGG ATC CCC GGG AAT TCA TCG TGA CTG1
l !n 1
SamHI Smai EcoRI
The pGEX system was employed to express the three overlapping fragments of gpl35 (map
shown in Fig.3.2). The 50-60 amino acid overlap between fragments was included in an
attempt to ensure that any putative domain structure was not lost. Fragments envB and envC
have been successfully cloned into and expressed in pGEX2T (Carey, 1992). These proteins
were shown to be toxic to bacterial cell growth and initial immunisations were performed in an
attempt to raise anti-gpl35 polyclonal sera. This chapter describes cloning and expression of
envA, expression studies of all three recombinant proteins and attempts at raising polyclonal
antibodies specific for gpl35.
3.2 RESULTS
3.2.1 Directional cloning of envA into pGEXl
Previous attempts at cloning envA fragment of gpl35 into BamHI site of pGEXl expression
vector resulted in the insertion of envA in the incorrect orientation, determined by restriction
enzyme mapping (Carey et al., 1992). To overcome this technical problem directional cloning
was performed. This involved the amplification of envA by PCR using primers that contained
restriction sites for BamHI and EcoRI in the 5' and 3' ends respectively. The details of these
primers (primers 1 and 2) are given in Fig.2.1 (see chapter 2). EnvA was amplified using a
pTZ19R clone containing envA, A46, as a template (Carey and Dalziel, 1994). PCR
conditions were as follows: 0.6 minutes at 96°C, 0.2 minutes at 55°C and 2.5 minutes at
72°C for 30 cycles and 1 cycle for 7.5 minutes at 72°C. The PCR product and pGEXl vector
were both digested with BamHI and EcoRI overnight at 37°C. The digested vector was treated
with Calf Intestinal Phosphatase to prevent self ligation. DNA was purified with glass beads
and ligation reactions set up as a molar ratio of 1:5, vector:insert, incubated overnight at 12°C
and transformed into competent E.coli JM101 cells. Transformed cells were plated out onto
three agar/amp plates and approximately 180 colonies grew up. The colonies were
significantly smaller than positive control colonies, i.e. self-ligated, non-phosphorylated vector
only, and grew very slowly. All colonies were screened by colony hybridisation, using high
stringency conditions and probed with envA derived from A46.
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Figure 3.2: Regions of gpl35 expressed in pGEX
The diagram illustrates the three overlapping regions of gpl35. The number above the lines
shows the amino acid position of fragments. Numbering is as in Sargan et al. (1991). Arrows







Screening resulted in the identification of 12 positive clones and these were selected for
analysis. Plasmid DNA was prepared by standard miniprep procedure and DNA cut with
Bgll. Bgll cuts pGEXl at positions 2009 and 4652, and envA at position 565. EnvA cloned
into pGEXl at BamHI and EcoRI site in the correct orientation would give fragment sizes 1.4,
1.7 and 2.6 kb when cut with Bgll. The 12 colonies analysed gave these predicted sizes when
cut with Bgll, demonstrating that envA had been successfully cloned into pGEXl in the
correct orientation-. Double stranded sequencing of the clones was performed to confirm the
restriction enzyme result.
3.2.2 Analysis of envA protein expression and the effect on bacterial cell growth
One of the clones that had been isolated above was selected for protein expression analysis.
Previous results from studies with envB and envC showed that yields of protein were
significantly improved by inducing cell cultures at a higher O.D.600 value than the standard
0.4 (Carey, 1992). This was shown to be necessary due to the toxic properties of envB and
envC on bacterial cell growth. 100ml cultures of pGEXl:envA were grown up and protein
purified as follows. Bacterial cell cultures were grown to an O.D.600 value of either 0.4 or 0.7
and induced for three hours with IPTG. Cells were harvested and protein purified. Proteins
were resolved by SDS-PAGE, fixed and silver-stained. Fig.3.3a shows a comparison of
protein yields at 0.4 and 0.7 O.D.600 values. Contaminants identified at 30kDa and 43kDa
were consistently observed in all GST:envA preparations. These could be breakdown products
of GST:envA (see discussion). The predicted size of envA is 61kDa. Two bands are present at
around 55-65kDa as seen in Fig.3.3a, the lower of which is predicted to be GST:envA and the
higher is a contaminant of unknown identity. It should be noted that this higher molecular
weight contaminant was occasionally observed in preparations of GST:envB and GST:envC.
There did not appear to be a significant increase in yield of GST:envA from an O.D.600 value
of 0.4 to 0.7.
To analyse the effect of GST:envA production on bacterial cell growth, transformed JM101
cells containing pGEXlienvA were grown and O.D.600 values measured every hour. Cells
were induced with IPTG after 3 hours growth and O.D.60o continued to be monitored up to 5
hours after induction. Growth characteristics were compared to JM101 cells transformed with
pGEXl only. Fig.3.3b shows these results graphically. As with envB and envC, production of
GST:envA appears to inhibit cell growth and hence is also toxic.
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Figure 3.3: An analysis of protein production from JM101 cells transformed with
pGEXlrenvA and its effect on bacterial cell growth
GST:envA purified from cell cultures induced at O.D.600 values 0.4 and 0.7 were run on a
12% SDS-PAGE gel and proteins were detected by silver-staining, shown in figure a. The
location of GST:envA is highlighted. pGEXl as the positive control is shown, indicating the
position of native GST. Protein markers are shown.
Figure b is a graph to show the effect of GST:envA on bacterial cell growth. pGEX control is
shown.
time point at which cell cultures were induced with IPTG.
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3.2.3 Expression studies on three overlapping fragments of gpl35, GSTrenvA,
GST:envB and GST:envC
Data presented so far has highlighted the problem in expressing gpl35 in a bacterial system
by the fact that the three protein fragments appear to be toxic to bacterial cells. This leads to
low levels of expression accompanied by protein contamination. To use these proteins for the
purpose of raising antisera it was necessary to obtain better and cleaner yields. The following
sections deal with attempts at increasing recombinant protein yields.
3.2Ji The effect of varying induction time on protein yield
A standard protocol had been developed in which cell cultures were induced for three hours
prior to protein purification (Carey, 1992). To analyse the effect of altering the duration of
induction on the yield of all three fusion proteins the following experimental procedure was
carried out. A 10ml preculture was set up and grown for 6-8 hours. This culture was
transferred to 100ml L-Broth/amp and grown up for a further 16 hours, and then added to
500ml L-Broth/amp in a 2-litre conical flask to allow for maximum aeration. When the
O.D.600 value reached approximately 0.8 the culture was induced with O.lmM IPTG. At
hourly intervals for 5 hours 100ml culture was removed, cells harvested and stored at -70°C.
Protein purification was carried out on all 5 samples simultaneously by the usual procedure.
Samples were analysed by SDS-PAGE, fixed and silver stained. The results are presented in
Fig. 3.4a, b and c for GSTrenvA, GSTrenvB and GSTrenvC, respectively. For GSTrenvA the
yield appeared to be maximum at 3-4 hours post induction. GSTrenvB shows maximum
production at 1 hour induction, with a definite decrease on increasing induction time. It is
noted that at 4 hours very little protein was recovered. At 5 hours very little fusion protein by
comparison to contaminants, is detectable by silver stain analysis. It is also noted that there is
an increase in contamination on increasing induction time. GSTrenvC showed an opposite
effect to GSTrenvB where maximum yield was at 5 hours. This however was accompanied by
an increase in contamination similar to that observed with GSTrenvB.
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Figure 3.4: The effect of varying induction time on the yield of fusion proteins
GSTrenvA, GST:envB and GSTrenvC
Purified recombinant proteins were separated on a 12% SDS-PAGE gel and detected by silver
staining. Figures a, b and c represent GST:envA, GSTrenvB and GST:envC, respectively, and
the position of each fusion protein is marked. Induction time is given in hours. Size of protein
markers are indicated.
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3.2Jii The effect of IPTG concentration on protein yield
Published data on the expression of recombinant proteins in the pGEX system uses a variety
of concentrations of IPTG. For example, expression of Human 68-kDa(Ul) ribonucleoprotein
antigen was performed by inducing bacterial cell cultures with 0.5mM IPTG (Frorath et al.,
1991), whereas expression of recombinant human PDC-Ela used only O.OlmM IPTG to
induce cultures (Iwayana et al., 1991). An initial experiment was performed with GST:envB
to see the effect of varying IPTG concentration on protein yield. Four 100ml L-Broth cultures
were grown up, 2 cultures induced at an O.D.600 value of 0.65 and 2 cultures induced at 0.9.
For each O.D. value, the cultures were either induced with O.lmM DPTG or with 0.5mM
IPTG. Induction was carried out for the standard 3 hours and protein purified as usual. Figure
3.5 shows the results obtained from this experiment. As can be seen there is no dramatic
difference in protein yield between O.lmM and 0.5mM IPTG. It was decided therefore to
maintain a working concentration of O.lmM IPTG for production of all three fusion proteins.
3.2Jiii Using different host bacterial strains for expression of fusion proteins
Data from the expression of Human 68kDa (Ul) ribonucleoprotein suggested that choice of
cellular host played a role in yields obtained for fusion proteins in the pGEX system (Frorath
et al., 1991). In the literature there appears to be a balance between JM101 and DH5a strains
of E.coli used to express recombinant proteins. Therefore pGEX:envA, pGEXienvB and
pGEX:envC were transformed into DH5a cells and protein yields compared to those in
JM101 cells. Minipreparations of plasmid DNA were purified from 10ml cultures of each
plasmid in JM101 cells. Plasmid preparations were checked by restriction enzyme digestion
and transformed into competent DH5a cells. Transformed cells were analysed for the presence
of plasmid by preparing minipreparations of plasmid DNA and checking with restriction
enzymes as before. Medium scale protein preparations were earned out for GST:envA,
GST:envB and GST:envC and yields compared at O.D.600 values 0.5 and 0.9 between
transformed JM101 and DH5a cells. The results are presented in Fig. 3.6 as silver stained
SDS-PAGE gels. There was no difference in the yield obtained for GST:envA in either cell
strain and the level of contamination was comparable in each (Fig.3.6a). GST:envB
production was slightly better in DH5a than JM101 (Fig.3.6b). The result obtained for
GSTienvC showed a maximum yield at an O.D.600 value of 0.5 in DH5a cells (Fig.3.6c). This
was accompanied by a greater increase in contamination. In summary, there was no marked
improvement in yield obtained for fusion proteins in DHa cells compared to JM101 cells.
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Figure 3.5: A comparison of yields obtained from cultures of pGEX2T:envB with
different concentrations of IPTG
Protein samples were separated on a 12% SDS-PAGE gel and silver stained to show the effect
of inducing pGEX2T:envB cultures with either O.lmM or 0.5mM IPTG. Protein markers and





Figure 3.6: A comparison of protein yields in two different strains of E. coli transformed
with pGEXl:envA, pGEX2T:envB and pGEX2T:envC
Figures a, b and c show the effect of producing GST:envA, GST:envB and GST:envC,
respectively in either JM101 (J) and DH5a (D) strains of E. coli and are presented as silver-
stained 12% SDS-PAGE gels. Protein markers and fusion proteins are indicated.
Figure d represents a growth curve to show effect of all 3 fusion proteins on bacterial cell
growth in DH5a strain of E. coli and compared to pGEX control.
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To analyse if fusion proteins were toxic to DH5a cell growth, O.D.600 values were monitored
at hourly intervals. Cultures were induced with O.lmM EPTG after 2 hours, and bacterial
growth continually monitored. Growth curves showed that these proteins were also toxic in
DH5a cells (Fig. 3.6d).
3.2Jiv An alternative lysis procedure for purification of fusion proteins
The standard procedure for lysing cells is by sonication using an ultrasonic probe. This system
has two major disadvantages; firstly, the intensity of sonication is difficult to control which
raises a problem in maintaining reproducibility from one preparation to the next. Secondly,
sonication results in the sample being heated considerably which will lead to an increase in
protein breakdown and therefore contamination products. This problem is controlled by
keeping samples on ice whenever possible. The use of lysis beads have been used as an
alternative to sonication (Dr. J.M. Sharpe, personal communication). These beads are made
from silica (supplied by Zerconia, 0.1mm diameter) and are prepared by thoroughly washing
with sterile distilled water and storing at 4°C in a 50/50 (v/v) suspension with sterile distilled
water. The lysis procedure was carried out as follows. After cells had been harvested they
were resuspended in PBS and equal volume of lysis beads were added. The suspension was
agitated on a vortex-mixer for 3x3 minute bursts with 1 minute on ice between each vortex.
The lysis was carried out at 4°C. The advantages of this system is that there is more control
on lysis temperature and the intensity of lysis. Therefore this procedure is more reproducible
than using an ultrasonic probe, and protein degradation is minimised. Comparison of the two
lysis procedures in purification of GST:envB showed a marked decrease in level of GST
contamination when using the lysis beads (data not shown).
3.2Jv The effect of inducing protein production at 25°C
A comparison was made with induction temperatures at 37°C and 25°C. This was carried out
with pGEX:envB to see if a difference in yield could be attained. 10ml precultures were grown
up for 16 hours, transferred to 100ml L-Broth/amp and grown to an O.D.600 value of 0.6. A
summary of the experimental procedure is shown in Table 3.1 below. As an added variable
(sample5), the effect of using a buffered L-broth on the level of contamination was assessed.
A buffered medium may be more favourable to the growth of the bacterial cells.
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Table 3.1: Growth conditions of bacteria for varying induction temperatures





Note: * Sample 2; prior to induction cells were harvested and resuspended in 200mls of
medium and induced as normal.
Cultures were induced for three hours, cells were harvested, lysed with silica beads as
described in 3.2.3iv and purified by usual method. Samples were ran on a 12% SDS-PAGE
gel, fixed and silver stained. Fig. 3.7 shows the results from this experiment. There was a
definite decrease in the level of contamination at 25°C compared to 37°C although the amount
of GST:envB remained the same. There was not a comparable difference between the two
cultures grown at 25°C indicating that the approach of growing cells to a higher density in
order to produce more protein was not necessary at this lower temperature. It is possible that
by inducing cultures at a lower temperature there will be a lower activity of host cell proteases
which will result in a lower amount of degradation products. No difference in contamination
was observed using a buffered L-Broth.
In summary, studies were undertaken in an attempt to improve the yield of fusion proteins. As
is discussed above, various parameters were introduced that did improve the yield of fusion
protein. This improvement however was not dramatic and was accompanied by increases in
contamination. Yields ranged between 50-100ug/litre of culture. This yield is at the bottom
end of the scale for anticipated yields of fusion protein, the usual being l-3mg/litre. Since
protein preparations were not pure it was not possible to determine protein concentration by
conventional means, and estimations were made from silver-stained SDS-PAGE gels
comparing to known concentrations of a standard protein such as Bovine Serum Albumin.
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Figure 3.7: The effect on yield of fusion proteins by inducing cultures at different
temperatures
100ml cultures of pGEX2T:envB were set up as described in the text. Recombinant protein
was purified, resolved on a 12% SDS-PAGE gel and detected by silver staining. The position
of GST:envB is indicated.
Lane 1, induced at O.D.600 =0.9 @ 37°C.
Lane 2, cultures grown to O.D.600= 0.6 @ 37°C, then to O.D.600=0.9@ 25°C. Cells
resuspended and induced @ 25°C.
Lane 3, grown to O.D.600= 0.6 @ 37°C, transferred and induced @ 25°C.
Lane 4, grown to O.D.600=0.6 and induced @ 37°C.
Lane 5, same conditions as 1, but using a buffered L-broth.











3.2.4 Raising immune sera against fusion proteins, GST:envB and GSTrenvC
GST:envB and GST:envC were used as a source of antigen for raising antisera against gpl35.
Initially polyclonal sera was made in rabbits with a view of extending immunisations to mice
for the production of monoclonal antibodies. GST:envA was not used as an antigen for
immunisation due to the consistent presence of contaminatioa
Large scale preparations were performed for pGEXrenvB and pGEX:envC, using
modifications described in section 3.2.3, notably a revised induction time and lysis conditions.
Rabbits 222 and 217 were given initial subcutaneous injections with approximately 50|ig of
purified GST:envB and GSTrenvC, respectively, bound to agarose beads. Proteins were
emulsified in Titre-Max™ and rabbits given 0.5ml injections in each hind limb. Pre-bleeds
were taken from each animal before immunisation. Rabbits were boosted every 3-4 weeks
with the same amount of fusion protein bound to agarose beads suspended in PBS. Rabbits
were bled at each immunisation and sera were tested by western blotting to assess the presence
of fusion protein antibodies. After 4 immunisations over a period of 4 months, animals were
sacrificed and bled out. Sera was tested by western blot against all three fusion proteins, and
compared to normal rabbit sera. Fig. 3.8a, b and c shows the results of these blots. Both R222
and R217 sera showed reactivity against all three fusion proteins. There was also an active
immune response against contamination products in both rabbits as indicated on the blots.
R217 and R222 sera recognised GST purified from control pGEX2T transformed cells (data
not shown). The presence of GST antibodies would explain cross reactivity of R217 with
GST:envA since anti-envC antibodies would not be expected to cross react with envA. In an
attempt to minimise cross reactivity, R222 sera was preabsorbed onto GST immobilised on
glutathione-agarose beads overnight at 4°C, beads collected and sera analysed on a western
blot The depleted sera did not cross react with GST but there was a decrease in the intensity
of reaction to GSTrenvB (data not shown). This finding suggests that immunised sera
contained a predominance of GST antibodies and envB and envC antibodies were of very low
titre. Preabsorbance of R217 antisera onto immobilised GST was not attempted. R217 and
R222 did not recognise a specific GSTrenvC band by comparison to NRS.
In addition, antisera specific for GST was made following the same protocols above. A rabbit,
R223, was immunised with GST purified from bacterial cells transformed with pGEX2T only.
Interestingly, antisera from R223 recognised the predicted fusion proteins and also
contaminant proteins, as well as GST (data not shown).
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Western blotting was carried out to see if GSTienvB and GST:envC antibodies specifically
recognised MW-derived gpl35. Crude cell lysates from MVV infected fibroblasts were
separated on a gradient gel and blotted with R217 and R222. These sera failed to recognise
gpl35 by comparison to MW-infected sheep sera, 848A (data not shown). Sera were also
tested by immunofluorescence on MW-infected sheep fibroblast cells and compared to
uninfected cells (data not shown). Immunofluorescence was unable to show specific binding of
antisera, R222 and R217 to infected cell, compared with normal rabbit sera and anti-GST
sera from rabbit 223.
In summary, attempts at raising polyclonal antisera with fusion proteins was not successful.
Problems encountered included immunogenicity of GST in rabbits which hindered production
of anti-gpl35 antibodies. The high level of contaminants also resulted in an unclean
preparation of polyclonal antibodies. Evidence highlighted above suggested the titre of fusion
protein antibodies were low and this may be due to low protein yields obtained from
purification of fusion proteins. It is unclear from the above studies whether antibodies to
gpl35 were raised with the recombinant fragments.
3.2.5 The ability of MVV-infected sheep sera to recognise recombinant env
fragments
To determine whether gpl35 antibodies in MVV infected sheep sera could recognise
GST:envA, GST:envB and GST:envC, western blots were carried out using sera from
experimentally infected sheep, 848A and 754N (a kind gift of Dr.B.Blacklaws, personal
communication) and compared to normal sheep sera. Results of these blots are shown in
Fig.3.9. Immune and normal sheep sera both recognised fusion proteins and contaminants.
This result is a reflection on the non-specific reactivity that sheep sera show on western blots.
No specific binding of MW-infected sheep sera to the three fusion proteins was
demonstrable.
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Figure 3.8: The screening of rabbit polyclonal sera, R222 and R217, against fusion
proteins GST:envA, GST:envB and GST:envC
Fusion proteins, GST:envA, GST:envB and GST:envC, were purified and resolved on a 5-
15% gradient SDS-PAGE gel, transferred to nitrocellulose and probed. Sera were blotted
against each fusion protein GST:envA, GST:envB and GST:envC at a 1/100 dilution and
compared to normal rabbit serum. Figures A, B and C represents GST:envA, GST:envB and
GST:envC respectively. The identity of each fusion protein is highlighted.




Lane c, normal rabbit serum
Figure 3.9: The screening of MW-immune sheep sera against fusion proteins,
GST:envA, GST:envB and GST:envC
Figures A, B and C show blots of 848A and 754N visna-immune sheep sera against fusion
proteins GST:envA, GST:envB and GST:envC, compared to normal sheep sera. Proteins were
resolved as described in figure 3.8. Sheep sera were diluted 1/20 and detected with
biotinylated anti-sheep and extravidin-AP. The identity of each putative fusion protein is
highlighted with an arrow.
Lane d, 754N
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The decision to express gpl35 into three overlapping fragments was a historical one in that
earlier expression studies of gp 135 in yeast required protein fragments less than 40 kDa to
ensure reasonable expression of recombinant proteins. For this reason it was decided to
attempt to express gpl35 as three fragments in the bacterial pGEX system.
Initial cloning of envA into pGEX2T proved to be unsuccessful suggesting that envA was the
least suitable of the three fragments for expression (Carey, 1992). The abnormal properties of
envA was evident by the morphology of the transformed bacterial colonies. Characterization
of protein production of GST:envA demonstrated that envA indeed had toxic effects on
bacterial cell growth. The presence of contaminants at 43kDa, 30 kDa and 65 kDa are of
concern in the fact that they are produced in equal amounts to GST:envA. This is in contrast
to GST:envB and GST:envC where the degree of contamination in GST:envB and GST:envC
preparations varied from experiment to experiment Reasons why envA is especially toxic and
hence the problems in expressing it may be related to its structure. EnvA lies at the amino
terminus of gpl35 and incorporates the putative signal peptide which lies between amino acids
78-100. This means that envA contains a significant degree of hydrophobicity and the
presence of a large number of hydrophobic groups is thought to hinder successful expression
of foreign polypeptides (Sisk et al., 1992). In addition it should be noted that earlier studies
expressing envA in the yeast Ty-system resulted in abnormal Ty particles. EnvA appeared to
be glycosylated suggesting that the signal peptide was transporting envA through the
glycosylation pathway of yeast cells. It is possible that this may be occurring in the bacterial
cells. Bacterial cells have their own protein transport system for targeting proteins to either the
plasma membrane, the periplasmic space or the outer membrane which shares various features
with the eukaryotic system. Thus bacteria may be manipulating the signal peptide encoded in
envA and directing it to one of the compartments mentioned above. This may result in the
subsequent cleavage of GST:envA by a bacterial signal peptidase, and hence explain the
consistent presence of contaminants in preparations of GST:envA. The ability for E.coli to
recognise foreign signal peptides and transport foreign proteins to the periplasmic space has
been reported (Gray et al., 1985).
Initial expression studies with all three fusion proteins had highlighted the potential problem in
obtaining recombinant protein, in that these proteins were detrimental to the growth of
bacteria, and protein was only detectable when bacterial cultures were induced at a higher cell
density. Two approaches were taken to improve expression, firstly by attempting to increase
the overall yield of protein and secondly to decrease the level of contamination.
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By analysing the effect of increasing induction time on the yield of fusion protein an
insight into the kinetics of protein production of all three fusion proteins was obtained.
GST:envB production appeared to decrease on increasing induction time and this was
accompanied by an increase in contamination products. It is possible that a longer induction
time allowed host cell proteases to breakdown fusion protein products, presuming that the rate
of GST:envB production was constant over time. Alternatively, at later time points the rate of
degradation may be greater than the rate of synthesis. With GSTienvC production the opposite
effect was observed by the fact that increasing induction time increased the overall yield of
fusion protein but this was also accompanied by accumulation of breakdown products. Whilst
there still seemed to be an effect on protein breakdown by host cell proteases the fact that
fusion protein also increased suggests that the expression of GST:envC may be slow and
hence a longer induction time is required for protein production. The production of GST:envA
was also accompanied by an increase in breakdown products on increasing induction time.
Reasons why there should be a difference between the production of all three fusion proteins is
not fully understood other than the actual nature of each polypeptide could be affecting
expression and this is discussed in further detail below.
An alternative approach to reduce the level of contamination was attempted. By inducing
protein production at a lower temperature it was expected that this would have a positive
effect on the build up of breakdown products by the fact that host cell proteases will be less
active at 25°C than 37°C. The initial results with GST:envB support this hypothesis by the
observed reduction in contamination. The assumption was made that protein expression would
be slower at a lower temperature, and therefore a three hour induction period was employed
instead of one hour. An investigation was also undertaken to see if increasing cell density and
resuspending in double the original volume would increase the yield of fusion protein. As was
shown in the results this did not result in an increase in protein yield.
The pGEX system uses direct expression of recombinant protein into the cytoplasm to
produce high levels of foreign proteins which can be released by cell lysis and purified. This
approach is usually rewarding provided that the level of expression is high enough to
overcome proteolytic degradation by E.coli proteases (Marston, 1986, Pluckthun, 1991). One
disadvantage to bacterial expression systems is that overexpression of foreign protein can lead
to its accumulation in inclusion bodies which must then be disrupted to release recombinant
protein (Harris et al„ 1983). It has been reported that by expressing foreign polypeptides
fused to bacterial proteins, such as (3-galactosidase, degradation is reduced and protein
synthesis is higher than by direct expression of recombinant protein (Shine et al„ 1980).
However, accumulation of inclusion bodies was also observed in this system (Shine et al.,
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1980). Although the fusion partner in the pGEX system is not a bacterial protein, fusion
protein is generally soluble (Current Protocols, 1990) which is consistent with the absence of
inclusion bodies in cell extracts of pGEXl:envA, pGEX2T:envB and pGEX2T:envC (data not
shown). Thus the low yields are not due to the accumulation of fusion protein in inclusion
bodies. It would appear that the toxic properties hindered overexpression of the recombinant
fragments of gpl35, such that they were subject to degradation by host cell proteases.
Important factors that influence the level of protein produced include mRNA stability, poor
translational or transcriptional efficiency due to the presence of rare codons (Robinson et al.,
1984), protein stability and host toxicity due to the overexpression of foreign polypeptides
(Reznicoff and Gold, 1986, Brosius, 1984). Areas of hydrophobicity (>15 amino acids) also
give toxic properties to recombinant proteins and these can be represented as signal peptides
and transmembrane regions in viral glycoproteins (Steinberg et al., 1986). The overexpression
of glycoproteins in bacteria is problematic usually by the fact that these proteins are toxic to
E.coli and inhibit growth resulting in low yields (Amam et al., 1984, Steinberg et al., 1986). A
study with envelope glycoproteins of HIV-1 and HTLV-1 showed that by excising
hydrophobic domains greater than 15 amino acids long, expression was increased from no
protein up to 15% of total cell protein (Sisk et al., 1992). Since envA contains a large section
of hydrophobicity (approximately 22 amino acids long) its toxic properties may be attributed
to this phenomenon. This applies also to a lesser extent to envB and envC which each contain
small regions of hydrophobicity.
There are reports that a large number of GST-fusion proteins are toxic to E.coli and die
presence of the 'leaky' tac promoter transcriptional control system means that it is unsuitable
with potentially toxic proteins. A novel vector has been constructed which incorporates the T7
polymerase promoter enabling tight control over expression. The GST moiety is situated at
both N- and C-termini. This is to assist in folding of the foreign polypeptide where GST at the
N-terminus may be incompatible to correct folding of the foreign protein (Sharrocks, 1994). It
is possible that this vector, pETGEXCT, would alleviate toxic problems encountered with
envA, envB and envC. In addition, this work highlights the potential problem in the
recombinant protein being folded correctly. If envA, envB and envC are not folding correctly
due to the presence of the GST moiety at the N-terminus, then this may explain their observed
toxicity in bacteria.
An alternative approach was adopted by a group working on the envelope glycoprotein of
HIV-1, gpl20. They employed an expression vector carrying the signal peptide of the major
outer membrane protein of E.coli and inserted gpl20 into this vector. Gpl20 was expected to
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be transported from the reducing environment of the cytoplasm to the more oxidising
environment of the periplasmic space allowing formation of disulphide bonds (Morikawa et
al., 1990a). This approach generally results in lower levels of recombinant protein compared
to direct cytoplasmic expression but proteins are more likely to be biologically active. The
three fragments of MVV gpl35 will each contain disulphide bridging motifs in the presence of
cysteine residues. It may be that by expressing in the cytoplasm disulphide bridging is
prohibited resulting in the incorrect folding of GST:envA, GST:envB and GST:envC, and
hence confer toxicity to the host cell.
The requirement of specific polyclonal and monoclonal antibodies against different regions of
gpl35 is important to gain knowledge of the relationship between structure and function.
Polyclonal sera could be used to identify the cellular receptor by immunoprecipitating
receptor/gpl35 complexes. Potential neutralization properties of these sera may provide a
crude form of mapping which could be investigated further in finer detail by peptide mapping.
The generation of immune sera from recombinant proteins is an approach that has been
adopted to study a wide range of viral glycoproteins, including those of lentiviruses such as
HIV-1 (Putney et al., 1986) and FIV (Ronde et al., 1994). Initial studies with HIV-1 showed
that by raising immune sera to recombinant gpl20, antibodies could be raised that recognised
native gpl20 and this was then used to inhibit neutralization in vitro. This was suggested to
have direct implications for use both as a vaccine and in understanding the biological function
of gpl20 (Lasky et al., 1986). Production of recombinant FIV surface glycoprotein was
undertaken by expressing it as overlapping fragments in bacterial cells. These recombinant
proteins were used successfully to immunise rabbits to produce hyperimmune semm that
contained antibodies to FIV envelope protein. This serum was used to identify a neutralizing
epitope (Ronde et al., 1994). Thus, the gpl35-derived fusion proteins would be expected to be
suitable for generation of immune sera. However attempts at raising polyclonal antibodies
against GST:envB and GST:envC were not successful. The sera appeared to have a low titre
as determined by western blotting and this was probably a reflection on relatively low yield of
fusion protein compared to contaminants. In fact, a predominance of anti-GST antibodies
were present within the sera. Neither of these sera recognised gpl35 derived from EV1-
infected cells, indicating that immunizations with these fusion proteins had not resulted in
raising antibodies specific to the gp 135 fragments.
The fusion proteins could have potential use to map immunodominant epitopes using MW-
infected sheep sera. This approach has been widely used in characterising immunodominant
epitopes in HIV-1 and FIV (Kowalski et al., 1987, Samuel et al., 1988, Crawl et al., 1985,
Putney et al., 1986, Ronde et al., 1994). There have been limited reports using recombinant
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fragments of gpl35 to assess the antibody profiles in MW-infected sheep. Reports by Kwang
and Cutlip (1992a and b) suggested that the N-terminus of gp40, the transmembrane protein,
was immunodominant compared to the external glycoprotein, and core proteins. They further
characterised a potential neutralizing epitope in the N-terminus of the external glycoprotein
(Kwang et al., 1995). Bacterially-expressed fragments of the surface and transmembrane
glycoproteins were able to induce neutralizing antibodies, suggesting that glycosylation may
not be necessary for mounting a humoral response against these proteins (Kwang et al., 1995).
In CAEV, the immunodominant epitope has been localised within the transmembrane region
(Bertoni et al., 1994), and expression of the hydrophilic portion in bacteria has resulted in its
possible use in a diagnostic ELISA (Rosati et al., 1995). Epitope mapping of the external
glycoprotein of MVV has been carried out with yeast-derived recombinant protein fragments
and three distinct epitopes within sheep sera have been located (Carey et al., 1993). Initial
studies with MW-infected sheep sera suggested that the preparations of recombinant protein
were not clean enough to use in epitope mapping studies. Non-specific reactivity of MW-
sheep sera to contaminants was also observed by Kwang et al. (1992a and b).
3.4 SUMMARY
This chapter describes the expression and characterisation of recombinant gpl35 fragments in
the bacterial pGEX system. These polypeptides proved to be toxic to the host cells as assessed
by inhibition of cell growth and resulted in poor yields. Slight improvements in yield were
achieved by altering the induction time, and modifying the lysis procedure. However, attempts
using the recombinant proteins for raising hyperimmune sera were not successful. This was
presumed to be attributed to the low levels of fusion protein compared to contaminants. The
potential use of the recombinant proteins in epitope mapping was limited by the non-specific
reactivity of sheep sera to contaminants within the protein preparations.
The toxic properties of the recombinant proteins is suggested to be due to hydrophobic regions
within the fragments and possible aberrant protein folding in the cytoplasm. More successful
expression may be achieved by removing hydrophobic regions, and using alternative bacterial
expression systems, such as the pETGEXCT system (Sharrocks, 1994).
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CHAPTER 4: GENERATION OF POLYCLONAL AND MONOCLONAL
ANTIBODIES AGAINST THE EXTERNAL ENVELOPE GLYCOPROTEIN
OF MAEDI-VISNA VIRUS
4.1 INTRODUCTION
This chapter describes attempts to raise specific antibodies to the external envelope
glycoprotein, gpl35, of MVV for use in characterizing functional epitopes such as receptor
binding domains and domains to which neutralizing antibodies are raised.
Epitope mapping of gpl35 has not been widely studied. Limited data has identified two
separate epitopes for neutralization and fusion on the envelope glycoprotein of the 1514 strain
of MVV (Crane et al., 1988). These epitopes were proposed by showing that antiserum
specific for the outer envelope protein from one strain of MVV was unable to neutralize an
antigenic variant, LV-V1. Inhibition of fusion, however, was observed for both strains by this
serum suggesting two separate epitopes. Fusion was monitored by a "fusion from without"
assay, which should be interpreted with caution since it does not represent a true physiological
occurrence. The assay relies on overloading the virus such that fusion occurs without the need
for virus infection. A hydrophobic peptide located within the transmembrane envelope protein
has been shown to have fusion activity (Crane et al., 1991b).
There are various reports that identify the existence of epitopes within the external
envelope glycoprotein that may be influenced by the host's immune system, and therefore
subjected to antigenic variation. Stanley et al. (1987) reported a panel of monoclonal
antibodies raised against lectin-purified envelope glycoprotein, which were used to
demonstrate topographical differences between antigenic variants of the 1514 strain of MVV.
None of these antibodies were neutralizing. Further characterization of this panel of
monoclonals has not been published. Another study using yeast-derived overlapping fragments
of gpl35 identified three distinct epitopes to which sheep infected with MVV mounted an
immune response (Carey et al., 1993). Sequence comparison between two antigenically
distinct strains of 1514 has identified a hypervariable site within the envelope gene which is
comparable in position to the V3 loop in HIV (Braun et al., 1987) but no function has yet
been attributed to this site. In summary, the data published so far is very limiting as to the
identification of functional epitopes within the envelope glycoprotein of MVV.
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In contrast to MVV, the characterization of the envelope glycoproteins of HIV-1 has been
widely studied, and epitope function has been mapped to the single amino acid level. Sequence
comparison between different isolates of HIV-1 has identified five hypervariable domains, VI
to V5 with five conserved domains, CI to C5 interspersed between them (Modrow et al.,
1987). The following studies are described as an example of the use of MAb for delineating
functional epitopes on viral glycoproteins. The existence of a neutralizing epitope on the
external glycoprotein, gpl20, was first described by Putney et al. (1986). The generation of
monoclonal antibodies against either lectin-purified gpl20 (Kinney-Thomas et al., 1988),
immunoafftnity-purified gpl20 (Matsushita et al., 1988), recombinant forms of gpl20
(Nakamura et al., 1993) or synthetic peptides (Durda et al., 1988), and assessing their ability
to neutralize virus infection has allowed the identification of epitopes within gpl20.
Monoclonal antibodies raised to lectin purified envelope resulted in the generation of four
MAb that recognised a central portion of gpl20, and these were able to neutralize the vims
(Kinney-Thomas et al., 1988). A fifth MAb directed against gpl20 mapped to a conserved
region at the carboxyl terminus and this was non-neutralizing. The neutralizing antibodies
were only effective against certain isolates of HIV-1 indicating that this epitope lies in a
variable domain (Kinney-Thomas et al., 1988). This work was supported by findings of
Matsushita et al. (1988), who isolated a MAb that was neutralizing. Epitope mapping using
various recombinant protein fragments, cyanogen-bromide fragments of native gpl20 and
overlapping synthetic peptides mapped this neutralizing domain to a 24 amino acid peptide
located within a hypervariable site (amino acids 296-331) known to contain neutralizing
epitopes (Matsushita et al., 1988), which had been earlier identified by Putney et al. (1986).
The MAbs described by Kinney-Thomas et al. (1988) were further studied using overlapping
peptides to finely map the principal neutralizing domain (PND) in order to understand the
criteria for a high neutralizing antibody. MAbs that bound to the tip of the loop showed the
greatest neutralization activity, whereas those with lower neutralization potential mapped to
the N-terminal of the loop (Lanjedijk et al., 1992). Also, antibodies that bound to the same
epitope on the loop differed in neutralization activities which was linked to their affinity to the
native gpl60.
The production of neutralizing MAbs has not been restricted to the PND. Production
of MAbs specific for the C4 domain showed that polymorphisms at a specific residue within
the C4 domain prevented the neutralization activity of these antibodies on various HIV-1
isolates (Nakamura et al., 1993). This suggested that the ability for some strains to escape
neutralization lies in the C4 domain as well as the hypervariable V3 loop. Neutralizing
monoclonal antibodies against gp41, the transmembrane glycoprotein of HIV-1, have also
been described (Dalgleish et al., 1988). These MAb were raised against a synthetic peptide of
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gp41 and were shown to be specific for neutralization of HIV-1 and not HIV-2, and the
epitope for binding was exposed before virus binding to the cell surface.
Characterization of the CD4-binding domain of gpl20 has also been elucidated with
the help of monoclonal antibodies. Dowbenko et al. (1988) describe the generation of a panel
of MAb directed against a recombinant form of gpl20. Those which blocked CD4 binding
were selected for further analysis and epitope mapping carried out using proteolytic fragment
of gpl20 and a random gpl20 expression library produced in the lamda gtll expression
system. These MAb were mapped to a conserved region of gpl20, residues 403-457, at the C-
terminus. Other MAbs were described that did not block CD4 interaction, but mutant analysis
within these domains disrupted gpl20 binding to CD4 suggesting they were involved in
maintaining the structural confirmation of gpl20 required for interaction with its receptor
(Dowebenko et al., 1988). A similar approach was taken using immnnnaffinity-pnrifieri
gpl20. Monoclonal antibodies that were able to block CD4 interaction were characterised and
the epitope mapped to the C3 region (Sun et al., 1989). One major difference in these
experiments was that these antibodies were able to neutralize virus infection. This was defined
to differences in antibody affinity and avidity for various MAb. Patient sera did not recognise
this epitope outlining a possible mechanism by which HTV is able to escape
immunosurveilance, by the inability of the host to raise neutralizing antibodies to this site.
Other domains of gpl20 have also been characterised with monoclonal antibodies. As
has been described above, the V3 loop is the principal neutralizing determinant. The role of
V2 as a target for neutralizing antibodies has been described (Ho et al., 1991). A panel of
monoclonal antibodies were raised that were dependent on the V2 domain for binding to
gpl20, as assessed by mutational analysis of the V2 domain. These MAbs were neutralizing
but were strain specific. However, no neutralizing antibodies in patient sera against VI and
V2 peptides were found so that the importance of these sites in natural infection is not clear.
The use ofpeptides may not be a true representative of the native confirmation of V2 in gpl20
and is therefore of limited value. A subsequent study using competition experiments between
human sera and monoclonal antibodies found that antibodies to the V2 loop were present in
patient's sera (Moore et al., 1993a). To date no structural analysis of gpl20 has been possible,
due to the inability to crystallise this protein. The use of MAbs and site-directed mutagemsis
has allowed topological characterization of gpl20, for example, the demonstration that V3
and C4 regions are in close proximity (Moore et al., 1993b). Subsequent analysis showed that
most conserved domains were not present on the surface of a recombinant monomelic form of
gpl20, and those that were exposed were at the N- or C-termini. These exposed conserved
regions were no longer accessible to MAbs in the oligomeric form of gpl20 (Moore et al.,
1994), presumably due to interaction with other gpl20 molecules or gp41. It appears that the
conserved regions are located within the core of gpl20, which is consistent with their
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hydrophobic nature and that very few monoclonal antibodies have been raised to them. The
major domains exposed on the surface of the oligomeric protein are V2 and V3 which are both
sites for neutralizing antibodies (Moore et al., 1994).
The studies described above are just a few examples of data published for HIV-1 gpl20
epitope mapping, but they highlight the importance and usefulness of monoclonal antibodies in
understanding protein function. At the commencement of this body of work, it was proposed
to generate a recombinant form of gpl35 that could be used as a reliable source of antigen to
use for generating antibodies. So far attempts at generating such a recombinant protein have
been unsuccessful (Chapter 3 and Carey, 1992). This chapter describes attempts at generating
monoclonal antibodies to a lectin-purified form of gpl35. Since no control monoclonal to
gpl35 was available within the department at the time of these experiments, various
approaches to a suitable screening assay are reported. The generation of two anti-gpl35
peptide polyclonal rabbit sera and their characterization is described.
4.2 RESULTS
4.2.1 The generation of monoclonal antibodies to the envelope glycoprotein of
MVV
4J2.1i Purification of envelope glycoprotein
For a standard preparation of antigen, sheep fibroblasts were grown to 80% confluency in 8L
tissue culture bottles and infected with approximately 0.05 TCID50 of EVl/cell in 30mls of
2% FCS/DMEM. By four days post infection extensive c.p.e. was apparent and infected cells
were knocked off the plastic surface using sterile glass beads. After clarification, the
supernatant was stored at -70°C, and an aliquot was tested on a standard virus titration assay
to confirm the presence of vims. The purification of gpl35 was carried out using a Lens
culinaris Sepharose 4B column (Pharmacia). The virus was pelleted, disrupted and loaded on
the column (3.5ml), following the manufacturer's instructions. After extensive washing of the
column, the glycoprotein was eluted in 3-6mls of elution buffer. 200|il aliquots were collected
and analysed by western blotting, probing with EV1 infected sheep serum, 848A, and normal
sheep serum as a negative control. It was usual for the glycoprotein to be eluted between the
sixth and fifteenth aliquots (data not shown). To ensure that all glycoprotein present in the
supernatant had been purified on the column, the 'flow through' was re-circulated on the
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column and elutant analysed as before. This revealed that all viral glycoproteins had been
purified in the first round of affinity chromatography. Analysis of purified protein showed a
single major protein band of approximately Mr 135 000 which was specifically recognised by
sheep 848A. To verify that the purified protein was vims-derived, a comparison was made to
crude EV1 infected cell lysate. Samples were analysed by western blotting using sheep sera
848A and normal sheep sera (Fig.4.1). A band of comparable size to the purified protein was
identified in the-crude cell lysates not seen in negative controls. A lectin purification was
carried out with supernatant from uninfected sheep fibroblasts and no protein band
comparable in size to gpl35 was identified (data not shown). To estimate the protein
concentration, aliquots containing purified glycoprotein were pooled, mn on a SDS-PAGE gel
and silver-stained. By comparing to known concentration of bovine serum albumin, the
concentration of gpl35 was estimated at 7pg/ml. Silver-stain analysis showed there was
minimal contamination and that gpl35 was the predominant protein (data not shown).
4.2.1ii Development of a screening assay for detection of anti-envelope antibodies
Since the yield of purified protein from the lectin purification was very low, this antigen was
reserved for the immunizations carried out below. Therefore, an alternative source of antigen
was required for the purposes of screening monoclonals and two approaches are described.
One shortcoming in developing a screening assay was the absence of an antiserum specific for
gpl35, and thus MVV infected sheep sera was used as a positive control.
a] Concanavalin A ELISA
This method was adapted from a protocol outlined by Robinson et al. (1990) developed for
screening HIV-1 infected patients.
1. Preparation of serum free virus stock
Sheep fibroblasts were grown in roller tissue culture bottles to 80% confluency and infected
with 0.05 TCID50 of EVl/cell in 30mls of 2%FCS/DMEM. Twenty-four hours later, the
medium was replaced with supplemented DMEM containing 1% Nutridoma (Boeringher
Mannheim). Three to four days later, extensive c.p.e. was apparent and cells were knocked off
the plastic surface with sterile glass beads. The supernatant was clarified and virus disrupted
by the addition of 10%(v/v)TritonX-100/PBS, to give a final concentration of l%TritonX-
100. This was incubated on ice for 30 minutes and supernatant was stored in 5ml aliquots at
-70°C.
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Figure 4.1: Lectin-affinity purification of gpl35 from MVV
Proteins were resolved on a 5-20% gradient SDS-PAGE gel and transferred to nitrocellulose.
Blots were probed with MVV-infected sheep sera, 848A (1/20) and normal sheep sera, NSS
(1/20). Proteins were detected with biotinylated anti-sheep IgG and extravidin-AP.
lane 1, lectin-purified gpl35.





The basic protocol for the ConA envELISA is as follows. Immulon n 96-well ELISA plates
(Dynatech) were coated with 200pg/ml of ConA diluted in 0.1M Na2C03, pH9.0, lOOpl/well,
for 16 hours at 4°C. The wells were washed 4 times with PBS containing 0.1%(v/v)TritonX-
100 (PBS-Tx) and 100pi of a predetermined dilution of serum-free virus stock was added to
each well. Virus negative controls were from mock infected cell supernatant, treated in the
same way as virus stock. A positive control for the ELISA was immunoaffinity-purified sheep
MHC classll, used at 8pg/ml (a kind gift of Dr.B.Dutia, Department of Veterinary Pathology,
Edinburgh). Samples were diluted in Hank's buffer (HBSS) and incubated for 1 hour at 37°C.
Wells were washed as before and blocked in HBSS/10% FCS, 200|il/well, for 1 hour at
37°C. To test antibody binding to immobilised viral glycoproteins, dilutions of heat-
inactivated sheep sera were made in blocking buffer and added at lOOpl/well for 1 hour at
37°C. The MHC classll positive control wells were incubated with a combination of two
anti-sheep MHC classO monoclonal antibodies (positive control) (a-DR and a-DQ), or a
Campylobacter specific monoclonal (negative control), lOOpl/well. The wells were washed as
before and incubated for 1 hour at 37°C with a anti-species biotinylated antibody, diluted
1/1000 in blocking buffer, lOOpl/well. Wells were washed and incubated in extravidin-AP,
diluted 1/1000, 100pl/well, for 1 hour at 37°C. The wells were washed and incubated in
developing solution at 37°C until colour had developed. ELISAs were read at optical density
of405nm.
3. Development of optimum conditions for ConA envELISA
To optimise the conditions for ELISA, serial dilutions of serum-free antigen were added to
ConA-coated ELISA plates as 1, 1/2, 1/4, 1/8 and 1/10 dilutions in duplicate wells. Plates
were set up with mock-infected serum-free antigen as background controls. After
immobilisation of antigen, wells were blocked and the following dilutions of MW-infected
sheep sera, 848A, and a negative sheep serum; 1/10, 1/100, 1/500 and 1/1000 were added to
the wells to each dilution of antigen. The results are shown in Fig.4.2, for the three serum
dilutions; 1/100,1/500 and 1/1000. Results from the serum dilution 1/10 are not shown since
readings were too high to be measured when plates were read at a given time point
Interpretation of the data indicate that at serum dilution 1/500 and 1/1000, MW-infected
sheep sera was reacting specifically with immobilised viral glycoproteins and that the
strongest reactivity was seen at dilution 1 and 1/2 of antigen. In subsequent experiments,
serum-free virus antigen was usually diluted 1/2.
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Figure 4.2: ELISA reactivity of MW-infected sheep sera against varying dilutions of
ConA-immobilised MVV glycoproteins
Details of the ELISA protocol are given in the text. Graphs a, b and c represent dilution of
sheep serum at 1/1000, 1/500 and 1/100, respectively. Standard deviations are shown.
Key: EV1, viral antigen
Mock, mock antigen
848A, MVV-infected sheep sera




The above experiment was extended to confirm that the reactivity of MVV-infected sheep sera
was directed to immobilised virus glycoproteins. The following dilutions were made; 1/500,
1/1000, 1/2000, 1/4000 using a 1/2 dilution of antigen. The results from this titration
confirmed that MVV-infected sheep sera reacted specifically with immobilised MVV
glycoproteins (Fig.4.3).
The optimum concentration of ConA for coating ELISA plates was determined using a 1/2
dilution of antigen, and sheep sera were diluted at 1/1000. Normal sheep sera background
controls were subtracted from MVV-infected sheep sera samples and results are presented in
Table 4.1. The greatest difference in optical density values was at a ConA concentration of
200[xg/ml and this concentration of ConA was used in future experiments.
The background controls gave relatively high O.D. readings. Experience showed that even in
the absence of antigen high backgrounds were seen for sheep sera comparable to the negative
control background readings. Various blocking agents were investigated, including varying
concentration of FCS, donkey serum, which was the species in which the conjugate was
raised, and BSA. No significant reduction in background was observed (data not shown), and
is a possible reflection of non-specific binding by sheep sera.
To test the presence of non-viral glycoproteins immobilised by ConA, an anti-sheep MHC
classl monoclonal was added to wells containing immobilised virus antigen and mock antigen.
No specific reactivity was detected suggesting that viral glycoproteins were the most abundant
antigen (data not shown). It is also possible that MHC classl does not bind to ConA, or that
binding was too low for detection by the monoclonal used.
Although the above results did show a promising screening ELISA, there were several
limitations to this assay. Different preparations of serum-free virus resulted in varied
concentrations of viral antigens, and thus the ability of MVV-infected sheep sera to detect
virus specific antigens was not consistent (data not shown). The lack of a control monoclonal
in this assay limits its use as a monoclonal screening assay.
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Figure 4.3: Titration of MW-infected sheep sera reactivity to ConA immobilised MVV
glycoproteins
Graph shows the results from the ELISA, details of which are given in the text. Standard
deviations are shown.
Key: EVI, viral antigen
Mock, mock antigen
848A, MVV-infected sheep sera
NSS, normal sheep sera
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SHEEP SERUM DILUTION
Table 4.1: Determination of optimum concentration of ConA for specific reactivity of
MVV-infected sheep sera to immobilised viral glycoproteins
The difference between optical values at 405nm of MW-infected sheep sera and normal sera
were calculated for each dilution of ConA, and are tabulated below.
[ConA] 200pg/ml 150pg/ml 100p.g/ml 50|Xg/ml 25|ig/ml none
SFVS 0.995* 0.645 0.749 0.508 0.645 0.081
SFMS 0.127 0.083 0.058 0.007 0.02 0.01
Note: SFVS, serum-free virus stock
SFMS, serum-free mock stock




96-well plates were seeded with 104cells/well in the inside 60 wells and incubated for a further
16 hours at 37°C. The cells were infected with 1 TCID50/cell, 0.5 TCID50/cell or mock-
infected in triplicate across the plate. After a 2 hour incubation, virus was removed fresh
medium was added. 72 hours later, the medium was removed and cells were fixed in ice-cold
acetone:methanol (1:1) for 5 minutes. Well were allowed to dry and stored at -20°C.
Prior to performing an ELISA, plates were thawed for 45 minutes at 18°C. Wells were
blocked with 2%BSA(w/v)/PBS for 30 minutes at 18°C (200pl/well). ELISA was then
carried out using the standard protocol. To test for the possibility of using this ELISA as a
screening assay for env monoclonals, the following monoclonal antibodies were tested; anti-
p24 (Reyburn et al., 1992), anti-ovine LFA3, anti-ovine LFA1 and anti-ovine MHC classl.
Anti-p24 was used to test for the presence of viral antigens, anti-LFA3 and anti-MHC classl
to test for surface antigens and anti-LFAl as a negative control. The results of testing the
fixed cell assay are given in Table 4.2. Anti-LFA3 and anti-p24 gave positive readings
compared to the negative control, anti-LFAl. Anti-MHC classl gave lower readings, and it is
known to give weak staining of fixed tissue by FACS (Dr.B.Blacklaws, personal
communication). Readings with anti-LFA3 and anti-MHC classl were higher in uninfected
cells than infected and is probably a reflection of cell density in those wells. The opposite is
seen for anti-p24 where readings in uninfected cells was comparable to anti-LFAl, indicating
a specific reactivity of anti-p24 for viral capsid protein.
Since both positive and negative control monoclonals were available for this assay and that
antigen preparation via fixing infected cells was reproducible, this assay was adopted for
screening anti-envelope monoclonals. The inside 60 wells of a 96-well plate were routinely
infected with an m.o.i. of 1, that is 1 TCIDS0/cell, for 30 wells, and the remaining 30 wells
were mock infected. Cells were fixed and plates were stored at -20°C.
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Table 4.2: Reactivity of a panel of monoclonals on a fixed-cell assay
m.o.i. of EV1 1 0.5 0
anti-LFAl (-ve) 0.348+/- 0.014* 0.321+/-0.018 0.408+/- 0.037
anti-LFA3 (+ve) 0.821+/-0.1 0.789+/- 0.048 1.059+/-0.129
anti-MHC classl 0.492+/- 0.08 0.428+/- 0.049 0.781+/-0.06
(+ve)
anti-p24 (+ve) 0.917+/-0.129 0.795+/- 0.049 0.418+/- 0.057
Note: * optical density values (405nm) +/- s.d.
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4.2-liii Preparation of anti-env monoclonal antibodies
a] Immunizations
Three 7 week old female BALB/c mice were injected at two sites subcutaneously with
approximately lug of lectin-purified gpl35 emulsified in Titer-Max™, to give a final volume
of 400ul. Each mouse was given two intraperitoneal boosts of lug of antigen in PBS (in the
same volume as the initial injections) with an interval of 4 weeks between each boost. Three
weeks later, tail bleeds were taken from each mouse and titres were tested on the fixed-cell
ELISA assay (Fig 4.4). The titre was measured as the 50% point between the maximum and
minimum O.D. values on the titration curve. Mouse 1 gave the highest titre and was selected
for fusion. It was noted that there was an immune response to cellular-derived proteins, and
although no significant difference was seen for an immune response against viral antigens, it
was assumed that since the serum was polyclonal then anti-gpl35 antibodies would be
present. The two remaining mice were continually boosted as before in an attempt to increase
antibody titres. Boosts were given every 10-14 days, and after two more boosts mouse 2 was
selected for fusion. Immunizations of mouse 3 was continued over a further two months and a
second tail bleed was taken. The titre of this serum, determined on the fixed-cell assay, was
estimated at 1/1800 and was much higher than in the original test bleed (Fig.4.5).
b] Preparation of hybridomas and screening
Fusions with the spleen cells of mouse 1 and 2 were unsuccessful, and therefore results from
the third fusion only will be reported. Three days prior to fusion, mouse 3 was given an
intravenous boost of lug of gpl35 in PBS (in a volume of lOOpl). Spleen cells were isolated,
washed and fused with HAT sensitive myeloma cells, SP2 (Schulman et al., 1978), at a fusion
ratio of 6:1 of spleen cells to myeloma cells. Ten days post fusion, the wells containing
hybridomas were scored and fed with 15%FCS/RPMI supplemented with HAT. When the
wells reached 80% confluency, 200jil of supernatant was removed and tested on the fixed-cell
assay. If the clone tested positive it was transferred to a single well in a 24-well plate. A total
of 350 wells were seeded with fused hybridomas and only 66 of these contained clones. After
primary screening, 5 of the 66 clones were positive, that is 7% (see Table 4.3). A positive
clone was termed as that which gave an O.D. value greater than the value of the negative
control reading plus double its standard deviation.
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Figure 4.4: Titration curves for mouse 1, 2 and 3 sera after inoculation with lectin-
purified gpl35
Mice were immunised as detailed in the text. Tail bleeds were taken and tested on a fixed-cell
ELISA by comparison to normal mouse sera. Standard deviations are shown. Graphs a, b and
c represent titration curves of mouse 1, mouse 2 and mouse 3, respectively.
Sera titres were estimated as : mouse 1; 1/700
mouse 2; 1/500
mouse 3; 1/450
Key: mock, uninfected fibroblast cells
EV1, MVV-infected fibroblast cells
ml/m2/m3, mouse 1, 2 and 3, respectively
nms, normal mouse serum
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Figure 4.5: Titration of mouse 3 sera on a fixed-cell ELISA after a prolonged
immunisation schedule
Mouse 3 was boosted with gpl35 as detailed in the text. A second tail bleed was taken and
tested on a fixed-cell ELISA, by comparison to normal mouse sera. Standard deviations are
shown.
The titre of mouse 3 sera was estimated as 1/1800.
Key: mock, uninfected fibroblast cells
EV1, MW-infected fibroblast cells
m3, mouse 3
nms, normal mouse semm
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dilutions of mouse serum
Table 4.3: Results from the primary screening of env specific-hybridomas
Clone no. infected uninfected LFAl(-ve) a-p24(+ve)
5F6 0.349* 0.338 0.302 0.614
6G4 0.660 0.597 0.550 0.892
2C7 0.459 ' 0.411 0.463 1.135
2C8 0.459 0.411 0.463 1.135
3F8 0.463 0.458 0.347 0.884
Note: * optical density values at 405nm.
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These positive clones were grown in duplicate wells of a 24-well plate and frozen down in
liquid nitrogen. Clones 5F6,2C8, 6G4 and 3F8 were selected for secondary screening by soft-
agar cloning. Twenty four colonies were picked for each clone from the agar plates and grown
up in 24-well plates. When the wells were confluent the supernatants were tested on the fixed-
cell assay. The positive hybridomas isolated from this cloning are listed in Table 4.4 in which
their O.D. readings are compared to the positive and negative controls. All these clones were
expanded into duplicate wells and stocks frozen down into liquid nitrogen.
Qones 3F8 C3, 5F6 Al, 5F6 C6 and 6G4 D5 were selected for a second round of agar
cloning since these clones gave the greatest difference in O.D. values between infected and
uninfected cells. Twenty four clones were picked from the agar plates and grown up as before.
When tested on the fixed-cell ELISA only 25% of the clones screened positive (data not
shown). Since at least 90% of clones would be expected to be positive in the third round of
cloning, it was decided to retest the original clones 5F6, 6G4, 2C7, 2C8 and 3F8. These
clones were resuscitated and grown up into a single well of a 24-well plate. Supematants were
tested in triplicate on a fixed-cell ELISA and gave negative O.D. readings. The supernatants
were also tested by western blotting with MW-infected cell lysates, using an EV1-infected
sheep immune serum and a anti-p24 monoclonal as positive controls. None of the test
supernatants bound to virus glycoprotein (data not shown).
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Table 4.4: Results of secondary screening by agar cloning
clone infected uninfected LFAl(-ve) a-p24(+ve)
3F8 A3 0.418* 0.370 0.385 0.667
3F8 C2 0.526 0.356 0.462 0.617
3F8 C3# 0.559 0.306 0.322 0.908
3F8 C4 0.354 0.282 0.322 0.908
3F8 D2 0.442 0.342 0.322 0.908
3F8 D3 0.673 0.562 0.510 1.325
3F8 D5 0.563 0.38 0.372 0.908
2C8 C4 0.450 0.406 0.462 0.617
5F6 Al# 0.673 0.445 0.510 1.325
5F6 C6# 0.706 0.338 0.510 1.325
5F6 D2 0.443 0.359 0.462 0.617
6G4 C6 0.508 0.365 0.372 0.908
6G4 D5# 0.508 0.365 0.672 1.325
6G4B3 0.615 0.534 0.778 1.358
6G4 C3 0.731 0.650 0.778 1.358
Note: # indicates clones selected for further cloning, as described in text.
* optical density values at 405nm.
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4.2.2 Preparation of rabbit anti-serum specific for gpl35-derived peptides
4.2.2i Immunizations and determination of antibody titre
Two peptides derived from the external envelope glycoprotein of MVV were synthesized and
obtained commercially. Peptide 1 included amino acids 190-209 and peptide 2 included amino
acids 419-438. Both are located in predicted hydrophilic sites within a-helical structures and
an additional cysteine was added to the carboxyl end of the peptide 1, for the purposes of
crosslinking (Fig.4.6). Peptides were crosslinked to ovalbumin, the carrier protein, using
SPDP as a linker molecule. Two female Dutch rabbits were immunized with either one of the
peptides. They were primed with approximately 0.8mg of crosslinked peptide emulsified in
Titer-Max™ by giving two injections subcutaneously. The rabbits were boosted with 300jig
of antigen in incomplete Freund's adjuvant 10 days later, followed by a second boost 14 days
later. Both rabbits were bled prior to commencement of the immunizations and 7 days after
the third immunization. Antibody titres were tested by ELISA following standard protocols.
Peptides were dissolved in 0.01 M HC1, ether extracted and neutralized with phosphate buffer.
ImmulonlV plates (Dynatech) were coated with peptide 1, 2 or PBS, 1 OOul/well at a
concentration of 10pg/ml in PBS. Peptides were allowed to adhere to the plastic for 16 hours
at 4°C. After blocking, ten fold dilutions of serum were added to the plate, including pre-
bleeds. The ELISA was developed with anti-rabbit alkaline phosphatase with the usual
developing solution. The titres were determined graphically as described in section 4.2.1iii
(Fig. 4.7). Titres were estimated at 1/2000 for rabbit PI and 1/17000 for rabbit P2. The
rabbits were continually bled once a month over a period of 4 months. Titres of each bleed
were compared on the ELISA described above, and no significant drop in titre was observed
(data not shown). After 6 months since the initial immunisation, it was decided to bleed out the
rabbits. They were given a boost of 500pg of peptide and 10 days later they were bled out.
Serum was stored at -20°C.
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Figure 4.6: The location and amino acid sequence of peptide 1 and peptide 2 on the
external glycoprotein ofMW
Amino acid numbering is as stated in Sargan et al. (1991). The location of the three
hydrophobic sites and the major hydrophilic region are those predicted in Sargan et al. (1991),














Figure 4.7: Determination of rabbit sera titre following immunisation with gpl35
peptides on ELISA
The conditions for the ELISA are given in the text. Graphs a and b represent titration curves
for rabbits immunised with peptide 1 and 2, respectively. Standard deviations are shown.
Key: RP1, rabbit peptide 1 sera
RP1 prebl, rabbit peptide 1 prebleed sera
RP2, rabbit peptide2 sera
RP2 prebl, rabbit peptide2 prebleed sera
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4.2.2ii Characterization of anti-gpl35 peptide sera
a] Recognition of native envelope protein
Both sera were tested for their reactivity to MW-derived glycoproteins. EVl-infected crude
cell lysates were run on a 5-15% gradient SDS-PAGE gel for western blotting and probed
with anti-Pi and anti-P2 sera and their prebleeds. EVl-infected sheep sera and normal sheep
sera were used as positive and negative controls, respectively. Both anti-Pi and anti-P2
recognised a protein approximately 135kDa in size, comparable to that recognised by MVV-
infected sheep sera (Fig.4.8). The negative control sera did not recognise a protein of this size.
In mock-infected cell lysates, no band of this size was observed (data not shown).
The ability of the anti-peptide sera to recognise viral glycoproteins was further investigated by
immunoflourescence. Sheep fibroblasts were grown on sterile cover slips and infected with
EV1 at 4 TCID50/cell, 2 TCID50/cell, 1 TCID50/cell or 0 TCID50/cell. After 3 days, cells
were fixed and dried. Cells were blocked for 30 minutes at 18°C with 10% sheep semm(v/v)/
0.01% Tween 80(v/v)/ PBS. The following rabbit sera were added: anti-Pi (1/100), anti-Pi
prebleed (1/100), anti-P2 (1/200), anti-P2 prebleed (1/200), anti-GST (1/100) and anti-p24
(1/500). Dilutions were made up in 2% sheep serum(v/v)/ 0.01% Tween80(v/v)/ PBS and
cells incubated for 1 hour at 18°C. Antibodies were detected using anti-rabbit biotinylated
antibody (1/250) and extravidin-FITC (1/1000). Coverslips were mounted and examined for
fluorescence. The staining pattern in the p24 positive control infected cells indicated that
immunoflourescent staining had worked (data not shown). By comparison, no positive staining
was seen for anti-Pi and anti-P2 sera on infected cells. In fact, these samples gave staining
patterns similar to negative control or uninfected cells (data not shown).
The ability of these peptide antisera to immunoprecipitate gpl35 was not investigated.
b] Neutralization properties of anti-peptide sera
The ability of anti-Pi and anti-P2 sera to neutralize virus infection was investigated by
monitoring the effect on the syncytium formation by the vims. Four 96 well plates were
seeded with 104fibroblast cells/well and incubated for 16 hours at 37°C. Ten fold dilutions of
each peptide antiserum and appropriate prebleeds were incubated with 500 TCID50 of EV1
for 16 hours at 4°C. The following day, a neutralization assay was performed and seven days
later cells were Giemsa stained. All wells except for the final row showed extensive c.p.e.
indicating that the amount of vims in each well was probably too high to expect a
neutralization effect. There was no reduction in TCID50 observed for cells incubated with
peptide serum.
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Figure 4.8: The ability for anti-peptide sera to recognise the envelope glycoproteins of
MVV
Peptide 1 and peptide2 sera were tested against EV1-infected crude cell lysates by western
blotting as detailed in the text. Sera were diluted 1/100.
lane 1, peptide 1 antisera (prebleed).
lane 2, peptide 1 immune antisera.
lane 3, peptide2 antisera (prebleed).
lane 4, peptide2 immune antisera.
lane 5, EV1-infected sheep sera, 848A.






The neutralization assay was repeated with a lower TCID50 start point and using an IgG
purified fraction of anti-peptide sera. Doubling dilutions of anti-Pi and anti-P2 were set up
starting with 2.4mg/ml of IgG, and 200 TCID50 of EV1 was added to each sample for 16
hours at 4°C. The following day, a neutralization assay was performed with doubling
dilutions of virus across the plate. Seven days later, cells were stained with Giemsa and
inspected for a reduction in TCID50. A control plate was set up with normal rabbit IgG. No
inhibition of infection was observed for anti-Pi and anti-P2 sera (data not shown).
4.3 DISCUSSION
This chapter has described attempts at generating antibodies against the external envelope
glycoprotein ofMVV.
4.3.1 Attempts at generating monoclonal antibodies
Due to the disappointing results on recombinant expression of gp 135, an alternative source of
immunogen was required for the purpose of raising antisera. A simplified protocol was
devised for the purification of envelope protein from virions, adapted from Pyper et al. (1984).
Lectin-affinity purification was successful in isolating the envelope glycoprotein of MVV,
although yields were not high. The use of lectin-puiified gpl35 as an immunogen for raising
monoclonal antibodies has been described by Stanley et al. (1987). This work resulted in a
panel of monoclonal antibodies raised against the envelope glycoprotein of the 1514 strain of
MVV, and these were used to localise antigenic variation within the glycoprotein envelope.
The absolute identity of lectin-purified gpl35 is not clear. In the above publications it is
referred as the envelope glycoprotein, and it is not characterised further as representing the
external glycoprotein. Crane et al. (1988) describe lectin-purified gpl35 as the outer
membrane glycoprotein within which two separate epitopes for neutralization and fusion are
characterized. During the purification protocol, especially the ultracentrifugation step, the
shedding of the external glycoprotein would be expected resulting in the predominance of the
precursor glycoprotein in the purified virions. Thus, it would seem probable that the 135kDa
protein purified by lectin-chromatography is the uncleaved precursor envelope. The identity
and size of the glycoproteins of MVV are discussed further in Chapter 6. It is also noted that
the transmembrane glycoprotein of MVV, gp40, was not purified by lectin affinity
purification as analysed by western blotting. This failure in purification may be due to its
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interaction with the plasma membrane, and possibly stronger detergents would be required to
release the transmembrane glycoprotein from the membrane. Alternatively the levels of the
transmembrane protein in the purified virions and its subsequent lectin purification may have
been too low to detect by western blotting.
The successful development of a screening assay was limited by the absence of an anti-
envelope glycoprotein. The first approach using ConA to immobilise viral glycoproteins
shared principles similar to that used for the purification of the immunogen. That is, the ability
of carbohydrate moieties, present on the surface of glycoprotein, to bind to lectins. Hie
method used for the purification of MW glycoproteins was less abrasive for the ConA assay
than the purification of virions, and thus the preservation of the outer envelope glycoprotein
would be expected. One shortcoming was that the concentration of viral glycoproteins in the
supernatant of EV1-infected fibroblasts may be too low for adequate binding to ConA. The
results for development of the ELISA suggested that EV1-infected sheep sera did recognise
immobilised viral glycoproteins (Fig. 4.2 and 4.3). There were several features of this assay
that limited its use as a screening assay. The use of sheep sera in development was adequate to
demonstrate the specific binding of viral glycoproteins. However, the high backgrounds due to
non-specific reactivity of normal sheep sera suggested that sheep sera would not be suitable
controls when screening for monoclonals. The non-specific reactivities of sheep sera was
suggested, in part, to be due to reactivity to ConA. Despite attempts using various blocking
agents, high backgrounds could not be reduced. Non-specific reactivity of sheep sera is seen in
western blotting procedures also, which supports the problem in using sheep sera as controls
in an ELISA. As was reported in the results, specific reactivity to viral antigens was not
observed with a panel of 4 additional EV1-infected sheep sera. There appeared to be a degree
of variation between different preparations of viral antigens. This could be due to the state of
fibroblasts at the time of infection which will reflect the titre of virus produced. Thirdly, the
time required to carry out this assay was longer than for the average ELISA which is not ideal
when screening monoclonal antibodies, since a short, concise assay is more favourable. It was
reported that MHC classl contaminants were not detectable. However, as was reported for the
fixed cell assay, this MAb shows only weak binding to sheep fibroblasts. Therefore the
possibility of non-viral glycoprotein contaminants cannot be ruled out, and these may have
contributed to the non-specific reactivities of the sheep sera.
The second approach proved to be more suitable for the purposes of screening monoclonals.
Firstly, an anti-MW monnrlnnal and an anti-sheep fibroblast surface molecule were
available. Both these monoclonals gave positive O.D. readings on the ELISA. This suggests
that the protocol used allowed the detection ofviral antigens as well as preserving the presence
110
that the protocol used allowed the detection of viral antigens as well as preserving the presence
of surface molecules. This is an important result since a control is necessary for the detection
of viral glycoproteins which are expected to be present at the surface of the infected cell. This
ELISA was more rapid than the ConA ELISA and the plates could be preprepared and stored
at -20°C until required. Since during all hybridoma screenings the anti-p24 monoclonal gave
positive readings, adequate viral antigens appeared to be present on the fixed-cell plates. The
presence of capsid protein is a common detection system for virus infection, suggesting that it
is this antigen which is produced to detectable levels during infection (Reyburn et al„ 1992). It
was not possible to measure whether envelope glycoproteins would be present in detectable
levels, due to the absence of anti-envelope antibodies at the time of the monoclonal studies.
Inoculations of three mice were performed. After three immunisations the sera was tested on
the fixed-cell ELISA. The titres obtained were at the lower end of the range acceptable for
performing fusions. Mice 1 and 2 did not result in successful fusions. In an attempt to increase
the antibody titre, mouse 3 was given additional boosts over a period of two months. Retesting
of the sera indicated that, the titre had increased to a level more acceptable for performing
fusions. The usual titre for perfonming fusions is between 1/1000 to 1/100 000. Although the
titration graphs indicated that an immune response had also been mounted against cellular
contaminating proteins, subsequent screening of monoclonal antibodies would allow
differentiation between these and anti-env monoclonals.
Isolation of spleen cells resulted in 9x107 cells, which is comparable to the expected result of
108 cells. It is usually expected following fusion that most wells would contain hybridomas,
and of those between 10 and 50% will secrete antigen-specific antibody. The results from the
fusion of mouse 3 spleen cells to SP2 myeloma cells was disappointing in that only 66 of 300
wells contained hybridomas. This is probably a reflection on the technical expertise required
for efficient fusions. However, approximately 7% of these wells screened positive for and-env
antibody. The O.D. readings for all these wells was low compared to the positive control. It is
noted that even negative hybridomas tested did not give readings comparable to positive
controls, thus suggesting that not even anti-cell antibodies were being secreted by the
hybridomas, whose presence was predicted on the serum titration curves. Subsequent cloning
did not result in the isolation of a single clone secreting mh-env antibodies.
Several factors may explain the failure of the fusion. The titre of antibody in the
serum may have been too low, such that the proportion of B cells in the spleen secreting the
antibodies of interest were low. This may be a reflection on the amount of antigen used to
prime the mice. It is usual to prime with 10-50pg of antigen (Hum and Chantler, 1980,
Vaitukaitis, 1981), which was not possible with the low yields obtained during lectin
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purification. The use of the prolonged immunisation protocol for mouse 3 would expect to
increase the titre, although the affinity of these antibodies would be low. Apart from the small
amount of antigen used to prime the mice, the preparation of an adequate emulsion with
adjuvant may affect the induction of an effective immune response. An emulsion allows the
slow release of antigen into the blood stream which is favourable when attempting to enhance
an immune response against a weak antigen. Since the immunization protocol only used
adjuvant in the primary inoculation, stimulation of the immune response may not have been
adequate on subsequent boosts.
Hybridomas are generally unstable cell lines with a tendency to loose chromosomes on
cell division. However, over two rounds of cloning the rate of chromosome loss is slow. In the
case of this work, the supernatants gave low readings on the first round of screening,
suggesting that the failure of the fusion was not due to chromosome loss during cloning of the
hybridomas.
The preparation of monoclonal antibodies is expensive and time consuming. In view of these
factors and the problems in developing a suitable screening assay, attempts at raising
monoclonal antibodies were halted.
4.3.2 Preparation of anti-peptide polyclonal antibodies.
To date, no antibodies specific for the external envelope glycoprotein of MVV were available
within the department. Two peptides derived from the external glycoprotein of MVV were
used as immunogens. Peptides can be used to characterize a gene of unknown protein product.
One of the shortfalls of using peptides is that they represent continuous epitopes which may
not be present on the native protein. However, denatured proteins and peptides can be
effectively used to generate antibodies against the native protein (Lemer, 1982). It could be
envisaged that the ability of an antibody specific for a continuous epitope to bind to the native
antigen is achieved by the mobility of that epitope within the native molecule (Westhof et al.,
1984). In a similar way, an antibody may exhibit enough flexibility at the hinge region to fit
the antigenic site (Oi et al., 1984). The use of the two peptides derived from gpl35 resulted in
a polyclonal serum that recognised native gpl35 by western blotting. These antisera were not
able to recognise antigen by immunoflourescence. In western blotting, proteins are denatured
before separation by SDS-PAGE, whereas immunoflourescence was set up to detect non-
denatured protein within infected cells. Thus these two peptides may not be present as epitopes
in the native protein, although they are both hydrophilic and thus would be expected to lie on
the outside of the protein. This is particularly applicable to PI which lies at amino acid 190 in
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gpl35, that is 90 amino acids from the N-terminus of the mature protein where the signal
sequence lies within the first 100 amino acids (see Chapter 5). The fact that these peptides do
not suggest to represent epitopes within the native protein is supported by the fact that the
antisera was non-neutralizing, and the peptides did not bind specifically to the surface of sheep
cells (see Chapter 5). These peptide antisera have use as a control for western blotting and
they could possibly used as a control in a monoclonal screening assay, depending on the
nature of the antigen used to coat the ELISA plate.
4.4 SUMMARY
This chapter has described attempts at raising a panel of monoclonal antibodies against lectin
purified gpl35. The development of two potential screening assays is described and their
shortfalls for detecting anti-envelope monoclonals discussed. Reasons why monoclonal
antibody production was not successful may be due to immunization strategy and amount of
antigen used. The production of polyclonal sera against two peptides derived from the external
glycoprotein of MVV is reported. These sera were able to recognise denatured envelope
proteins, but did not appear to be represented as epitopes on the native protein.
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CHAPTER 5: EXPRESSION AND FUNCTIONAL STUDIES OF THE
EXTERNAL GLYCOPROTEIN OF MVV, GP135, IN THE BACULOVIRUS
EXPRESSION SYSTEM
5.1 INTRODUCTION
Previous attempts to express the external glycoprotein of Maedi-Visna Virus as a recombinant
protein have been frustrated by the toxic properties of this protein which has resulted in low
yields accompanied by contaminating products (Carey, 1992, and Chapter 3 of this thesis).
The two expression systems employed in this laboratory to date are the yeast Ty system and
the bacterial pGEX system. Both systems are simple to manipulate and have the potential to
produce large quantities of recombinant protein on a large scale. However, these systems lack
the more sophisticated post-translational modifications, such as the glycosylation pathway,
that are a feature of the higher eukaryotic systems. Expressing a protein in a eukaryotic
system requires the introduction of the gene of interest into mammalian cells via a vector. The
vaccinia expression system is the most widely used for production of recombinant protein by
constructing recombinant vaccinia virus which can infect mammalian cell lines to express the
protein of interest. Preliminary experiments in our laboratory have been unsuccessful in
raising a recombinant vaccinia vims, although expression of the surface protein of CAEV,
which is the most closely related lentivirus to MVV, in this system has been published
(Lichtensteiger et al., 1991). Other mammalian expression systems are more useful to confirm
the identity of a certain gene and its function, and involve generating a stable cell line that
expresses the protein of interest. An expression system which is becoming more popular is the
baculovirus expression system and recent advances in understanding the molecular biology of
these insect-specific viruses, especially the very late gene promoters, has lead to refinements in
production of recombinant viruses.
Baculoviruses are unique to invertebrates and their infection can lead to complete obliteration
of insect populations. It is this for which they first gained their importance as a potential for
pest control. Baculoviruses have large, double-stranded, covalently-closed circular DNA
genomes that range from 80-200kbp in size. The DNA is associated with a 6.5kDa, highly
basic nucleoprotein (Tweeten et al., 1980) and this complex is surrounded by a rod-shaped
nucleocapsid containing a 39kDa protein (Theim and Miller, 1989). The nucleocapsids are
further packaged into a lipid envelope to form a vims particle which may be assembled into
polyhedra depending on the stage of the vims life cycle. Polyhedrin is a 29kDa protein that
accumulates in large quantities at the late stages of the vims life cycle (reviewed by
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Rohrmann, 1986). Baculoviruses are classified into subgroups depending on the packaging
characteristics of the polyhedra. Subgroup A, known as the nuclear polyhedra viruses (NPV)
are the type that have been most widely studied, in particular for their potential to control
insect pests and manipulation for the production of recombinant protein. This subgroup is
characterized by the presence of several virus particles occluded in a single polyhedron, and
each virus particle may contain several nucleocapsids. The virus that has been most widely
used for expression purposes is Autographica californica multiple nuclear polyhedrosis virus
(AcMNPV).
Baculoviruses have two life cycles (reviewed by Webb and Summers, 1990): the extracellular
virus is the lytic form and is predominant in the initial stages of infection where it is
responsible for spread of virus from cell to cell. The polyhedra-associated virus is important in
the later stages of the virus life cycle where it is vital for survival outside the insect and
therefore for transmission to other hosts. In vivo, polyhedra are ingested by the insect host and
the polyhedrin protein dissolves in the gut to allow release of the virus particles which then
fuse with the plasma membrane of the host cells. The nucleocapsid is important for the entry
of the DNA into the host's nucleus where viral replication commences. Nucleocapsids form in
the nucleus where they bud from the nuclear membrane. This membrane coat is lost in the
cytoplasm and the virus gains a new envelope coat when it buds from the plasma membrane
and also aquires a virus encoded glycoprotein, gp67 (WMtford et al., 1989), which is
responsible for attachment of the virus to other cells in the host. At later stages in the life cycle
the production of extracellular viruses is replaced by the production of virus particles in the
nucleus which acquire a lipid coat that is made de novo in the nucleus and lacks gp67. These
particles accumulate into polyhedra which eventually results in the swelling and destruction of
the insect and release ofpolyhedra into the external environment
The replication cycle in vitro is essentially similar to in vivo with the production of polyhedrin
in cells at the later time points of infection. The most widely used cell lines that support
infection in vitro are derived from the Fall army worm, Spodoptera frugiperda (Sf) (Vaughn
et al, 1977). However, propagation of AcMNPV in vitro can lead to incorporation of host cell
DNA and transposable elements within its genome so precautions must be undertaken when
passaging recombinant viruses in vitro. The virus genome is susceptible to mutations but this
will rarely affect the production of recombinant protein (Bissard and Rohrmann, 1990). With
regard to the use of baculoviruses as expression systems the polyhedrin protein and pi0,
which forms a crystalline matrix in the polyhedra, are of most importance. These proteins are
under the influence of very efficient promoters and can account for up to 50% of total cell
protein mass. These proteins are non-essential for the production of progeny virus allowing
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them to be manipulated for expression purposes. Baculoviruses are an ideal expression system
for the following reasons:
1. The merits of the polyhedrin and P10 have already been highlighted and enable a foreign
gene to be expressed in large quantities.
2. The expression of these very late genes occurs after the maturation of the virus particle
such that any potentially toxic foreign protein will not disrupt vims replication.
3. Baculovirus genomes are very large and variable in size which allows the insertion of
relatively large genes without affecting normal replication.
4. Since baculoviruses infect eukaryotic cells, proteins will be post-translationally modified,
although glycosylation pathways are less sophisticated.
5. They are safe to work with since they only infect invertebrates and can be worked up to
large scale (500-1000ml preparations) which is not practical with mammalian cell lines.
However, since protein production requires infection of vims in insect cells leading to eventual
cell death it is necessary to use fresh cells for every round of protein synthesis.
In summary, the baculovims expression system involves manipulation of the polyhedrin gene,
where it is replaced with the gene of interest resulting in production of large quantities of
recombinant protein at the later stages of vims replication. The first proteins to be expressed
in this system were (3-interferon (Smith et al., 1983) and (3-galactosidase (Pennock et al.,
1984). Since then a wide variety of proteins have been expressed including viral glycoproteins,
for example the hemagglutinin glycoprotein of Influenza vims (Kuroda et al., 1989, Kuroda et
al., 1990), the human parainfluenza vims type 3 glycoproteins (Lehman et al., 1993), the
membrane fusion and hemagglutinin proteins of the measles vims (Vialard et al., 1990), the
envelope fusion glycoprotein gp85 of Epstein-Barr vims (Pulford et al., 1994), the equine
herpesvirus 1 glycoprotein D (Love et al., 1993), retrovims glycoproteins of the avian
leukaemia vims (Noteborn et al., 1990) and of the human T cell leukaemia vims type I (Arp et
al., 1993). Lentivirus glycoproteins have also been expressed in baculovims of which HIV-1
has been most widely studied (Hu et al., 1987, Rusche et al., 1987, Murphy et al., 1990,
Morikawa et al., 1990b, Culp et al., 1991, Murphy et al., 1993, Wang et al., 1995), the
expression of the envelope surface glycoprotein of EIAV (Wang et al., 1994) and of Maedi-
Visna vims envelope glycoprotein (Kwang et al., 1995 {published after initiation of this
work}) has also been reported.
Attempts at expressing the external glycoprotein of MVV have been hindered by the toxic
properties of this protein in the systems chosen so far. The baculovims system was employed
as preference to a mammalian expression system since it generally produces much higher
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yields at a significantly lower cost. The production of a glycosylated protein by the
baculovirus system is an added benefit since its biological properties would be expected to be
similar to that of the native protein. The first consideration taken when expressing a protein in
the baculovirus system is choice of transfer vector. Since the genome of baculoviruses is large
(128kbp), it is not possible to insert a gene of interest directly into the genome by restriction
enzyme manipulation. The original production of a transfer vector for introducing the foreign
gene into baculovirus DNA involved the insertion of viral sequences that spanned the
polyhedrin gene into bacterial plasmids, followed by removal of the polyhedrin gene by
restriction enzyme digestion but leaving the promoter intact. A unique restriction enzyme site
was inserted downstream of the polyhedrin promoter to allow insertion of the gene of interest
(Smith et al., 1983). The production of recombinant viruses is based on cotransfection of viral
DNA with the transfer vector. This leads to recombination between the sequences flanking the
foreign gene within the transfer vector and homologous sequences in the viral DNA resulting
in the replacement of the polyhedrin gene in viral DNA with that of the foreign gene. The
recombinant viruses are then isolated by plaque assay and screened for a non-occlusion,
polyhedrin negative phenotype.
There are a wide variety of transfer vectors containing the polyhedrin promoter
available (Lucklow and Summers, 1988a and b), including the pAcYMl type which contain
the complete 5' non-coding leader sequence of the polyhedrin gene which is essential for
expression of high levels of recombinant proteins (Matsuura et al., 1987), the pAcCL29 series
which have a Ml 3 intergenic region necessary for production of single stranded DNA which is
useful if modifications to the foreign gene need to be made after the initial insertion
(Livingstone and Jones 1989), and the pAcDZl type (Zuidema et al., 1990) which have a lacZ
gene inserted upstream of the polyhedrin promoter such that recombinant viruses can be
selected for foreign genes and production of (3-galactosidase. Other transfer vectors available
use the plO promoter or allow insertion of two genes of interest (Weyer et al., 1990).
Several considerations were necessary when choosing a suitable vector for the production of
external envelope glycoprotein. Yields of glycoproteins in expression systems are generally
lower than non-glycosylated proteins. It has been observed in the baculovirus system that
maximum yield is achieved earlier in virus infection, rather than later in infection when the
activity of the polyhedrin promoter is at its maximum (Murphy et al., 1990). The reasons for
this are unclear but the problem may he in the host cells being unable to recognise processing
signals of the foreign protein, such as signal peptides required for efficient translocation
through the cell's glycosylation machinery. In fact, there has been some success in increasing
yields of recombinant proteins by replacing the signal sequence of the foreign protein with an
insect-derived signal peptide, such as the honeybee melittin signal peptide (Tessier et al.,
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1991). This approach has been taken further with the construct of baculovirus transfer vectors
containing the signal sequence of the membrane glycoprotein of baculovirus, gp67 (Whitford
et al., 1989) inserted immediately downstream of the polyhedrin promoter (Murphy et al.,
1993, Wang et al., 1995). This approach showed that yields of the external glycoprotein of
HIV-1, gpl20, was increased by 6- to 20-fold (Muiphy et al., 1993). Since expression work in
the bacterial pGEX system suggested that the N-terminus of gpl35 was especially difficult to
express (see Chapter 3), the env gene of MVV was manipulated to remove the putative signal
sequence and to place env under the influence of the baculovirus gp67 signal peptide. The
second consideration taken on choosing a transfer vector was the method of purification that
would be used. Novel vectors, pAcGl, pAcG2T and pAcG3X, have been described where the
coding sequence of ghitathione-S-transferase, GST, derived from the pGEX expression system
has been introduced into the baculovirus transfer vectors downstream of the polyhedrin
promoter (Davies et al., 1993). This allows the gene of interest to be cloned downstream of the
GST tag and be produced as a fusion protein which can then be purified by substrate affinity,
essentially similar to the bacterial pGEX system. Wang and colleagues have produced a
vector, pAcSG2T, which combines both of these attributes, that is the baculovirus-derived
signal sequence and the GST tag (Wang et al., 1995). This results in the recombinant protein
being secreted into the culture medium, and protein can then be purified by affinity absorption
onto glutathione-agarose beads. The fusion protein can also be cleaved with thrombin to
remove the GST tag. The map of this vector is given in Fig. 5.1 showing the position of the
signal sequence, the GST tag and the multiple cloning site for insertion of the gene of interest.
The original screening of recombinant viruses for a polyhedra negative phenotype required
experience and practice to visualise cells that did not contain inclusion particles. Vectors were
modified so that recombination resulted in the introduction of (3-galactosidase as well as the
foreign gene (Pennock 'et al. 1984) into the baculovirus genome. This allowed recombinant
viruses to be screened for a blue phenotype in the presence of X-gal, but the recombinant
protein would always be contaminated by the presence of (3-galactosidase. However the
underlying problem in screening for recombinant viruses was the relative inefficiency of
recombination. A novel method was developed by Kitts et al. (1990) which was based on the
observation that linear DNA molecules in yeast and mammalian cells are highly
recombinogenic (Orr-Weaver et al., 1983, Bollag et al., 1989). Although linear DNA is
regarded as non-infectious (Kelly and Wang, 1981), it was proposed that linear DNA would
be able to recombine with homologous sequences present in the transfer vector resulting in the
recircularisation of the baculovirus genome to produce infectious recombinant viruses. A
unique restriction enzyme site (Bsu361) was introduced into AcMNPV DNA to allow it to be
linearised. Cotransfection of linear AcMNPV DNA and vector lead to a higher proportion of
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progeny being recombinant with a reduction in the background of non-recombinant viruses
due to lower infectivity of the linear DNA. The source of wild-type viruses was thought to be
derived from recircularisation of linear DNA in the absence of recombination, or incomplete
linearisation of the genomic DNA prior to transfection (Kitts et al„ 1990). To eliminate this
background, the baculovirus DNA was further manipulated by inserting an additional Bsu361
restriction enzyme site within an essential gene, ORF1629. Thus digestion of viral DNA lead
to the loss of part of this essential gene that could only be replenished by recombination with
the transfer vector which contains an intact copy of ORF1629, and this ensures that the gene
of interest is inserted into the viral genome in the correct orientation. Results from
cotransfection showed that between 85-99% progeny viruses contained the gene of interest
(Kitts and Possee, 1993). A further modification was made to the baculovirus genome
whereby the polyhedrin gene was replaced by the LacZ gene so that recombinant viruses could
be screened for the loss of (3-galactosidase phenotype, a simpler phenotype to screen with
compared with the more difficult polyhedra phenotype (Kitts and Possee, 1993). This virus,
BacPAK6, has been patented, it can be purchased from Clontech and was used as the source
of baculoviral DNA in this work.
This chapter describes the expression of the external envelope glycoprotein of Maedi-Visna
virus in the baculovirus system. The vector, pAcSG2T was chosen as the transfer vector and
was a kind gift from Dr.I.Jones, NERC, Oxford. A recombinant virus is successfully
generated and protein production and purification is described. The characterization of the
recombinant protein by its ability to be recognised by MVV infected sheep and attempts at its
uses in preliminary functional studies are also presented. The BacPAK™ baculovirus
expression system was purchased from Clontech to generate recombinant viruses. Additional
technical assistance was referenced from King and Possee (1992).
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Figure 5.1: The structure of the pAcSG2T transfer vector (adapted from Wang et al„
1995)
AMP is the gene for (3-lactamase giving ampicillin resistance to the plasmid.
IG is the Ml3 intergenic region.
Ph and Pt are the polyhedrin promoter and terminator, respectively.
The vector backbone is derived from pAcCL29 (Livingstone and Jones, 1989).
The DNA sequences at the 5' and 3' ends of the GST cassette are shown, indicating the
position of the multiple cloning site and the thrombin cleavage site. The GST cassette was
subcloned from the Sj26 gene, encoding glutathione-S-transferase, and was in phase with the
signal peptide sequence from the baculovirus major surface glycoprotein, gp67.
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pAcSG2T-tag
gp67 signal GST + thrombin SMAI
I J I J BAM HI ECO RI
ATG TTG.GCG.GAT.CTG.ATG CGT.GGA. TCC.CCG.GCA.ATT.CCA...
5.2 RESULTS
5.2.1 Isolation of env fragment by PCR
The putative signal sequence of the envelope glycoprotein of MVV is thought to be the first
major hydrophobic region from the N-terminus of env (Sargan et al„ 1991). It is
approximately 20 amino acids long and is preceded by a 80 amino acid hydrophilic sequence.
PCR primers were designed to amplify the external glycoprotein minus its signal sequence.
The sequence of these primers, primer 4975 and primer 4976, are given in Fig.2.1 (see
Chapter 2), with their relative restriction enzyme sites and positions on the env gene. PCR was
carried out using a clone containing the entire env gene (Dr.R.G.Dalziel, personal
communication) as a template to amplify the external envelope glycoprotein of MVV minus its
signal sequence. The conditions for PCR have been described previously in section 2.2.2vi and
were followed with the addition of varying amounts of DMSO; 10%, 5%, 2% and 0%, to
optimise the PCR conditions. The env template described above was used as a positive control
for validity of reagents used in the PCR, using primers known to amplify the whole env gene.
The primer sequences, primer 271P and primer 272P, have been given in Fig.2.1. A negative
control was included and comprised of all reagents with primers 4975 and 4976 but no
template. After completion of PCR, all the samples were analysed on a 1% agarose/TAE gel
to identify a specific band of 1.7kb. The results of the PCR are shown in Fig 5.2. A 1.7kb
band was observed in samples containing 0%, 2% and 5% DMSO but not 10% DMSO. The
positive control gave a band of 2.9kb in size which is the approximate size of the entire env
gene and hence all reagents used in the PCR were functional. No bands of any size were
observed in the negative control indicating that bands observed in the other samples were
specific and were not contaminants.
Since the sample that contained 2% DMSO gave the most efficient PCR, determined by the
relative amount of DNA amplified, this was chosen as the optimum conditions. The PCR was
repeated to confirm the PCR and 1/1 Oth samples analysed this time on a 1% agarose gel. The
concentration was estimated as 4ng/pl by comparing band intensities with those of known
amounts of DNA markers.
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Figure 5.2: Generation of env coding sequence minus the signal peptide sequence
Varying concentrations of DMSO were added to experimental PCR as shown. The negative
control was set up as experimental samples, without DMSO and template. The positive
control comprised of DNA template with two control primers known to amplify the whole env
gene. The PCR products were analysed on a 1% agarose/TAE gel.
The 1.7kb fragment is indicated which represents the env fragment encoding the external
envelope glycoprotein minus its signal sequence.
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DNAmarkersinkb
The PCR product was then cloned into pCRII™ using the TA cloning kit (Invitrogen, USA)
following the manufacturer's instructions. Ligations were carried out with equimolar amounts
of vector and insert, and lpl of the ligation mix was transformed into 'one-shot' INVa-F cells.
1.5% agar plates, precoated with X-gal, were coated with either 25pi or lOOpl of transformed
cells and colonies allowed to grow for 16 hours at 37°C. The colonies were screened for
blue/white phenotype where white colonies represented transformed bacteria containing cloned
plasmids. Eight white colonies were picked and one blue colony was picked as a negative
control. Colonies were grown up in 5mls of L-Broth/amp for 16 hours and plasmid DNA
purified using Qiagen-spin columns. Prior to plasmid DNA purification, lOOpl of the cultures
were retained and stored in 20% glycerol at -70°C. To determine which of the colonies
contained the correct sized PCR fragment, DNA samples were cut with EcoRI and analysed
on a 1% agarose/TAE gel. Three out of eight colonies contained a 1.7kb fragment, whilst the
other samples contained various sized fragments which were probably contaminants from the
PCR. The blue colony selected as a control showed only the 3.9kb fragment of the pCRII™
plasmid when cut with EcoRI.
One of the three colonies that contained the correctly sized fragment was used for further
experiments. However, it was necessary to confirm that this fragment was the external portion
of env and to ensure that no major mutations or deletions had arisen during PCR. The
majority of the fragment was sequenced using an automated sequencer with the dye labelled
primers described in section 2.2.2v. Approximately 1.3-1.4kb of env was sequenced by this
method. The remaining 300-400 bases were sequenced by 35S-labelling using two reverse
primers (193L and 415H) first described by Carey and Dalziel (1994) and sequences given in
Fig 2.1. Sequences were checked against the published sequence of MVV (Sargan et al.,
1991) and did not contain any major deletions or other types of mutations. The amino acid
sequence was read and compared to that of the published polypeptide sequence (Sargan et al.,
1991). The amino acid changes, highlighted in fig.5.3, are consistent with those observed by
Carey and Dalziel (1994). Therefore it was acceptable to continue with this clone for further
expression work.
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Figure 5.3: Amino acid sequence comparison between the published EV1 sequence and
the 1.7kb env fragment generated by PCR
The predicted amino acid sequence of the env clone was compared to that of the published env
sequence (Sargan et al„ 1991). Variable amino acids in the clone are highlighted by astericks.
Potential N-glycosylation sites are underlined. Amino acid numbering of the published EV1











































































































































































5.2.2 Cloning the gene encoding gpl35 into the transfer vector, pAcSG2T
A description of pAcSG2T is given in the introduction and it was chosen for the generation of
a recombinant baculovirus expressing gpl35. The transfer vector contains a multiple cloning
site with BamHI, EcoRI and Smal restriction enzyme sites to facilitate the cloning of foreign
DNA. The required portion of env was generated by PCR incorporating BamHI and EcoRI
restriction sites at the 5' and 3' ends, respectively, to enable directional cloning of env.
Initial attempts at inserting env into pAcSG2T employed the directional cloning approach.
Typically 5pg of pCRII™:env and 8pg of pAcSG2T were both cut with BamHI and EcoRI
simultaneously using one-Phor-all™ reaction buffer (Pharmacia, U.K.), following the
manufacturer's instructions. Restriction enzyme digests were carried out for 16 hours at 37°C
sometimes followed by the addition of an extra aliquot of enzymes for a further 2 hours.
Controls were included as two separate digestions of pAcSG2T cut either with BamHI or
EcoRI. To prevent religation of the vector pAcSG2T, 1 pi of Calf Intestinal Phosphatase (CIP)
was added and incubated at 37°C for 1 hour followed by deactivation at 65°C for 15 minutes.
The sample was phenolxhloroform extracted twice and DNA was precipitated and
resuspended in lOpl TE, pH8.0. An aliquot of cut vector was retained prior to
dephosphorylation to control for the efficiency of T4 DNA ligase. All digested samples were
analysed on a 1% agarose gel and the correctly sized bands were cut out, extracted from the
agarose and resuspended in lOpl TE, pH8.0. 2pl of each sample was mn on a 1%
agarose/TAE gel to estimate the amount of DNA in the sample. Ligations were set up as
previously described in a total volume of KM with env and pAcSG2T set up in ratios of 4:1,
8:1 and 12:1. Dephosphorylated and phosphorylated, linearised pAcSG2T were included as
controls to assess the efficiency of dephosphorylation and activity of the T4 DNA ligase,
respectively. 5pi of each ligation reaction was transformed into INVa-F cells and colonies
grown on agar plates for 16 hours at 37°C. This approach was repeated 3-4 times without
successful ligation between env and pAcSG2T, although controls indicated that both CIP and
T4 DNA ligase were working.
A second approach was taken whereby cloning was attempted with a single restriction
enzyme. The orientation of env in pCRII™ was investigated by cutting with BamHI and the
rational of this approach is illustrated in Fig.5.4. Option 1 would result in env being retained
in the vector whereas option 2 would allow env to be cut out of the vector and hence cloned
into pAcSG2T. Option 2 would result in the additional removal of a small region of the
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Figure 5.4: Schematic representation of the orientation of env in pCRII™
Option 1 and option2 show the two possible orientations of env in pCRII™ and subsequent
position of restriction enzyme sites in env.
The relevant restriction enzyme sites in pCRII™ vector are underlined and the T.A. cloning
site (T.A.C.S.) is indicated.








pCRII TCG GAT CCA CTG GAA TTC GGC TT AGCCGAATTC. -






pCRII - _ JCG GAT CCA CTG GAA TTC GGC TT A GCC GAA TTC
BamHI EcoRI I 1 EcoRI
TA c.s.
pCRII™ vector with env but this would not affect the reading frame of gpl35 since a stop
codon was inserted at the 3' end of env by PCR. Cutting with EcoRI was not an option since it
would be impossible to determine the orientation of env in pCRII™. Subsequent digestion of
pCRII™:env with BamHI gave a 3.9kb fragment of pCRII™ and a 1.7kb fragment of env
indicating that env had been cloned in the 3-5' orientation (Option2).
Cloning was therefore carried out as follows. Equal amounts (2.5|ig-4|ig) of pCRII:env and
pAcSG2T were both cut with BamHI for 16 hours at 37°C and processed as before, except
that dephosphorylation of pAcSG2T was carried out with a Shrimp Alkaline. Phosphatase
(SAP) using the same method as with CIP. Ligations were set up with appropriate controls
and transformed into INVa-F cells. Ligations were successful and resulted in a total of 47
colonies between all three ratios, i.e. 1:4, 1:8 and 1:12 of vector to env. Control ligations
showed that T4 DNA ligase and SAP were both working. 12 of the 47 colonies were selected,
4 from each ratio and grown in 5mls of L-Broth/amp for 16 hours at 37°C. Prior to plasmid
purification with Qiagen-spin columns, lOOjol of culture was removed and stored in
20%glycerol at -70°C. Plasmid DNA was analysed by restriction enzyme digestion to
determine both the presence of env and its orientation in pAcSG2T. A correct orientation
would give fragments 1.7kb and 8kb when cut with BamHI but only a single cut with EcoRI
to give a lOkb fragment. If env was in the opposite orientation, 3' to 5', cutting with either
BamHI or EcoRI would give a 1.7kb and a 8kb fragment. Two of the 12 colonies analysed
gave the correctly sized fragments. However the other 10 colonies did not contain ercv-sized
fragments, only contaminating DNA, possibly originating from aerosols in the laboratory.
5.2,3 Generation and isolation of a single recombinant baculovirus expressing
gpl35
5.2Ji Cotransfection of transfer vector and baculovirus DNA
Insect cells, Sf21, were cotransfected with pAcSG2T:env and baculovirus DNA using
Lipofectin™ to introduce DNA into the cells. The viral DNA, BacPAK6, was obtained from
Clontech and is supplied as a Bsu361 digested, linear viral DNA. Transfection mixtures
included 500ng of transfer vector and lOOng of viral BacPAK6 DNA (Bsu361 digest) made
up to 50fil with SDW. As a positive control, the plasmid pBacPAK8-GUS, supplied by
Clontech, was cotransfected with viral DNA. This vector has the ^-glucuronidase gene located
downstream from the polyhedrin promoter and recombination with baculovirus DNA will
result in a recombinant virus expressing P-glucuronidase, the presence of which can be
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detected by the addition of X-gluc (5-bromo-4-chloro-3-inodyl-(i-D-glucurinic acid) to the
medium giving a characteristic blue colour. A plasmid map for pBacPAK8-GUS is given in
Appendix 1. A negative control was set up with pAcSG2T:env only, to test for contamination
in the reagents. To each sample an equal volume of Lipofectin was added and transfection
carried out as detailed in section 2.2.5ii. After a 5 hour transfection, medium was replaced
with fresh medium. The positive control transfection contained 300pg/ml of X-gluc in the
medium. 72 hours after transfection the medium was removed and stored at 4°C as the
primary source of recombinant virus. The negative control remained clear and the positive
control gave a blue colour in the presence of X-gluc suggesting successful cotransfection and
recombination.
5.2Jii Isolation of a single clone of recombinant virus
To isolate a single clone of recombinant vhus it was necessary to perform one round of plaque
assay purification. Three ten-fold dilutions were made; 10-1, Kb2 and 10"3, of the
cotransfection supernatant which contained progeny viruses. A plaque assay was set up with
these dilutions, as well as a mock infection and a positive control assay using the BacPAK6
virus, diluted to 10~5. The plaque assays were stained with neutral red in the presence of
X-gal. The positive control assay showed numerous plaques that were all stained blue. No
blue plaques were observed in the experimental plaques and no plaques were observed in the
negative control. A control plaque assay was set up with the cotransfection supernatant
derived from the pBacPAK8-GUS transfection to determine the yield and success of
generation of recombinant vims expressing GUS. All plaques stained blue in the presence of
X-gluc proving a successful and efficient recombination and plaque number increased ten-fold
on each dilution indicating a good plaque assay technique. From the experimental assays, 19
plaques were picked, each added to 1ml FCS/TC100 medium and recombinant viruses
allowed to diffuse out of the agar for 16 hours at 4°C.
5.2.3iii Screening single recombinant viruses by slot blot hybridisation
The 19 "plaque picks" isolated above were analysed by slot blot hybridisation for the presence
of env specific sequences. 35mm petri dishes were seeded with 5x10s cells in 1.5ml of
FCS/TC100 and incubated for approximately 2 hours to allow cells to attach to the plastic
surface. The medium was removed and each dish was infected with lOOpl of one of the
"plaque picks". As controls, lOOp.1 of FCS/TC100 only, lOOpl of a Id4 dilution of BacPAK6
(parental) vims and lOOul of a Id4 dilution of AcMNPV (wild-type) vims were used to infect
separate dishes. After a 1 hour incubation, a further 2mls of medium was added to each dish.
128
Two to three days post infection the dishes were examined under a light microscope to assess
the level of infection. At 72 hours post infection all experimental dishes showed signs of virus
infection, that is cells were grainy and misshapen. There were no signs of polyhedra within
cells infected with recombinant viruses, a morphology also seen with the parental BacPAK6
vims-infected cells. It was noted that cells from the experimental plates were not as numerous
as those in the parental infection. Polyhedra were clearly visible in the AcMNPV infected cells
allowing clear differences to be seen between wild-type and BacPAK6 originated viruses.
Mock infected cells appeared healthy and showed no signs of vims infection.
The supernatant was removed from each dish and stored at -70°C as the primary stock of that
particular vims isolate. 1ml of PBS was added to the infected cell monolayer and cells scraped
off into 1.5ml microcentrifuge tubes. DNA was extracted and purified from the cells as
described in section 2.2.5ii. Following ethanol precipitation, the viral DNA was incubated in
50pl of TE, pH8.0 for 16 hours at 4°C since baculoviral DNA solubilises slowly due to its
large size. The DNA was gently resuspended to avoid shearing. A slot blot was prepared using
all 19 experimental samples of DNA, the control DNA and 5pg of pAcSG2T:env as a positive
control. Each slot was washed with 200pl of SDW to ensure all viral DNA had passed
through onto the filter. The slot blot was probed with 32P-labelled env, prepared from
pCRII™:env which had been digested with EcoRI and the env fragment purified. The filter
was exposed to film and allowed to develop for 72 hours at -70°C. The results from the slot
blot are shown in Fig. 5.5. A positive band is seen for pAcSG2T:env, although the intensity is
weak compared to the experimental samples, due to overloading of cell-extracted DNA. All
recombinant viruses gave a positive signal, except 4, compared to negative control
backgrounds, BacPAK6, AcMNPV and mock.
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Figure 5.5: Slot blot hybridisation of 19 recombinant env baculoviruses
Recombinant baculovirus DNA was extracted, purified and probed for env sequences by slot
blot hybridisation. Samples 1 to 19 represent the recombinant viruses. AcMNPV, BacPAK6
and mock are negative controls and pAcSG2T:env is the positive control.
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5.2.4 Evaluation of recombinant viruses
5.2.4i Analysis of recombinant virus genomes by Southern hybridisation
Analysis of the "plaque picks" by slot blot hybridisation identified 18 recombinant virus by
comparison to the background controls of BacPAK6 viral DNA and AcMNPV DNA. To
confirm the presence of env within the genomes of the recombinant viruses, 7 of the 18
samples were selected; samples 1, 3, 7, 9, 12, 14 and 16. 35mm dishes were set up as before
and infected with 100pi of each virus. Controls were also set up as before with BacPAK6
virus, AcMNPV and mock. 72 hours post infection the cells were scraped off and viral DNA
extracted. The concentration of DNA in each sample was measured by reading O.D. values at
260nm and yields ranged typically between 2.5pg to lOpg per 106 cells. The sample
containing the least amount of DNA was used as a reference point and the other samples were
diluted to give the same concentration (approximately 125ng/pl). All samples including the
controls were digested with BamHI for 16 hours at 37°C in a total volume of 25pi, followed
by the addition of fresh enzyme and digestion was continued for a further 2 hours. A positive
control was included: approximately 120ng of pAcSG2T:env which was also cut with BamHI
in a volume of lOpl. BamHI was chosen for the digests since this would allow the whole of
env to be cut out of the viral genome. One fifth of the volume of each sample was run on an
analytical 1 % agarose/TAE gel to confirm complete digestion of the viral DNA. 20pl of the
samples, adjusted to equal concentrations (500ng/20pl), were run on a 0.8% agarose/TBE gel
for 16 hours at 18°C. pAcSG2T:env and BacPAK6 DNA were run as positive and negative
controls, respectively. The positive control was diluted to 6pg/pl and lOpl was loaded onto the
gel as well as an undiluted aliquot to ensure that the position of env on the gel could be
recorded. The gel was visualised by U.V. illumination and photographed, marking the position
of env with a ruler. Analysis of the DNA by ethidium bromide staining showed the
characteristic band pattern for BamHI-digested AcMNPV DNA. This is explained and
illustrated in Fig.5.6a, where the position of env is also indicated in respect of the fragments of
AcMNPV DNA. DNA was denatured, neutralized and transferred to a nylon membrane. The
blot was probed with 32P-labelled env prepared as described in section 5.2.3iii. The blot was
exposed to film for 3-5 days at -70°C and the autoradiograph developed. The results are
shown in Fig.5.6b. All 7 recombinant viruses showed a band of equal size to env in the
positive control (pAcSG2T:env), that is 1.7kb, and this band was not observed in the negative
control, BacPAK6 DNA. A non-specific band, approximately 2.3kb in size, was occasionally
observed in all virus derived samples, wild-type or recombinant. An additional band is seen in
sample 16 at approximately 2.6kb, and this is explained fully in the discussion. The intensity
131
of the 1.7kb band in each sample is not equal, despite attempts to load equal amounts of
DNA.
5.2.4ii Analysis of protein expression by western blotting
Recombinant protein was expected to be secreted into the medium. Therefore the supernatants
from the above experiment were retained for analysis of the protein content. Each sample was
dialysed against PBS for 16 hours at 4°C in 1.5ml microcentrifuge tubes sealed with dialysis
tubing. This was necessary since the pH of insect medium is between 6.1-6.4, and a pH of 7.2
is required for maximum absorption onto glutathione beads. 50pl of 50% glutathione-agarose
bead slurry was added to each sample and mixed for 30 minutes at 4°C. Control samples of
AcMNPV, BacPAK6 and mock infected cells were treated in the same way. The beads were
washed twice in ice-cold PBS and resuspended in 5Op] of PBS. An equal volume of 2x
reducing buffer was added to each sample, boiled and loaded onto a 5-15% gradient gel.
Proteins were separated by SDS-PAGE using normal conditions and transferred onto a
nitrocellulose membrane. After blocking, the blots were probed either with rabbit anti-GST
serum or normal rabbit serum, each diluted 1/100. The production of the anti-GST serum is
described in Chapter 3. Protein analysis was performed by western blotting since this method
is easy to set up and has sufficient sensitivity for detecting small quantities of protein,
compared to coomassie-blue staining and radiolabelling. The results from these blots are
shown in Fig. 5.7a and b. A single, specific band was observed in all 7 recombinant virus
samples which was absent in the negative controls. The estimated molecular weight of this
band is 97-100kDa and will be referred to as GST:SUenv. To confirm the identity of
GST.SUenv, the protein was run down a second gel and probed with the following antisera:
rabbit anti-Pi serum, rabbit anti-P2 serum, including their pre-bleeds (descriptions of these
sera are given in Chapter 4), and an anti-Mouse Herpes Virus serum which contains anti-GST
antibodies (this was a kind gift from Dr.J.Stewart, Department of Veterinary Pathology,
Edinburgh). All three immune sera recognised GST:SUenv, as shown in Fig. 5.7c, and no
comparable band was identified by the negative control sera. This confirmed that the band
observed was GST:SUenv.
The titres for each recombinant virus stock was calculated by performing a plaque assay.
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Figure 5.6:Southern hybridisation of DNA from baculovirus-infected cells
a] Ethidium bromide stained 1% agarose gel of BamHI-digested DNA
Lane 1, recombinant baculovirus; BacPAK:envl2
Lane 2, parental virus; BacPAK6
Lane 3, wild-type virus; AcMNPV
Lane 4, mock infected Sf21 cells
Lane 5, transfer vector containing env, pAcSG2T:env
The BamHI-digested fragments of baculovirus DNA are indicated (N.B. fragments F and G
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b] Hybridisation results of screening recombinant virus DNA
DNA purified from seven different recombinant viruses were digested with BamHI and probed
with a 32P-labelled env fragment derived from pCRILenv.
Lane 1,7,9,12,14,16, recombinant baculoviruses; BacPAK:env (refer to Fig.5.5)
Parental virus, BacPAK6 (negative control) and pAcSG2T:env (positive control) are labelled.






Figure 5.7: Characterization of recombinant protein, GST:SUenv, secreted by
baculovirus-infected cells
a and b] Seven recombinant viruses were selected and used to infect insect Sf21 cells.
Supematants were harvested and analysed on 5-15% SDS-PAGE gels, followed by transfer to
nitrocellulose for western blotting. Blots were probed with a rabbit antiserum specific for GST
(1/100 dilution) (A) or normal rabbit serum (1/100)(B).
Lane 1,3,7,9,12,14 and 16, Recombinant viruses; BacPAKrenv
Parental (BacPAK6), wild-type (AcMNPV), uninfected Sf21 cells (mock) are labelled.
c] The identification of GST:SUenv was confirmed using two rabbit antisera specific for a
gpl35-derived peptide (1/100) (PI and P2) and a rabbit anti-MHV IgG containing anti-GST




lane 3, anti-Pi, prebleed
lane 4, anti-P2
























































5.2.5 Characterization of recombinant protein production
Sample 12 gave the strongest band by western blot analysis indicating that it was expressing
the greatest amount of recombinant protein. It was selected for further analysis and will be
referred to as BacPAK:envl2.
5.2.5i Determination of the optimum time point for virus production
To quantify the production of GST:SUenv over time, it was necessary to verify that western
blotting was a suitable method for quantifying the production of protein. Protein samples
obtained from the previous experiment were pooled, titred and proteins separated by SDS-
PAGE. Western blot analysis showed that quantitative differences could be visualised by this
method (data not shown). Western blotting was chosen as the method for detecting
recombinant protein because of its relative ease to perform and it was sufficiently sensitive for
detecting recombinant protein (data not shown). Since nomaal rabbit serum controls did not
recognise GST:SUenv, all subsequent figures do not show the results from the negative
control. Normal rabbit serum controls (negative) were included in all western blotting
experiments.
The polyhedrin promoter in most expression studies is maximum between 18 and 72 hours,
and therefore a time course was set up as follows. Ten 35mm petri dishes were each seeded
with 1.5x10s cells and these were allowed to attach over a period of 2 hours. 7 of the 10
dishes were each infected at a m.o.i. of 10 p.f.u. of BacPAK:envl2 per cell. The remaining
three dishes were set up as controls with a 104 dilution of BacPAK6, a 104 dilution of
AcMNPV and a mock infection. The supernatant from the experimental dishes were harvested
at the following time points: 18, 24, 30, 42, 48, 66 and 72 hours post infection. The control
infections were also harvested at 72 hours. The recombinant protein was purified and analysed
as described in section 2.5.2ii. Fig. 5.8a shows that there is a gradual increase in protein
production up to 48 hours post infection. After this time point there did not appear to be any
increase in protein production and a steady state was reached. The time course was extended
and samples were harvested at 24, 48, 72, 96 and 120 hours post infection. This time course
showed a similar profile as before in that protein production increased up to 48 hours and
remained maximum until 72 hours, after which there was a decline in protein production (data
not shown). This is in contrast to recent work published by Kwang et al. (1995) who reported
that the production of recombinant envelope is still maximum after 72 hours post infection.
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The kinetics of protein production was investigated further. To understand if protein
production was maximum at 48 hours followed by a steady state being reached between
protein production and protein degradation, the following experiment was devised. A 35mm
dish was seeded with 1.5xlOscells as usual and infected with BacPAK:envl2 at an m.o.i. of
10 p.f.u. per cell. Every 24 hours, the supernatant was removed and replaced with fresh
medium. GSTrSUenv was purified from the supernatant as before and mixed in an equal
volume of 2x reducing buffer and then analysed by western blotting with anti-GST serum.
Fig.5.8b shows the result of this "milking" experiment. Protein production was shown to be
maximum at 48 hours after which protein production was no longer detectable suggesting that
recombinant protein remains stable in the supernatant for up to 72 hours as was observed in
the extended time course experiment.
A comparison was made between cell-associated recombinant protein and secreted protein to
extend the above kinetic studies. Ten 35mm dishes were each seeded with 1.5xl06cells in
1.5ml of FCS/TC100 medium as before. 7 of the dishes were each infected with 1.5xl07 p.f.u.
of BacPAK:envl2, and the remaining three were set up as controls described previously. The
supematants were harvested and purified every 24 hours as before. The cells were scraped off
from the dishes into 1ml of PBS, pelleted, resuspended into lOOpl of PBS/0. l%(v/v) TritonX-
100 and repelleted. The supernatant was removed and 50pl of glutathione-agarose slurry was
added and mixed for 30 minutes at 4°C. Cell-associated protein and secreted protein were
compared and analysed by western blotting using anti-GST serum. The results are shown in
Fig.5.8c. The principal observation made was that there appears to be a greater yield of
protein from the supernatant than from that extracted from the cells. At 24 and 48 hours the
size of recombinant protein seen in cells is approximately 5-10kDa larger than the secreted
protein. However at 72 hours, protein purified from cells shows the presence of the same sized
protein as the secreted form as well as the larger protein. The significance of these different
sized proteins is discussed later. The presence of other contaminating products such as those
between 20-35kDa may be a reflection on the state of the insect cells on infection. If cells are
past their log-phase the presence of proteases in the medium secreted by dying cells may lead
to degradation of recombinant protein.
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Figure 5.8: Analysis of the kinetics of GST:SUenv expression
a] A time course for recombinant protein production
Insect sf cells were infected with recombinant baculovirus and protein harvested at: 18, 24,
30, 42, 48, 66 and 72 hours post infection. Protein was purified, analysed on 5-15% SDS-
PAGE gels and transferred to nitrocellulose for western blotting. Blots were probed with
rabbit anti-GST serum (1/100). Control infections are shown.
b] Determination of the maximum time point for GST:SUenv production.
Supernatant was collected every 24 hours from insect sf cells infected with recombinant
baculovirus and fresh medium was added to the cells. Proteins were purified and analysed as
in [a],
c] Characterization of GSTrSUenv release from infected cells
A time course was set up and protein was purified from the infected cells as well as the
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5.2.5H Determination of the optimum multiplicity of infection
To assess the optimum m.o.i. required for the production of GST:SUenv, a comparison was
made between three different m.o.i.; 5, 10 and 20 p.f.u. per cell. Since the kinetics of protein
production will be altered according to the proportion of insect cells infected at any given time
point, the experiment was followed over time. 35mm dishes were set up as before, infected
with the appropriate p.f.u. of BacPAK:envl2 and harvested at the following time points; 18,
24, 30, 42, 48, 60 and 72 hours post infection. Analysis was carried out by western blot and
the results are given in Fig. 5.9. The protein production showed as similar pattern over time at
m.o.i. of 10 and 20, whereas an m.o.i. of 5 gave lower levels of protein at all time points. It
was decided to carry out all subsequent experiment at an m.o.i of 10 as opposed to 20, since
this would be a more efficient use of virus stocks.
5.2.5iii A comparison between different cell types for protein production
High Five™ cells (Invitrogen, USA) have been reported to produce a five-fold increase in
protein production compared to Sf21 cells (Davis et al., 1993). An experiment was set up to
compare the yields between these two cell types. Four T25 tissue culture flasks were each
seeded with 2xl06cells in 5ml of appropriate medium. Cells were allowed to adhere over 3
hours, after which medium was removed and cells infected with 2xl07 p.f.u. of
BacPAK:envl2 or mock infected in 1ml of appropriate medium. After an hour incubation a
further 4mls of medium was added to each flask and cells incubated for a further 48 hours.
The supernatants were harvested, dialysed and purified with lOOpl of glutathione-agarose
slurry. The samples were analysed by western blotting, probing with anti-GST serum.
Fig.5.10 shows these results. There does not appear to be a dramatic increase in protein
production in H5™ cells compared to Sf21 cells, and further analysis by silver-staining
confirmed this observation (data not shown).
5.2.5iv Analysis of the glycosylation state of GST:SUenv
Recombinant GST:SUenv was identified as a 97-100kDa protein. The estimated size of the
non-glycosylated protein is 90kDa, which suggests that GST:SUenv is a glycosylated protein.
To verify this, an experiment was set up to asses the effect of tunicamycin on the size of
GST:SUenv. Four T25 tissue culture flasks were set up as in section 5.2.5iii and infected with
BacPAK:envl2 at a m.o.i. of 10 or mock infected, in the presence or absence of l|ig/ml of
tunicamycin (lmg/ml stock in DMF, stored at -20°C). The supernatant was harvested and
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purified as normal 48 hours post infection. Recombinant protein was analysed by western
blot, probing with anti-GST serum or an anti-gpl35 peptide serum. The results are shown in
Fig. 5.11. In the presence of tunicamycin, the size of GST:SUenv is reduced to approximately
85-90kDa, suggesting that GST:SUenv is indeed glycosylated. An accurate prediction of the
size of each protein species is difficult to deduce on a mini protein gel, but was deemed
sufficient to demonstrated that GST:SUenv is a glycosylated protein. Both sera recognised the
same sized protein confirming that it was GST:SUenv which had not been glycosylated in the
presence of tunicamycin.
5.2.6 Further purification of GSTrSUenv
To further purify GST:SUenv by elution from glutathione beads or removal of the GST
moiety, large scale preparation of recombinant protein was routinely carried as follows. 100ml
spinner cultures were set up with 2xl05cells/ml and grown for approximately 48 hours until
the cell density reached lxl06cells/ml. Either H5 or Sf21 cells were used depending on the cell
viability at the time of preparation. The culture was infected with lxlO9 p.f.u. of
BacPAK:envl2, that is a m.o.i. of 10 p.f.u. per cell. 48 hours post infection the infected cell
culture was collected and the supernatant clarified. Following dialysis against PBS, the
supernatant was mixed with 2mls of glutathione-agarose slurry for 30 minutes at 4°C.
5.2.6i Elution of GST:SUenv from glutathione beads
Attempts at eluting GST:SUenv from the beads were initially unsuccessful. Elution was
carried out at room temperature using lOmM reduced glutathione/50mM Tris-HCl, pH8.0,
mixing the beads with elution buffer for 2 minutes for every elution. This protocol was not
successful, despite increasing both the concentration of reduced glutathione to 20mM and
elution time to 30 minutes. An alternative protocol has been reported by Davies et al. (1993),
in which elution was carried out at 4°C. Elution was therefore attempted at this temperature
using lOmM reduced glutathione and a two minute incubation period and proved to be
successful with the majority of protein eluting in the first elution (data not shown). The yield
of eluted GST:SUenv was measured by the Bio-Rad protein assay. Typically yields ranged
between 0.5-0.8mg protein per 1 litre of infected cells, that is per lxlO9 infected cells.
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Figure 5.9 Determination of the optimum m.o.i. for protein expression
Time courses were carried out at three different m.o.i.;"20, 10 and 5 p.f.u. per cell (a, b and c,
respectively in figure) and protein harvested from the supernatant at the following time points:
18, 24, 30, 42, 48, 66 and 72 hours post infection. Recombinant protein was purified,
analysed on 5-15% SDS-PAGE gels and transferred to nitrocellulose for western blotting.
Blots were probed with rabbit anti-GST serum (1/100). Control infections were included as
shown.
Figure 5.10 A comparison of GST:SUenv expression in two insect cell types
High five or sf cells were infected with recombinant virus at an m.o.i. of 10 p.f.u. per cell and
secreted protein was harvested and purified. Proteins were analysed as above, and uninfected
cells were included as controls.
lane 1, H5 cells, uninfected.
lane 2, H5 cells infected with BacPAK:envl2.
lane 3, Sf21 cells, uninfected.
lane 4, Sf21 cells infected with BacPAK:envl2.
Figure 5.11 Effect of tunicamycin on GST:SUenv expression
Insect cells were infected with recombinant viruses at an m.o.i. of 10 p.f.u. per cell, with or
without tunicamycin. Uninfected cells were treated in the same way. Proteins were purified
and analysed as above, and probed with rabbit anti-GST serum (1/100) (GST) or a rabbit
serum specific for a gpl35-derived peptide (1/100) (P2).
T+, tunicamycin treated cells
T-, untreated cells
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5.2.6ii Cleaving gpl35 from the GST moiety
A thrombin cleavage site is situated between the GST moiety and the foreign protein to allow
purification of the protein of interest as a non-fused recombinant protein. Two experimental
approaches were attempted to cleave gpl35 from its fusion partner, GST. The standard
protocol for cleaving is directly from the beads. 0.5ml of purified GST:SUenv/agarose-bead
slurry was taken and an aliquot analysed by SDS-PAGE and silver staining and protein
concentration was estimated at lmg/ml. The beads were washed once in 0.5ml of
0.1%TritonX-100(v/v)/PBS followed by two washes in wash buffer (50mM Tris-HCl,
pH7.5/150mM NaCl) and finally resuspended in 0.5ml of thrombin cleavage buffer (2.5rnM
CaCl2 in wash buffer). 2.5p.g of thrombin was added and incubated for 1 hour at 25°C. The
beads were eluted four times with 0.5ml of cleavage buffer and each sample analysed by
comparison to a sample that was not cleaved and to the beads remaining after cleavage.
Western blotting was performed, probing with either anti-GST serum or anti gpl35-peptide
serum. Analysis revealed that cleavage was not successful in that GST:SUenv was still
detectable on the glutathione-agarose beads post cleavage (data not shown).
A second approach was taken to cleave the fusion protein. Following a large scale preparation
and elution, the resulting product was dialysed against the thrombin cleavage buffer for 16
hours at 4°C. The sample was then divided into four equal amounts each containing
approximately 50pg of recombinant protein. Thrombin was added in the following
proportions; 0%, 0.5%, 1% and 2% and incubated at 25°C for 1 hour. To remove GST and
leave the cleaved product in solution, lOOjil of glutathione-agarose slurry was added to each
sample and mixed for 30 minutes at 4°C. The supernatant was retained and beads were
resuspended in a volume equal to the supernatant. Samples were compared by western blot
analysis as above. Non of the supernatants contained any cleavage products and it appeared
that all recombinant protein had been reabsorbed onto the beads (data not shown).
5.2.7 Screening of MVV-infected sheep sera
To further characterize gpl35 expressed in the baculovirus system, a panel of MW-infected
sheep sera, both naturally and experimentally infected, were used for screening purposes.
Previous experience working with sheep sera has shown that it is generally "sticky" giving
high backgrounds. Indeed, pilot experiments where GST:SUenv was loaded onto SDS-PAGE
gels, irrespective of protein concentration, showed a cross-reactivity of normal sheep sera with
GST:SUenv. In order to successfully screen sheep sera, it was necessary to titrate out the
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antigen to establish the amount of antigen required for specific detection of anti-gpl35
antibodies in sheep. Antigen was loaded as three different amounts; 160ng, 80ng and
40ngAane and probed with four normal sheep sera, one MW-infected sheep sera and rabbit
anti-GST serum. These blots confirmed earlier observations that normal sheep sera does
cross-react with antigen but this was reduced to undetectable levels at 40ng/lane (data not
shown). The ability of anti-MW infected sheep sera to recognise GST:SUenv was not
proportional to the amount of antigen loaded as determined by the intensity of the specific
band for GST:SUenv. Subsequent screening with a panel of sheep sera was carried out as
shown in Fig. 5.12. Sheep sera used in this screening where from naturally infected sheep
(Dr.N.Watt, personal communication) or from experimentally infected sheep sera
(Dr.B.Blacklaws and Dr.P.Bird, personal communication). All sera contained anti-em'
antibodies as determined by western blot analysis with MVV-infected crude cell lysates (data
not shown). The results of the screening showed that MW-infected sheep sera were able to
recognise GST:SUenv but not GST (derived from bacteria containing pGEX2T plasmid).
Normal sheep sera did not recognise GST:SUenv nor GST. Rabbit anti-gpl35 peptide serum
(P2) and its prebleed were used as controls (data not shown).
5.2.8 Functional studies with GSTrSUenv
Preliminary experiments were carried out to determine the ability of GST:SUenv, expressed in
the baculovirus system, to bind specifically to sheep fibroblasts.
5.2.8i Detection of GSTrSUenv binding to sheep fibroblasts by immunoflourescence
Twenty four well plates were seeded with lxl05fibroblast cells/well with each well containing
a sterile glass coverslip, and incubated for 16 hours in a 5%C02/37°C incubator. The
following dilutions of GST:SUenv and GST were made up in 2%FCS/DMEM: 8pg/ml, 4p
g/ml and 2|ig/ml, and 0.5ml of each dilution was added to a single well in duplicate. As
controls, a mock incubation was carried out with medium only. Cells were incubated with
antigen for 2 hours in a 5%C02/37°C incubator. Cells were washed three times with
unsupplemented DMEM and either rabbit anti-GST serum or normal rabbit serum (diluted
1/100 in 2%FCS/DMEM) was added to the cells. After an hour incubation using the same
conditions as previously the wells were washed and incubated in anti-rabbit IgG-FITC (diluted
1/250) for a further hour. After washing, the cells were fixed with ice-cold methanol for 5
minutes, air-dried and mounted onto glass slides in 2-3pi of Citiflour. Cells were examined
using a fluorescent microscope to analysis the intensity of fluorescent staining. As a positive
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Figure 5.12: Reactivity of MW-infected sheep sera with GST:SUenv
GST:SUenv was purified from a large scale (100ml) infection. Protein concentration was
calculated and analysed on a 5-15% SDS-PAGE gel at a concentration of 400ng/gel. As a
control, bacterial-derived GST was also analysed at the same concentrations. Proteins were
transferred to nitrocellulose for western blotting and strips were probed with the following
panel of sheep sera, using pre-bleeds or normal sheep sera (sheep 05,151,G16) as background
controls. Sera were diluted 1/20. Protein markers are not shown to allow comparisons between
GST and GST:SUenv to be made. The position of GST:SUenv is indicated by an arrow.
type of date of date of reactivity on
sheep number infection pre-bleed final bleed immunoblot
186 natural UN UN +
187 natural UN UN +
848A experimental UN UN +
123 IT experimental 29:10:92 25:5:94 +
1299T experimental 5:12:91 17:10:94 +
1244T experimental 29:10:92 25:5:94 +
1550 experimental 13:12:88 6:2:91 +
1540 experimental 13:12:88 2:4:92 +
1091R experimental 20:1:92 30:6:93 +
1071R experimental 20:1:92 30:6:93 +
1078R experimental 20:1:92 30:6:93 1 +
05 - I - -
151 i - - - -
G16 - - - -
note: UN; unknown
lane a= GST + normal sheep serum
lane b= GST:SUenv + normal sheep serum
lane c= GST + immune sheep serum
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control, MVV-infected sheep cells that had been prefixed with ice-cold acetone were probed
with a rabbit anti-p25 (MVV core protein) serum, diluted 1/1000 (Dr.B.Blacklaws, personal
communication). Examination of the positive control indicated that staining procedures were
successful, although it is noted that this is not a true control for the experimental procedure.
Since the experimental protocol required cells to be fixed post antibody binding, p25 would
not be detected since it is not expressed on the surface of MW-infected sheep fibroblasts. No
rabbit sera raised against sheep fibroblast surface molecules were available. No specific
fluorescence was seen for GST:SUenv binding to fibroblasts, only background staining
comparable to GST controls and the negative controls (data not shown).
5.2.8ii Detection of GST:SUenv binding to sheep fibroblasts by FACS analysis
Immunoflourescence is a less sensitive approach compared to other immunodetection methods
available. One of these is flow cytometry. A protocol was set up where sheep fibroblasts were
incubated with antigen and this was than detected by FACS analysis. Prior to antigen
incubation it was necessary to concentrate the eluted samples of GST:SUenv and this was
achieved by acetone precipitation to give an approximate concentration of 150pg/ml. Sheep
fibroblasts were grown in T150 tissue culture flasks until they reached 80-90% confluencey.
The monolayers were then washed twice in 5mM EDTA/PBS, followed by a 30-45 minute
incubation with 5mls of 5mM EDTA/PBS until the cells had detached from the surface of the
flask. Cells were counted and adjusted to 2xl06cells/ml. Two 200(0.1 aliquots of cells were
taken and incubated with 20(ig of either GST (derived from pGEX2T) or GST:SUenv in a
total volume of 0.5ml. The incubation was carried out for 2 hours at 4°C. Half of each
samples was fixed in 1% paraformaldehyde as well as three lOOpl aliquots of untreated cells
(Fig.5.13A). All samples were then incubated with primary and secondary antibodies as
outlined in Table 5.1.
As discussed in the immunoflourescence experiment there was no absolute positive control
available. To test for the validity of FACS staining a monoclonal specific for sheep LFA3 was
chosen. All samples were fixed with 1% paraformaldehyde at the end of staining and then
analysed on a FACS machine. The positive control showed positive staining (Fig. 5.13a)
compared to the autoflourescence observed with the negative controls (Fig. 5.13b and c).
There appeared to be a small amount of positive staining for the experimental samples but
there was no difference between GST:SUenv and GST (Fig. 5.13d and e). It was noted
however that the staining was stronger with cells that had been fixed after incubation with the
antigen, by comparison between Fig 5.13A and 5.13B, particularly Fig. d.
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cells + GST:SUenv cells + GST:SUenv R-anti-GST anti-R IgG-FITC
cells + GST cells'+ GST R-anti-GST anti-RIgG-FITC
cells cells R-anti-GST anti-R IgG-FITC
cells cells - anti-R IgG-FITC
cells cells M-anti-LFA3 anti-M IgG-FITC
N.B. R= rabbit, M= mouse
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Figure 5.13: Binding of GST:SUenv to the surface of sheep fibroblasts
Frequency histograms showing binding of GST:SUenv (d) to the surface of sheep cells with
comparison to GST binding (e). Figures A and B represent different experimental protocols
described in the text. Figures a are positive control staining with mouse anti-LFA3. Negative
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5.2.8iii Inhibition of MW-infection by GST:SUenv binding to the surface of sheep cells
An indirect method was investigated to monitor the ability of GST:SUenv to block EV1 vims
infection of sheep fibroblasts. Two 96 well tissue culture plates were seeded with
lxl04cells/well and incubated for 16 hours in a 5%C02/37°C incubator. Samples of
GST:SUenv and GST were diluted to lpgAnl in 2%FCS/DMEM and added to the first row of
wells (lOOpl/wcll). Two-fold dilutions were made down the plate, using only the inside 60
wells, with the sixth and final row with 2%FCS/DMEM only. Cells were incubated with
antigen for 2 hours in a 5%C02/37°C incubator. Medium was removed and doubling dilutions
of EV1 was made across the plate starting with 100 TCID50 in the first column, 50pl/well.
The final column contained medium only as a control for the toxicity of GST and GST:SUenv
to the cells. After a 1 hour incubation, vims was removed and each well fed with 100pi of 2%
FCS/DMEM. 7 days later, the plates were fixed and stained with Giemsa stain. Each well was
examined for the presence of syncytia and the results are presented in Table 5.2. No reduction
in TCIDS0 was observed with either antigen in comparison to mock incubations. However,
syncytia in the row containing lOOng/well of GST:SUenv were smaller than in its equivalent
row with GST, but no reduction in TCID50 was recorded. The cells "infected" with medium
showed no signs of toxic effects by the GST or GST:SUenv proteins at these concentrations.
5.2.8iv Binding of GST:SUenv to sheep cellular proteins using an overlay protein blot
Although there was little success in demonstrating that GSTtSUenv specifically binds to sheep
cells, an experiment was carried out to determine if baculovims-derived gpl35 could
recognise proteins present in sheep cells. Sheep fibroblasts and mouse epithelial cells (CI27
line, Dr.J. Stewart, personal communication) were harvested and adjusted to a cell density of
8xl06cells/ml in- PBS. Cells were sonicated in a water-bath sonicator for 5 minutes and an
equal volume of 2x reducing buffer was added. Proteins were resolved by SDS-PAGE and
titrated into the following amounts: 6xl04cells, 4xl04cells, 2xl04cells and lxl04cells/lane.
Proteins were transferred to nitrocellulose and blocked in 5% Marvel/Hepes Binding Buffer
(HBB: 20mM Hepes, pH7.5/5mM MgCl2/lmM KC1) for 1 hour at 18°C. Blots were either
incubated in GST or GST:SUenv, 4pg/ml, diluted in 5% Marvel(w/v)/HBB/5mM EDTA for
16 hours at 4°C. Proteins were then probed with rabbit anti-GST serum, followed by
biofinylated anti-rabbit IgG(l/1000) and extravidin-AP(l/1000), where all incubations were
carried out in 5% milk powder,w/v/PBS) for 1 hour at 18°C. The results are shown in Fig.
5.14. GST:SUenv appears to be binding to a 30kDa protein that is not recognised by GST
(Fig. 5.14c and d) but a similar sized protein is also identified with the mouse cells by
GST:SUenv (Fig. 5.14b). The probable identity of this protein is discussed later.
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Table 5.2 Inhibition of MVV infection of sheep fibroblasts by GST:SUenv
TCID50 100 50 25 12 6 3 1.5 0.8 0.4 o !
lOOng/well GST ** ** ** * * * * * * #
GST:SUenv * * * * * * * # # #
50ng/well GST ** ** ** * * * * * * #
GST:SUenv ** ** ** * * * * * * #
25ng/well GST ** "
** ** * * * * * # #
GST:SUenv :jeje ** ** * * * * * * #
12ng/well GST
** ** ** * * * * * * #
GST:SUenv ** ** ** * * * * * * #
6ng/well GST
** ** ** * * * * * # #
GST:SUenv ** ** ** * * * * * # #
Gng/well GST
** ** ** * * * * * # #
GST:SUenv ** ** **
* * * * * # # i




Figure 5.14: Identification of polypeptides which bind to baculovirus-derived gpl35
Cell lysates of mouse epithelial cells (C127) and sheep fibroblasts (123 IT) were resolved by
SDS-PAGE and transferred to nitrocellulose. The filters were incubated with either GST or
GST:SUenv and probed with anti-GST serum (1/100).
lane a, 6xl04 cells
lane b, 4xl04 cells
lane c, 2xl04 cells
lane d, lxlO4 cells
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b] GST:env
C127 cells C127 cells
c] GST
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5.2.9 Functional studies with PI and P2 peptides
In addition to the above functional studies with GST:SUenv, the two peptides described in
Chapter 4 were assessed for their ability to bind to sheep fibroblasts. These studies were
necessary to determine if these two peptides represented functional epitopes on the native
protein. They are included here for completeness.
5.2.9i Binding of PI and P2 peptides to the surface of sheep cells
Twenty four well plates, containing sterile coverslips, were seeded with 105cells/well of sheep
fibroblasts, 123 IT, or mouse epithelial cells, C127, and incubated for 16 hours at 37°C. The
following dilutions of PI and P2 were made in 2%FCS/DMEM: 50pg/ml, 25pg/ml and
12pg/ml. 0.5ml of each peptide dilution or medium only was added to each well and incubated
for 2 hours at 37°C. Peptides were removed and cells were incubated with either anti-Pi or
anti-P2 serum for cells containing PI or P2, respectively. Mock incubated cells were treated in
the same way and control wells were incubated with appropriate prebleeds. Serum dilutions
made in 2%FCS/DMEM at 1/100. After a 1 hour incubation at 37°C, cells were washed with
unsupplemented DME and further incubated with anti-rabbit-FITC, diluted 1/250. Cells were
washed and fixed for 5 minutes in ice-cold methanol. Coverslips were mounted and examined.
No specific staining for PI and P2 binding was seen. P2 appeared to give a grainy type of
staining which was not associated with cell morphology, indicating that P2 was binding non-
specifically (data not shown). It is noted that P2 was generally more difficult to solubilize than
PI, possibly due to the hydrophobic amino acids, valine (V) and leucine (L), within P2 (see
Fig. 4.6). This may explain its non-specific binding observed in immunoflourescence.
5.2.9ii Ability of PI and P2 peptides to block infection
In the above experiment binding of peptides to the surface of sheep cells was not observed.
The ability of the peptides to block infection was investigated as a means of demonstrating
binding of peptide to sheep cells. 96 well plates were seeded with 104cells/well, either with
sheep fibroblasts (123IT) or mouse epithelial cells (CI27). The following day dilutions of
peptides 1 and 2 were made up in 2%FCS/DME as 500, 250, 50, 25, 5 and 2.5pg/ml and
lOOpl of each dilution was added to each well. A mock incubation was made up with
2%FCS/DMEM only. Peptides were incubated with the cells for 1 hour at 37°C, removed and
doubling dilutions of EV1 made across the plate starting with 500 TCID50. After a 2 hour
incubation, the virus was removed and cells were fed with fresh medium. Seven days later
cells were Giemsa stained and examined. The CI27 controls showed that they were not
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permissible to virus infection. At higher concentrations, greater than 50pg/ml, the peptides
were toxic to cells. At lower concentrations of virus, the number of syncytia were fewer with
PI-incubated cells than mock incubated (data not shown). This experiment was repeated using
the following dilutions of peptide: 50, 40, 30, 20, 10 and 0pg/ml with 100 TCID50 of EV1 as
the starting point for virus. No reduction in TCID50 in the presence of either peptide was
observed (data not shown), suggesting that the peptides did not represent functional epitopes
on the native envelope protein of MVV.
5.3 DISCUSSION
This chapter has reported the production of a recombinant baculovirus expressing the external
envelope glycoprotein, gpl35 of MVV. One of the main advantages in using the baculovirus
expression system is the ability for recombinant proteins to become glycosylated. This
requires the presence of a signal sequence to allow the protein to be transported through the
glycosylation machinery of the insect cells. Preliminary data reported by Rafnar et al. (1994),
highlighted the toxic properties of the signal peptide of gpl35, in that production of
recombinant protein in the baculovirus system was only possible when the signal peptide was
replaced, in this case with that of mouse-7-interferon. Work in the HIV field has reported that
increase in yield can be achieved by using the signal peptide of gp67, the membrane
glycoprotein of AcMNPV (Murphy et al., 1993). Presumably, this signal sequence is more
readily recognised and efficiently transported through the translocation machinery of insect
cells, and has the additional benefit of producing a secreted protein which can be more easily
purified. Our own experience with expressing gpl35 as a recombinant protein has shown that
the N-terminus of gpl35 is especially difficult to express (see chapter 3), and this is most
probably due to the presence of a large hydrophobic domain, approximately 80 amino acids
from the N-terminus, which is thought to represent the signal peptide. Toxic properties of the
signal sequence of other lentiviruses has also been described, such as the expression of HIV-1
gpl20 in CHO cells (Lasky et al., 1986). The absolute identity of the signal peptide of gpl35
has not been conclusively demonstrated. The presence of the hydrophilic tail preceding the
signal peptide is a characteristic of retroviruses (Perez et al. 1987a) and is especially long in
FIV, the feline lentivirus (Stephens et al., 1992). The function of the leader sequence prior to
the signal peptide of lentiviruses is believed to be non-functional so it was presumed not
necessary for the successful production of recombinant MVV envelope protein. It should be
noted that this region of the envelope gene incorporates the first exon of rev (Sargan et al.,
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1991). The signal peptide was thus identified as the first hydrophobic region from the N-
terminus of gpl35 and primers were designed to generate a fragment lacking the first 100
amino acids of gpl35.
To facilitate the cloning of env into pAcSG2T, two primers were designed, primer 4975 and
primer 4976, that contained different restriction sites in order to generate a fragment with a
BamHI site at the 5'' end and EcoRI site at the 3' end. A stop codon was introduced in the 3'
end of the env fragment since this is absent in the transfer vector. PCR was successful in
generating gpl35 without the signal peptide as determined by double-stranded sequencing,
which showed that no major mutations had arisen from the PCR.
5.3.1 Generation of a recombinant baculovirus
Having generated and confirmed the sequence of the required fragment of env, it was
necessary to introduce env into the baculovirus transfer vector, pAcSG2T. Since pAcSG2T
possesses a multiple cloning site, attempts were made to introduce env by directional cloning.
This proved to be unsuccessful although controls included in restriction enzyme digests
indicated that both BamHI and EcoRI were working. It was not possible to determine
experimentally if the vector was indeed cut by both enzymes, and if this was not the case it
may explain for the failure in cloning env into the transfer vector. Reasons why the enzymes
may be inefficient at cutting the vector may be explained by the proximity of the two
restriction sites in the transfer vector such that both enzymes are unable to cut their respective
site. However cloning was possible using the single BamHI restriction enzyme site. Due to the
relatively large size of the transfer vector, 8kb, in comparison to env, 1.7kb, it was necessary
to force env into the vector by increasing its proportion relative to that of the vector. As was
reported, only two out of the 12 colonies picked contained a 1.7kb fragment of env and that
env was inserted in the correct orientation.
The use of linear viral DNA for the generation of recombinant viruses is described in the
introduction. Although most of the viruses in the cotransfection supernatant will be
recombinant, this "soup" is not ideal for reproducible results when expressing and purifying
recombinant protein. It was therefore necessary to employ a single round of plaque assay to
isolate single recombinant viruses and this would also confirm the efficiency of the
cotransfection. It should be noted that the use of linearised baculovirus DNA greatly reduces
the work required to isolate a single recombinant virus, since original protocols required
several rounds of plaque assay purification or limited-dilution assays, before a reliable source
of recombinant virus was purified. Plaque assay purification of the cotransfection supernatant
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confirmed that all viruses were recombinant by the absence of blue colour in the plaques in the
presence of X-Gal.
Following the isolation of single recombinant viruses, all 19 viruses were screened for the
presence of env by slot-blot as it was felt necessary to confirm recombination between viral
DNA and pAcSG2T:env before selecting a smaller number of viruses for characterization.
The results from this additional screening step again confirmed the efficiency of recombination
to generate recombinant viruses.
It was noted in the results that the number of cells in the experimental dishes were markedly
lower than in the control dishes. This observation has also been described for HIV-1 gpl20
expression, where a faster decrease in cell viability upon infection with recombinant viruses
was noticed (Murphy et al„ 1993). This was attributed to the potential toxicity of the signal
peptide. Since the signal peptide was not included in this experiment, it could be proposed that
other hydrophobic sequences in the envelope are affecting cell viability. These hydrophobic
regions were predicted to cause toxic properties when expressed in the bacterial pGEX system
(see Chapter 3).
Detailed analysis of seven recombinant vimses was carried out by Southern blot hybridisation
to confirm the presence of env-specific sequences within the viral genome. The use of Bsu361
digested BacPAK6 Viral DNA ensures that the gene of interest is inserted in the correct
position and orientation in the viral genome, as described in the introduction. The gene of
interest will be inserted within the 0.8-0.9kb F fragment (not visible in Fig 5.6a), which spans
the polyhedrin locus In Fig. 5.6b, sample 16 contained an extra band approximately 2.6kb,
which possibly represents incomplete digestion of env sequences from the viral genome.
Insect cells infected with all seven recombinant baculoviruses were shown to secrete a
recombinant protein that was recognised by GST-specific polyclonal serum. The size of this
protein was estimated at approximately 97-100kDa, which gives SUenv a predicted size of
71-74kDa. The expected size of the surface glycoprotein without its signal sequence, in the
absence of glycosylation, is 63kDa, suggesting that SUenv has been glycosylated. This is
discussed more fully in section 5.3.4. The reported size for the external glycoprotein of MVV
varies from 70kDa to 135kDa. Therefore, SUenv produced in the baculovirus system is
smaller than the native form. It is usual to observe a smaller recombinant protein expressed in
the baculovirus system compared to the native protein due to an immature glycosylation
pathway in insect cells. This is well documented and was observed with HIV-1 gpl20
expression (Wang et al., 1995, Morikawa et al., 1990b). The identity of the recombinant
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protein was confirmed since it was recognised by anti-gpl35 peptide antibodies and by
another source of anti-GST antibodies.
A recent report has expressed the external glycoprotein of the ovine lentivirus, that is
MVV, in the baculovirus system (Kwang et al„ 1995). They describe the native external
glycoprotein as gp70 and report a 66kDa protein that was recognised by OLV naturally
infected sheep sera. Interestingly, they describe a recombinant protein that is transported to the
cell surface as demonstrated by immunoflourescence. As far as can be determined, the signal
sequence of the external glycoprotein was not included. They do comment that the expressed
envelope is glycosylated although no experiment was carried out. Since no signal sequence
was incorporated, glycosylation of the recombinant protein would not be expected. Therefore,
the 66kDa protein observed is probably comparable to the expected size of the non-
glycosylated envelope (63kDa) described in this chapter.
5.3.2 Kinetics of recombinant protein production
In the life cycle of baculoviruses, the polyhediin promoter is usually active between 18 and 72
hours post infection, and production of polyhediin protein shows a rapid accumulation
between 24 and 30 hours followed by a gradual increase up to 72 hours. The polyhedrin
protein is very stable in the cell and will accumulate into characteristic polyhedra crystals.
Replacement of the polyhedrin gene with that of the foreign protein does not necessarily mean
that the recombinant protein will be stable, and it is more usual to see a maximum time point
for production after which protein production is unable to match the degradative processes.
The production of GST:SUenv was maximum at 48 hours and thus there is a lag in protein
expression compared to polyhedrin production. The kinetic studies suggested that after 48
hours protein production declined considerably, since it was not usual to see accumulation of
breakdown products in the supernatant. The varying degrees of contaminating products
observed from one preparation to the next may be a reflection on the cell viability at that time.
Work on the expression of gpl20 by Morikawa et al. (1990b) observed that the
kinetics of protein production differed for secreted and cell-associated protein. A study was
undertaken to compare protein production in the cells and that secreted. Protein production in
the cells was maximum between 24 and 48 hours, whereas secreted was maximum at 48 to 72
hours. It was noted that examination of cellular-associated proteins identified two species of
GST:SUenv, and that the production of larger of the two decreased with time. The smaller
protein was identical in size to that of the secreted form. This size difference was presumed to
be due to a difference in carbohydrate content, although an experiment to confirm this was not
performed. This would require the addition of tunicamycin to the cells with the expected
disappearance of both protein species being replaced by a protein of size reported in section
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5.2.5iv. Loss of carbohydrate moieties at the later stages of infection was observed by
Murphy et al. (1990) and is discussed below.
The optimum m.o.i. was also determined. It is usual in production of recombinant proteins in
the baculovirus system to infect at a high m.o.i. to ensure that all cells are infected
synchronously which will allow for reproducible results when purifying recombinant protein.
5.3.3 Further characterization of protein production
High five™ (H5) cells are a relatively new cell line. They are derived from the eggs of die
native host of AcMNPV, the cabbage looper, Trichoplusia ni. They are larger in size than the
conventional Sf cells and have a more efficient post-translational modification machinery, and
thus give much higher yields of recombinant protein (Davis et al., 1993). These cells are
reported to produce 20-fold more protein than Sf21 cells on a cell-to-cell basis (Davis et al.,
1992). The cells can also be grown in suspension like Sf21 cells, and this is favourable for
protein production since H5 cells are susceptible to contact inhibition. However, a comparison
between these two cells for production of GST:SUenv has shown that there was no dramatic
increase in the yield of protein in High five™ cells. If the expression of recombinant envelope
in the baculovirus system is limited by the toxicity of the protein, then protein production may
not be influenced by different cell types. Choice of host cell was governed by cell viability
when routinely expressing recombinant protein.
The ability to grow insect cells in suspension lends itself to large scale production. However,
suspensions of more than 500ml result in slower growth rates presumably due to a limiting
supply of oxygen to the cells (Maiorella et al., 1988). Therefore only 100ml spinner cultures
were used to ensure cells were growing in log phase at the point of infection. Another
drawback to suspension cultures is ensuring synchronous infection of all the insect cells. This
was monitored by checking that the majority of cells showed signs of virus infection prior to
harvesting. An alternative method is available instead for infecting spinner cultures but is
more cumbersome. This involves the harvesting of cells and allowing viruses to absorb onto
the cells. However synchronous infection is still not guaranteed. It is essential that a high-titre
virus stocks are used to infect spinner cultures to ensure that the cell density of the culture is
not dramatically reduced to the effect that virus-cell interaction is inefficient The routine
yields reported in the results were consistent with those reported for expression of HTV-1
gpl20 (Wang et al., 1995).
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The affinity purification system using glutathione-agarose beads is a reliable, straightforward
system, and elution from the beads resulted in a reliable source of recombinant gpl35 in
solution. Attempts to remove the fusion partner, GST, from gpl35 were not successful. No
positive control was available to ensure that thrombin was working, but the expected size, 71-
84kDa, of cleaved product was not seen indicating that cleavage had not occurred. Cleaving
fusion proteins with thrombin is generally difficult (Dr.J.Stewart, personal communication,
Dr.I.Jones, personal communication), requiring the need for various conditions such as
detergents for cleavage. Time considerations meant that determination of cleavage conditions
to remove GST could not be pursued, and the sequencing of the cleavage site to ensure that it
had not been disrupted during cloning was not undertaken.
5.3.4 The glycosylation state of GST:SUenv
As has been discussed previously one of the main advantages of the baculovirus expression
system is the ability to produce large quantities of glycosylated recombinant protein.
Glycosylation is initiated in-the endoplastic reticulum by the addition of an oligosaccharide to
the asparagine residues on the protein and this initiation of N-glycosylation is a feature in both
mammalian and insect cells. Mammalian cells extensively trim the core oligosaccharide,
followed by the addition of sugars such as frucose, glucosamine-galactose and sialic acid to
give complex branched oligosaccharides. The glycosylation pathway of insect cells is less
refined, such that insect-derived glycoproteins are smaller in size to their mammalian
counterparts (Noteborn et al., 1990). The different pathways involved in glycosylation
processes in insect cells are not understood. Recently studies on the glycosylation status of the
membrane glycoprotein, gp67, of AcMNPV has been undertaken, and it was found that
galactose and sialic acid residues were not present on this protein (Jarvis and Finn, 1995).
However, studies with plasminogen expression has described sialic acid residues on this
recombinant protein when expressed in baculoviruses (Davidson et al., 1990) and the presence
of N-acetyl glucosaminyltransferases in insect cells has been demonstrated (Altmann et al.,
1993). In depth studies as to the glycosylation state of insect-derived HA of the influenza vims
has characterized the carbohydrate content to consist of 50% N-Acetylgalactosamine
(GlcNAc) residues and the remaining a variable number of mannose residues (Kuroda et al.,
1990). These studies were carried out with a combination of oligosaccharide-modifying
enzymes and chromatographic techniques to analyse the type of carbohydrate on the surface of
HA.
A variety of techniques can be employed to confirm the presence of oligosaccharides
on recombinant protein. The choice of method chosen to investigate the glycosylation state of
GST:SUenv was the use of tunicamycin. This is an active irreversible inhibitor of N-
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glycosylation in the E.R., where it acts as an analogue to UDP-N-acetylglucosamine
preventing the addition of N-acetylglucosamine to dolichol phosphate, the first step in the
formation of the core oligosaccharide. Twenty-one of the twenty-three putative glycosylation
sites within env had been retained (see Fig.5.3) by comparison to the published sequence of
EV1 (Sargan et al., 1991). The expected size of the non-glycosylated GST:SUenv is 89kDa;
GST is 26kDa and the predicted size of the representative polypeptide portion of gpl35 is
63kDa. A protein of approximately this size was identified in the presence of tunicamycin as
reported in section 5.2.5iv proving that GST:SUenv is indeed glycosylated in the baculovirus
system.
Other methods for detecting the presence of carbohydrate on recombinant proteins
include labelling with 3H-mannose, since mannose residues represent a large proportion of
carbohydrate on insect-derived glycoproteins. This technique is only feasible when large
quantities of recombinant protein are produced and can be distinguished from cellular
proteins. Baculovirus-expressed proteins are also sensitive to endoglycosidase H and F and N-
glycanase which remove immature high mannose-type oligosaccharides (Notebom et al.,
1990). The use of enzymes is less appealing since conditions will play an important role in the
complete removal of the carbohydrate residues which could result in a variety of protein
species emerging following digestion.
The kinetics of glycosylation has been investigated fully in the expression of HIV-1 gpl20 by
the baculovirus system (Murphy et al., 1990). An observation was made on analysing the
expression of recombinant protein in that the extent of glycosylation of the recombinant
protein was dependent on the time point post infection. At earlier time points or at low levels
of expression, glycosylation was efficient. However, at 72 hours post infection, when protein
production was maximum the majority of recombinant protein produced was non-glycosylated
and insoluble, suggesting that host cell processes had shut down and components required for
glycosylation were limiting. Alternatively, the baculovirus itself may affect the glycosylation
machinery of the host cell at later time points in infection (Muiphy et al., 1990). A 5-10kDa
larger protein identified in BacPAK6:envl2 infected cells at earlier time points of vims
infection, an observation similar to Murphy et al. (1990). The reduction in size of GST:SUenv
at later time suggests a loss in carbohydrate. Thus it would seem that the extent of
glycosylation was less on the secreted form of SU:env than the cell-associated. However, the
yield was better, a reflection on the efficiency of the baculovirus signal sequence. An
experiment to see if cell-associated GST:SUenv became insoluble at later time points was not
performed. It is noted that Murphy et al (1990) did not incorporate a signal sequence in to the
transfer vector. This may reflect the reduction in yields of glycosylated protein at later time
points in infection. The fact that the system used in this chapter allowed the secretion of
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recombinant protein, may explain why at later time points in infection recombinant protein
was still glycosylated, a reflection of subsequent work by Murphy et al (1993). Murphy et al.
(1990) comment on the type of vector used may influence the expression of glycosylated
proteins. They used the pVL941 transfer vector, whereas pAcSG2T was derived form the
pAcCL29 vector. However, they also used the pVL941 vector for expression of secreted
gpl20 and protein was secreted efficiently at later time points in infection (Murphy et al.,
1993). It would suggest that it is the use of a signal sequence allows for more efficient protein
production and glycosylation, rather than the transfer vector used. It is noted that the size of
the cell-associated protein, 107kDa, is closer in size to that expected of the native protein
fused to GST, 116kDa (90kDa plus 26kDa) (see Chapter 6). Whether the secreted foim of
GST:SUenv is the more mature protein is not known. It would be interesting to know if the
extent of glycosylation of the recombinant protein influences its interaction with the host cell
receptor.
5.3.5 Potential use of GST:SUenv as an immunogen
Production of glycoproteins in the baculovirus system usually results in the retention of their
antigenicity, giving rise to a high titre of antibody. Antibodies are not always neutralising and
this may be a reflection on the glycosylation state of the recombinant protein which indirectly
effects its conformation and potential exposure of neutralising epitopes (Noteborn et al., 1990,
Arp et al., 1993, Bristow et al., 1994). Their use as therapeutic proteins and possible subunit
vaccines is debatable, since it has been shown that glycoproteins terminating in mannose,
galactose and GlcNAc are more rapidly cleared in the bloodstream (Stahl, 1990).
Immunisation with a baculovirus-expressed envelope protein of HTLV was ineffective in
inducing neutralising antibodies, and a combination of antigens was required to raise
neutralising antibodies as a potential for subunit vaccines (Arp et al., 1993). To determine if
the antigenicity of gpl35 had been retained by expression in the baculovirus system, the
reactivity of MVV-infected sheep sera was assessed by western blotting. As was reported, all
infected sheep sera tested were able to recognise GST:SUenv specifically. For controls of
naturally infected sheep it was necessary to use non-infected sheep sera since pre-bleed of
these sheep were not available. The lower contaminating bands observed between 40-66kDa
were present in the negative controls also, and were probably due to non-specific reactivity of
sheep sera in immunoblotting. The authenticity of the baculoviras-derived gpl35 is an
important result, since this allows for the potential of this protein to be used in an ELISA
screening assay. This approach has been undertaken with the envelope glycoprotein of HIV-1,
which was used in a solid-phase ELISA and was successful in screening 48 positive sera (Hu
et al., 1987). Western blot screening involved using sheep experimentally infected with the
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EV1 strain of MVV only. Sera from sheep infected with other strains of MVV were not
available at the time of screening. However, the ability of naturally-infected sheep to recognise
recombinant envelope, suggests that conserved epitopes between different strains of MVV had
been retained, since infection in the field will involve a variety of antigenic distinct strains.
Development of a screening assay for MVV was not attempted at this stage. Due to time
considerations no attempts were made to use GST:SUenv as an immunogen, although the
adequate yield and absence of contamination products would suggest that preparations of
these reagents would be straightforward.
5.3.6 The use of GST:SUenv in functional studies
The use of baculovirus-derived viral glycoproteins in functional studies has been widely
demonstrated with HIV. It is well documented that CD4 is the principal receptor for HIV.
Morikawa et al. (1990b) expressed gpl20 and CD4 in the baculovirus system and
demonstrated that they interacted in vitro. A similar approach was taken to examine the ability
of another putative receptor for HIV, CD26, to bind to baculovirus-derived gpl20. Although
binding to CD4 was demonstrable in a variety of assays, this was not reciprocated with CD26
(Wang et al., 1995). The role of carbohydrate in gpl20 binding to CD4 was undertaken, and
found that removal of carbohydrate from gpl20 reduced binding to CD4 (Murphy et al.,
1990). It appeared that the high mannose N-linked carbohydrate influenced binding but
whether this was due to specific interaction of the carbohydrate with CD4 or that the
carbohydrate allows the recombinant protein to fold properly is not well understood.
Preliminary studies undertaken to examine the functional activity of GST:SUenv
were inconclusive. Initial studies were carried out using immunofluorescence. The protocol
chosen was adapted from that published by Kozak et al. (1995), whereby cells were fixed
following staining in an attempt to reduce the disruption of protein-protein interactions. The
alternative method of fixing cells prior to protein binding may result in the disruption of
epitopes important in receptor binding. Although no specific binding was observed, these
experiments were preliminary and adaptations to the protocol are necessary, such as
increasing the amount of antigen and fixing cells post-antigen binding.
FACS analysis was used since it is more sensitive than immunoflourescence. Again
cells were fixed post antigen binding in an attempt to preserve receptor epitopes that bind to
gpl35, and this fixing gave a slightly better staining pattern than not fixing presumably by
preserving the interaction of surface proteins with antigea There was high background
staining from GST so conditions are needed to be altered to identify specific binding of
GST:SUenv to the surface of sheep fibroblasts.
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Since binding of recombinant gpl35 to the surface of sheep fibroblasts was not
shown by the two above methods, an indirect approach was attempted. This involved binding
GST:SUenv to the cell surface prior to infection and monitoring of vims-induced c.p.e.
visually. If baculovirus-derived gpl35 is able to bind to the putative receptor of MVV, it
should reduce the c.p.e. of the vims. A reduction in c.p.e. at a concentration of 1 ug/ml
suggests that GST:SUenv is able to bind to sheep celluar proteins, although gpl35 was not
shown to neutralise vims infection. Neither GST nor GST:SUenv were toxic to the sheep cells
as determined by cell viability after mock infection. In summary, these three experiments were
cmde in approach but time considerations prevented them from being further developed. The
functional studies with the two peptides suggested that they did not represent functional
epitopes within the native envelope.
The binding ability of GST:SUenv was supported by the results from the overlay
protein assays. The 30kDa protein identified corresponded in size to that seen in sheep choroid
plexus cells, thought to represent the putative receptor for MVV (Crane et al., 1991a, Dalziel
et al., 1991). The observation that GST:SUenv bound to a 30kDa protein on mouse epithelial
cells was also seen in studies by Crane et al. (1991a) who found that MVV did bind at low
levels (see fig.5.14). Mouse cells are not permissible to MVV infection as determined by a
virus titration assay (data not shown), but have been shown to support vims fusion in "fusion
from without" assays (Gilden et al., 1981). Far-western blotting provides only preliminary
data as to the identity of the virus receptor. Further experiments would be required to further
characterize the identity of the receptor and this is discussed more fully in chapter 6.
5.4 SUMMARY
This chapter describes the construction of a recombinant baculovirus, which expresses a
secreted, glycosylated form of the external envelope glycoprotein of MVV. This protein is
made in greater amounts than previous experience with other expression systems and is devoid
of major contamination. It can be easily purified due to a GST tag and has the potential to be
cleaved from its fusion partner, although attempts to do this were not successful. It is
recognised by MVV-infected sheep sera and thus could be used to develop a diagnostic assay.
It is also of use in identifying the putative host cell receptor, and the presence of the GST tag
would allow detection of protein-protein interactions without interfering with important
epitope binding sites. Initial attempts to investigate specific binding to sheep cells were
inconclusive.
160
CHAPTER 6: CONCLUSIONS AND FUTURE WORK
This thesis has presented efforts at expressing the external glycoprotein of MVV as a
recombinant protein in the bacterial pGEX system and the baculovirus expression system.
Attempts at raising monospecific antisera against this protein are also reported. The results
have already been discussed in detail at the end of each chapter, and a general discussion will
be presented here as to the significance of this work and the use of the generated reagents in
future studies.
6.1 Expression of the external envelope glycoprotein of MVV as a recombinant
protein
The generation of a recombinant form of the external glycoprotein of MVV has proved to be
problematic. The choice was made initially to express the envelope protein as three
overlapping fragments. This approach stemmed from earlier expression work in the Ty-VLP
expression system (Carey et al., 1993). Expression in fragments would allow the recombinant
proteins to be used in epitope mapping, as well as the generation of monospecific sera against
three different regions of gpl35. The pGEX bacterial system was chosen to express these
fragments, due to its relative ease of use with usually high yields. However, all three
fragments were found to be toxic to bacterial growth and yields were too poor to use either as
immunogens, or in mapping immune responses in sheep.
It was suggested that the regions of hydrophobicity were potentially responsible for die
toxicity of gpl35 in the bacterial expression system, as seen in other expression work (Sisk et
al., 1992). The region that appeared to be especially problematic was the putative signal
sequence. This hydrophobic region may haVe been the cause of unsuccessful cloning, such that
directional cloning was required to insert envA into the pGEXl plasmid. Rev, whose first
exon is present in the N-terminal portion of env is also toxic when expressed in the bacterial
pGEX system (M.Fotheringham, personal communication). Reports on the expression of the
envelope glycoproteins of ungulate viruses in bacterial systems are limited. The N-terminal
portion of the transmembrane, and the C- and N-terminal portions of the external
glycoproteins of MVV have been expressed in the pGEX system (Kwang and Cutlip, 1992a
and b). They also do not include the signal sequence in the N-terminal portion of the external
envelope glycoprotein, but do not comment on this. The authors do not state why they chose
only to express certain portions of the envelope proteins, but it may be that they also found
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these envelope proteins to be toxic. Thus, yields may be improved in the bacterial system by
cutting out major hydrophobic regions from the external envelope protein. The pET
expression system would probably be a better choice as it incorporates the tightly controlled
T7 promoter. This may be more productive since there are reports that the tac promoter is
leaky' (Sharrocks, 1994), which is undesirable when attempting to express toxic proteins.
The toxicity of the recombinant proteins expressed in the pGEX system may also be
attributed to the inability to form disulphide bridges when retained in the cytoplasm and thus
folding would be abnormal. Incorrect folding may disrupt protein production by some
unknown mechanism. Hence, bacterial expression may not be the best choice in the future
even with modifications in the hydrophobic regions.
The approach was taken to attempt expression in a eukaryotic system. A eukaryotic system
would allow the recombinant protein to be folded correctly, thus reducing the potential risks of
toxicity. Since the recombinant protein would be glycosylated in a eukaryotic system, it may
be more likely to adopt its native conformational form. From experience in the bacterial
system, and the Ty-VLP, it was decided to remove any large regions of hydrophobicity,
namely the putative signal sequence. The baculovirus system was chosen, since preliminary
efforts in our laboratory to express the envelope glycoprotein in the vaccinia system were
unsuccessful. The baculovirus system allows recombinant protein to be folded correctly and
glycosylated. In view of the desirability to produce a recombinant protein as close to its native
form as possible, the envelope protein was expressed as a whole protein and not as three
fragments. The size problem that was of consideration when expressing in the Ty-VLP
system, was not an issue in the baculovirus system. The baculovirus transfer vector chosen
incorporated a baculovirus-specific signal sequence which is expected to be recognised by the
insect cells, and thus transport through the glycosylation machinery will be efficient
This thesis reported the successful production of recombinant gpl35 in the baculovirus
system. However, it was noted that there was a reduction in cell viability on infection with
recombinant baculovirus, compared to the parental baculovirus. Since recombinant protein
yield was at the lower end of the scale expected for the baculovirus expression system
(l-500|Xg/litre), it is possible the gpl35 was toxic to the insect cells as well as bacteria. This
toxicity may be attributed to the various short hydrophobic regions outside the signal sequence
region (Sargan et al., 1991). However, compared to the results obtained in the pGEX system,
the expression was considerably improved. The recombinant protein was devoid of major
contamination, provided the insect cells were growing at log phase and were at least 95%
viable.
162
6.2 Using baculovirus-derived envelope for raising anti-env antibodies
The result that baculovirus-derived gpl35 was recognised by MW-infected sheep sera was
an important one (see Chapter 5). As well as its potential use in a diagnostic assay, it has the
potential to be used as an immunogen. The existence of neutralizing epitopes in the
recombinant protein could be investigated by incubation of immune sheep sera with the
baculovirus-derived envelope to assess the ability to inhibit neutralization. If neutralization
epitopes are retained in the baculovirus-derived envelope, it has the potential to be used as an
immunogen for producing a panel of neutralizing monoclonal antibodies. The baculovirus-
derived envelope would be a suitable immunogen for immunization, because it is produced in
adequate amounts and it is free of major contamination. These two criteria proved to be the
limiting factors in attempts to generate polyclonal sera against the pGEX-recombinant
proteins and in the attempts to generate monoclonal antibodies. Since baculovirus-derived
envelope is produced as a soluble protein it could also be used as the source of antigen in the
screening assay. The anti-peptide sera potentially provide a positive control for the screening
ELISA. However, it is not known whether the peptide sera would be able to recognise
GST:SUenv on an ELISA.
If the baculovirus-derived envelope protein is unsuitable for generating neutralizing
antibodies, alternative approaches are available. GST:SUenv could be used to raise
monospecific polyclonal sera, and this then used to immunopurify envelope glycoproteins
from MVV-infected cell extracts. This would then provide an alternative source of native
envelope for monoclonal production to be used in a similar manner as the lectin-purified
envelope protein. Due to time considerations, the suitability of the fixed-cell ELISA, described
in Chapter 4, to detect viral envelope proteins with the anti-peptide sera was not tested.
Although the pGEX-recombinant proteins proved unsuitable in generating immune sera, they
may be of use when mapping functional epitopes with MAb. Thus it would be possible to
distinguish at least five different domains from the three overlapping fragments, and the
properties of the MAb would allow a crude map of functional epitopes on the external
envelope glycoprotein.
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6.3 Using baculovirus-derived envelope to characterize the host cell receptor
Preliminary studies were undertaken to assess the use of baculovirus-derived envelope as a
source of protein for identifying the host cell receptor. One of the considerations when using
the fusion moiety, GST, tagged to the envelope glycoprotein is its potential to interrupt the
interaction of the envelope with its putative receptor. Studies involving HIV-1 gpl20/CD4
interaction indicated that GST did not disrupt binding (Wang et al., 1995). In fact, the GST
tag could be seen as a useful marker for detecting immune complexes between the envelope
and its receptor, since an antisera to GST is available (see Chapter 3). This was used as a
method of detection both in binding assays to sheep fibroblasts, and in the protein overlay
assay. Another consideration when using baculovirus-derived recombinant protein is the
immature glycosylation state of the protein. However, the binding of HIV-1 gpl20 to CD4 has
not been impaired by the use of baculovirus-derived gpl20 (Murphy et al., 1990, Wang et al.,
1995). Once the identity of the receptor has been evaluated then the role of carbohydrate in
binding could be investigated, since it possible that carbohydrate may play a non-specific role
in determining the structure of the external envelope protein (Murphy et al., 1990). The use of
tunicamycin in producing a non-glycosylated recombinant protein was reported in Chapter 5.
The data from the protein overlay assay suggested that baculovirus-derived envelope
recognised proteins present in sheep fibroblasts, and the size was consistent with that seen in
earlier work (Dalziel et al., 1991, Crane et al., 1991a). Although this assay was
straightforward to set up there are several drawbacks. Conformational epitopes that are
required for virus binding would be destroyed by resolving cellular proteins on SDS-PAGE.
To further characterize the size of the host cell receptor, co-immunoprecipitation studies
would be necessary. This would require radiolabelling sheep fibroblast cells, followed by
incubation with recombinant envelope. Receptor/envelope complexes would be pulled out with
GST antiserum bound to protein A sepharose beads and resolved by SDS-PAGE. Extensions
to these studies would include the ability of baculovirus-derived envelope to interact with
sheep MHC classll, which has been implicated as a putative receptor for MVV (Dalziel et al.,
1991). Co-immunoprecipitation studies would also be carried out with radiolabeled
macrophage cells, since these cells are the major target for MVV infection in vivo (Narayan et
al., 1982). Macrophages could also be used in the binding studies described in Chapter 5,
section 5.2.8ii, to show that baculovirus-derived envelope recognises MVV receptors on the
surface of these cells.
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6.4 The size of the external envelope glycoprotein of MYV
Throughout the literature on both MVV and CAEV there are no consistent reports as to the
size of the external and the transmembrane proteins. Genetic analysis of the MVV genome
predicts a 114kDa polypeptide backbone as the envelope precursor (Sonigo et al., 1985,
Sargan et al., 1991). This 114kDa protein was interpreted as the 150kDa envelope precursor
described by Vigne et al. (1982), which would then be processed to the more mature form of
gpl35, a predicted 105kDa polypeptide (Sonigo et al., 1988). This mature protein is presumed
to have lost the signal sequence, which is proposed to he within the first 100 amino acids at
the N-terminus of the envelope protein (Sonigo et al., 1988). The presence of a protease
cleavage site at amino acid residue 657, approximately, would result in a 64kDa polypeptide
and a 38kDa polypeptide, representing the external and transmembrane proteins, respectively
(Sonigo et al., 1988). A gp70 protein has been described which could represent the external
envelope protein (Bruns and Frenzel, 1979).
Protein studies are even more ambiguous as to the identity of the external glycoprotein
of the ungulate lentiviruses. As has been mentioned, pulse-labelling studies have shown that a
150kDa precursor of the envelope protein is replaced by a 135kDa protein (Vigne et al.,
1985). By increasing the [35S]methionine labelling time from 40 minutes to 24 hours, two
polypeptides of Mr 85,000 and 50,000 were observed. Glycosylation studies revealed that the
150kDa and 135kDa proteins were glycosylated, but they did not report whether the 85kDa
and 50kDa proteins were glycoproteins (Vigne et al., 1985). Most studies that are directed at
the function of the envelope glycoprotein use a monospecific guinea-pig antiserum raised
against a lectin-puiified glycoprotein (see Chapter 4, Crane et al., 1988). This lectin-purified
gpl35 was used to raise a panel of monoclonal antibodies, although it is not specified whether
this is the entire envelope glycoprotein or the external glycoprotein (Stanley et al., 1987).
However, studies in identifying the neutralization and fusion epitopes on the envelope protein
using this monospecific antisera, describe gpl35 as the external glycoprotein (Crane et al.,
1988). Work involving the expression of the entire envelope glycoprotein in transgenic sheep
characterize the existence of both the external protein, gpl35, and the transmembrane, gp50,
in the transgenic sheep cells (Clements et al., 1994). The antisera used to carry out these
immunoprecipitation studies used the guinea-pig antisera raised against the lectin-purified
gpl35, that is the external glycoprotein. This clearly shows the inconsistency in identifying the
glycoproteins of MVV.
A similar pattern is seen with CAEV. Gpl35 was identified as the major glycoprotein
of CAEV, and used in immunodiffusion serology (Adams and Gorham, 1986), although they
do not speculate whether this is the entire envelope or just the surface glycoprotein. By
analogy with MVV, gpl35 is commonly described as the surface protein in papers on CAEV
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biology (Knowles et al., 1990). Antibody responses to the surface glycoprotein were thought
to be correlated with the severity of arthritis, but more recent studies have mapped this to an
immunodominant epitope in the transmembrane glycoprotein, gp38 (Bertoni et al., 1994). This
suggests that gpl35 could be the uncleaved form of the envelope protein, as described by
Huso et al. (1988).
In summary, the size of the external envelope glycoprotein is reported to range from 70kDa to
135kDa. Throughout the thesis the external glycoprotein has been referred to as gpl35.
Howver, results from the baculovirus expression data suggest that this may not be the true
size of the external glycoprotein ofMW.
Experience with MW-infected sheep antisera in our laboratory has lead to
observations of a 90kDa protein as well as the 135kDa protein in MW-infected cell lysates.
This 90kDa protein is predicted as the external envelope glycoprotein. The presence of the
gp90 protein is not consistent, and greatly depends on the state of the cell cultures at the time
of infection and at harvest. It should be noted that gp90 was not purified from the lectin-
afftnity column described in Chapter 4. This may be explained by the methodology of the
purification. Since the virus was collected by ultra-centrifugation, it is likely that the spikes on
the surface of the virion will be knocked off, and thus gp90 is lost. This explanation may also
be relevant in standard harvesting of MW-infected cells.
The expression of the external glycoprotein of MVV in the baculovirus system
reported in this thesis, described a secreted protein of 70-75kDa, and a cell-associated of
approximately 80kDa (see Chapter 5). Since baculovirus produced recombinant proteins are
generally smaller than their native form (Morikawa et al., 1990b), the baculovirus-derived
protein could be seen as a true representative of gp90. This suggests that gpl35 is more likely
to represent the uncleaved precursor, with gp90 representing the external. This would predict
a 45kDa protein as the transmembrane glycoprotein.
By raising a monospecific antisera against the baculovirus-derived external
glycoprotein, the true identity and size could be studied. Immunoaffinity columns could be set
up as described above to pull out both the envelope precursor and the external envelope
protein form MW-infected cell lysates. A combination of pulse-chase labelling followed by
immunoprecipitation would confirm earlier studies by Vigne et al (1982), and reveal the true
identity of the glycoproteins of MVV.
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6.5 Conclusions
This thesis has presented studies on the expression of the external glycoprotein of MVV as a
recombinant protein. Work in this field has been hampered by the toxicity of the envelope
protein as was seen both in the bacterial system and the Ty-VLP expression system. The toxic
properties of the envelope fragments was thought to be due to areas of hydrophobicity within
the protein. Subsequent expression in the baculovirus system showed that recombinant protein
could be produced in adequate amounts with little contamination. Thus, it lends itself to be
used in a number of studies, including as a source of antigen and characterization of the host
cell receptor. A number of monospecific sera have been raised, including the two anti-peptide
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